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Abstract 
The aim of this thesis was to extend the understanding of molecular mechanisms of asbestos 
exposure related diseases asbestosis (lung fibrosis), lung cancer and mesothelioma. This thesis 
consists of three parts. The first study investigated the responses that asbestos exposure induced in 
lung epithelial cells. Epithelial-to-mesenchymal transition (EMT) is implicated in fibrosis and in 
cancer, both asbestos induced diseases. It was therefore tested whether asbestos fibers induced 
EMT. In the next two studies, the focus was on mesothelioma. Mesothelioma is an aggressive 
cancer that is characterized by chemoresistance and local invasion. In these two studies, the aim 
was to recognize novel potential therapeutic target molecules and pathways involved in 
chemoresistance and invasion.  
By analyzing alterations in cellular protein levels in two (2D) and three dimensional (3D) cell 
cultures, we found that exposure to asbestos led to loss of epithelial characteristics when lung 
epithelial cells retained the type II airway epithelial cell phenotype. This loss of epithelial 
characteristics was found not to depend on TGF-β or Smad signaling cascades. Comparing 
activities of cancer associated signaling pathways between normal and cancer cells provided us with 
three candidate pathways. We exposed the cells to asbestos and analyzed the impact of specific 
inhibitors on epithelial plasticity and phosphorylation levels of intracellular signaling proteins. The 
MAPK/ERK pathway was found to mediate epithelial plasticity in response to asbestos exposure.   
A screen for new gremlin-1 interacting proteins discovered fibrillin-2. This finding was validated in 
mesothelioma tumor samples in which gremlin-1 and fibrillin-2 were found to co-localize. Primary 
mesothelioma cells were harvested from pleural effusion samples from mesothelioma patients. 
These cells recapitulated primary tumor characteristics and overexpressed gremlin-1, fibrillin-2 and 
transcription factor slug. The association of gremlin-1 with slug was validated in vitro and in the 
tumors. The link between chemoresistant EMT phenotype and high gremlin-1 and slug expression 
was analyzed using siRNA interference and exposure to chemotherapeutic drugs. Silencing of 
gremlin-1 downregulated slug, reverted the EMT-phenotype and sensitized the cells to the cytotoxic 
effect of chemotherapeutic drugs. The concomitant overexpression of gremlin-1 and fibrillin-2 
enables gremlin targeting to fibrillin-2 containing fibers in mesothelioma extracellular matrix, 
where it supports the chemoresistant EMT phenotype through transcription factor slug.   
Mesothelioma tumors as well as primary mesothelioma cells and mesothelioma cell lines were 
found to overexpress activin-A and activin-B. Canonical Smad3 response to activin stimulation was 
attenuated in mesothelioma cells. Attenuation of the Smad3 response associated with migratory and 
invasive phenotype analyzed by conventional and live cell imaging in 2D systems as well as in 3D 
matrigel matrix. Analysis of phosphorylation levels of intracellular signaling proteins revealed that 
activins induced the MAPK/ERK signaling cascade. Invasion, migration and ERK activation was 
impaired by sequestering extracellular activins by soluble activin-receptor. Likewise, inhibiting 
MAPK/ERK upstream kinase impaired migration and invasion. Mesothelioma cells switch from 
canonical Smad3 signaling to non-canonical MAPK/ERK pathway, and this promotes migration 
and invasion.  
The results presented in this thesis support the concept that pathological EMT is a central 
mechanism in the development and progression of asbestos induced fibrotic and malignant diseases. 
They also suggest gremlin-1 and activin-A as new potential therapeutic targets in mesothelioma. 
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Tiivistelmä 
Tämä väitöskirjatyö tutki asbestin aiheuttamien sairauksien molekyylimekanismeja. Asbestialtistus 
aiheuttaa keuhkojen sidekudostumista (asbestoosi), keuhkosyöpää sekä keuhkopussin syöpää 
(mesoteliooma). Epiteeli-mesenkyymi-transitio (EMT) on tärkeä mekanismi syövän ja 
sidekudossairauksien etenemisessä. Tämä väitöskirja koostuu kolmesta osasta. Ensimmäisessä 
osatyössä tutkittiin asbestin aiheuttamia vasteita keuhkon epiteelisoluissa ja testattiin, aiheuttaako 
asbesti EMT:tä. Kaksi seuraavaa osatyötä keskittyivät mesotelioomaan. Näissä osatöissä etsittiin 
molekyylejä ja solunsisäisiä viestireittejä, jotka vaikuttavat mesoteliooman kykyyn tunkeutua 
aggressiivisesti ympäröiviin kudoksiin ja kykyyn vastustaa solunsalpaajahoitoja. 
Asbestille altistettuja keuhkon epiteelisoluja tutkittiin kaksi- (2D) ja kolmiulotteisissa (3D) 
kasvuympäristöissä. Havaitsimme, että tyypin II keuhkoepiteelisolut, menettävät epiteliaalisia 
ominaisuuksiaan asbestialtistuksen seurauksena. Tällainen plastisuus viittaa EMT tapahtumiin. 
Nämä tapahtumat eivät olleet riippuvaisia TGF-β tai Smad- viestireiteistä. Vertailtaessa normaalien 
keuhkoepiteelisolujen ja syöpäsolujen solunsisäisten viestireittien aktiivisuuksia löydettiin eroja 
kolmen viestireitin välillä. Näistä reiteistä MAPK/ERK viestireitti osoittautui olevan se, joka 
aktivoituu asbestialtistuksen seurauksena ja joka sai aikaan epiteeli-mesenkyymi-transitioon 
viittaavaa plastisuutta keuhkojen epiteelisoluissa. 
Systemaattisessa etsinnässä fibrilliini-2 paljastui uudeksi gremliini-1:teen sitoutuvaksi proteiiniksi. 
Analysoitaessa mesotelioomapotilaiden kudosnäytteitä havaittiin, että sekä gremliiniä että 
fibrilliiniä ilmennettiin juuri syöpäkudoksessa ja että nämä proteiinit lokalisoituivat hyvin lähelle 
toisiaan. Mesotelioomapotilaiden pleuranesteestä eristettiin ja kasvatettiin 
primaarimesotelioomasoluja. Nämä solut yli-ilmensivät gremliiniä, fibrilliiniä sekä 
transkriptiofaktori slugia syöpäkasvaimen tapaan. Gremliinin ja slugin välinen yhteys varmennettiin 
syöpäkudosnäytteissä sekä soluviljelmissä. Gremliinin ja slugin välistä yhteyttä sekä niiden 
merkitystä lääkeresistentissä EMT-fenotyypissä tutkittiin vähentämällä gremliini-1:n ilmenemistä ja 
altistamalla soluja solunsalpaajille. Gremliinin ilmenemistasojen lasku johti slugin 
ilmenemistasojen laskuun, EMT-fenotyypin peruuntumiseen ja lisäsi solujen herkkyyttä 
solunsalpaajille. Gremliini-1:n ja fibrilliini-2:n samanaikainen yli-ilmentäminen mesotelioomassa 
mahdollistaa gremliini-1:n lokalisaation soluväliaineeseen mesotelioomassa. Gremliini-1 ylläpitää 
lääkeresistenttiä EMT- fenotyyppiä slugin välityksellä.   
Aktiviini-A:ta ja aktiviini-B:tä yli-ilmennetään mesotelioomasyöpäkudoksessa sekä primaari-
mesotelioomasoluissa ja solulinjoissa. Havaittiin, että mesotelioomasoluissa kanoninen Smad3 
vaste aktiviineille on heikentynyt ja tämä piirre kytkeytyi solun kykyyn invasiiviseen kasvuun 3D 
ympäristössä ja migraatioon 2D ympäristössä. Analysoimalla signalointiproteiinien 
fosforylaatiotasoja havaittiin, että aktiviinit aktivoivat mesotelioomasolussa Smad3-reitin sijaan 
MAPK/ERK-viestireitin ja tämä pystyttiin estämään sitomalla spesifisti solunulkoiset aktiviinit 
liukoisella aktiviinireseptorilla. Tämä heikensi huomattavasti mesotelioomasolujen migraatiota ja 
invaasiota. Samoin teki MAPK/ERK-viestireitin salpaus. Havaitsimme, että muutos Smad3-
viestireitiltä MAPK/ERK-viestireitille edistää mesotelioomasolujen invasiivisuutta ja migraatiota.  
Tämän väitöskirjatyön tulokset tukevat näkemystä, että patologinen EMT on keskeinen mekanismi 
asbestisairauksien kehittymisessä ja etenemisessä. Tutkimuksen valossa gremliini-1 ja aktiviini-A 
ovat uusia potentiaalisia kohdemolekyylejä mesoteliooman hoidossa.     
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1. Review of the literature 
Tissue homeostasis requires tightly regulated interplay between intra- and extracellular 
environments and involves various cell types. These two environments sustain the balance by 
reciprocal communication. Disturbance of this balance can lead to a disease. Damage activates 
tissue repair processes. Organisms have various means to eliminate damaged cells, foreign 
organisms or materials that try to disturb the balance. These mechanisms include innate and 
adaptive immune systems. Damaged and aberrant cells are removed by apoptosis. If these 
surveillance mechanisms fail and the balance is permanently disturbed, the condition can develop 
into a malignant or fibrotic disease. Often in these diseases developmental genes are reactivated 
and the cellular processes associated with tissue repair are deregulated. This can promote disease 
progression.   
1.1 Asbestos fibers  
Asbestos is a common name for a group of silica fibers. These naturally occurring fibers are strong 
and flexible; resistant to heat and most chemicals; and have therefore been used for various 
construction and insulation purposes.  
1.1.1  Fiber types and exposure 
Asbestos fibers are categorized into serpentine and amphibole fibers. Chrysotile is the only form of 
serpentine asbestos. These serpentine fibers are curly, whereas amphibole fibers are straight. 
Amphibole fibers include crocidolite, amosite, anthophyllite, tremolite and actinolite asbestos. 
Serpentine fibers are cleared from the lung more efficiently than amphiboles, meaning that the 
biopersistence is greater for amphibole fibers 1, 2. However, all forms of asbestos are associated 
with increased risk of malignant as well as non-malignant diseases 3. Exposure to airborne asbestos 
fibers is usually work related. However, asbestos is a naturally occurring mineral, and exposure can 
also happen when people live near natural asbestos deposits. The burden of the asbestos fibers in 
the lung depends on the amount of fibers deposited and the clearance of the fibers 1.      
1.1.2  Cessation of asbestos usage and current exposure  
In Finland, the use of new asbestos was ceased in 1988, and the manufacture, import, sale and 
utilization of asbestos containing products was forbidden in 1992 4. Furthermore, the European 
Union has banned asbestos use since 1999 (1999/77/EY) and this EU directive eliminated the last 
exceptions for asbestos use in Finland by 2005. Nowadays, in Finland a risk for exposure still 
remains in demolition and renovation work of old buildings.        
 
1.2 Asbestos exposure related diseases 
Asbestos fibers cause genetic and cellular damage and chronic inflammation 5. Asbestos can cause 
lung cancer and mesothelioma as well as non-malignant pleural changes, such as pleural plaques, 
benign pleural effusion, fibrosis of visceral pleura and fibrosis of lung tissue (asbestosis). 
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1.2.1 Latency  
The worldwide asbestos consumption peaked in 1980’s 3 and in Finland in 1970’s 4. All asbestos 
exposure related diseases are preceded by a long latent period of 10-40 years, or even longer 3, 4. 
Considering the long latency together with the rather recent termination of asbestos consumption, it 
is clear that the peak in the incidence of asbestos exposure related diseases is yet to come. In 
Finland, the peak is expected to occur 2010-2015 4 and in Europe 2010-2020 3. When the view is 
expanded worldwide, the peak runs further to the future, as many countries have only recently 
restrained the use of asbestos.   
1.2.2 Asbestosis 
Asbestosis is an asbestos induced lung fibrosis, which shares common features with another 
devastating lung disease idiopathic pulmonary fibrosis (IPF) 6. Histological findings in IPF include 
usual interstitial pneumonia (UIP) 7. These lesions are also found in the histology of asbestosis 8. In 
asbestosis, also asbestos bodies and fibers are detectable in lung tissue 9, 10. Both asbestosis and IPF 
eventually lead to the loss of lung function, and the treatment options are limited. Lung 
transplantation may rescue a patient with lung fibrosis (http://www.hus.fi/sairaanhoito/ 
sairaanhoitopalvelut/elinsiirrot/keuhkonsiirrot/Sivut/default.aspx, accessed 1.9.2014). In Finland, 
20-30 lung transplantations are done each year for different reasons, including lung fibrosis, and the 
prognosis is usually rather good. After five years of the operation 80% are alive and after ten years 
50 %. Both asbestosis and IPF increase the risk for lung cancer 6, 11, 12. If a patient with asbestosis or 
IPF is a smoker the cancer risk increases further 11, 13. Annually, 60-90 new cases of asbestosis are 
reported in Finland (Finnish Institute of Occupational Health). The progression of the disease and 
the prognosis differs between the patients. Although not curable, anti-fibrotic drug pirfenidone has 
shown efficacy and is available for the treatment of IPF in Europe 14. No comprehensive data is 
available for pirfenidone treatment in patients with asbestosis.    
 
1.2.3 Lung cancer 
The location and histology of asbestos-induced lung cancer (bronchogenic carcinoma) is 
indistinguishable from lung cancer not related to asbestos exposure 4, 11. Asbestos-induced lung 
cancer, however, tends to occur at a younger age. Asbestosis and smoking increases the risk for 
lung cancer in asbestos exposed individuals 1, 11. Smoking does this likely through impairment of 
fiber removal from the lung. Impaired fiber removal is likely also one of the mechanisms by which 
fibrosis increases the cancer risk. When the carcinogenic fibers remain longer in the airways, the 
prolonged exposure can contribute to increased cancer risk. No significant differences in the 
prognosis of non-asbestos-related or asbestos-induced lung cancer have been reported 11. More than 
2000 lung cancers are reported in Finland each year 4 and majority of them have dismal prognosis. 
After careful staging and defining the histological type of the lung cancer the treatment is designed 
for the cancer patient according to the Finnish Current Care Guidelines 
(http://www.kaypahoito.fi/web/english/guidelines/guideline?id=ccs00057, accessed 13.10.2014). 
Treatment with combinations of surgery (when possible) and radiotherapy with single or multi-drug 
chemotherapy prolongs survival but is rarely curable.  
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1.2.4 Molecular mechanisms in asbestosis and asbestos induced lung cancer 
In all asbestos exposure related diseases, changes occur in gene expression, epigenetic regulation 
and in intracellular signaling cascades which contribute to the disease initiation and progression 1. 
These changes are brought by the fibers directly, as well as by oxidants that are generated on the 
surfaces of the fibers and generated and released by the cells. In the lung, asbestos initiated 
inflammatory reactions and accumulation of alveolar macrophages is followed by a loss of alveolar 
epithelial cells, fibroblast accumulation and collagen deposition 6. Fiber deposition in the lungs also 
induces persistent inflammation 1. The cellular responses initiating different diseases (asbestosis, 
lung cancer or mesothelioma) probably overlap. However, there are likely some specific differences 
that will lead to development of distinct disease. There are probably also genetic differences in the 
susceptibility to asbestosis among exposed individuals 15, 16.  
The cellular responses to asbestos fibers can be different during disease initiation and progression 1. 
Common early events in asbestosis and in IPF are injury, repair and apoptosis of alveolar epithelial 
cells (AEC) and recruitment of inflammatory cells 6, 17. There are two types of alveolar epithelial 
cells; type I and type II 18, 19. The type II cells can differentiate into type I cells. Type I cells make 
the gas exchange surface of the alveoli and comprise ~90% of the alveolar surface area 6. The type 
II cells synthesize, store and release pulmonary surfactant proteins and function as a plastic 
proliferative repertoire for type I cells 18, 19.  
Many of the same factors that direct tissue repair also promote fibrosis 20. Repeated injury induced 
by the fibers and aberrant repair leads to persistent and progressive fibrosis. In vitro and in rodent 
models, asbestos induces lytic cell death and apoptosis of epithelial and mesothelial cells and this 
stimulates wound healing processes including compensatory cell proliferation 2. Asbestos initiates 
the accumulation of alveolar macrophages, which produce profibrotic growth factors and cytokines. 
Implicated in asbestos related lung diseases are various bioactive molecules for example 
transforming growth factor- β (TGF-β), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and 
platelet derived growth factor (PDGF) 1, 6, 20. The inflammatory cytokines attract inflammatory cells 
and affect lung epithelium and fibroblasts. Inflammation promotes fibroblast dysfunction and 
epithelial cell proliferation. Accumulating evidence suggests TNF-α regulated TGF-β1 production 
to be important in the pathogenesis of asbestosis 1. PDGF isoforms are implicated in organ fibrosis 
and also in the development of asbestosis. PDGF binds its specific receptors (PDGFR, α-and β-
receptors) on fibroblasts and promotes myofibroblast growth and survival 20. Asbestos also induces 
production of reactive oxygen and nitrogen species (ROS and NOS) 6, 21. ROS are generated at the 
surfaces of asbestos fibers; they are released by macrophages as a result of unsuccessful 
phagocytosis of large fibers and ROS can also originate from mitochondria of inflammatory cells or 
lung epithelial or mesothelial cells. Asbestos induced oxidative stress promotes ROS dependent 
signaling, pulmonary inflammation, matrix remodeling and degradation as well as fibrogenesis.  
After interaction with the cells, asbestos fibers and ROS initiate various signaling cascades and 
activate transcription factors, including mitogen activated protein kinases (MAPK), activator 
protein-1 (AP-1), nuclear factor-κB (NF-κB) and protein kinase C (PKC) 1, 2. AP-1 is a redox 
sensitive transcription factor and its binding to DNA is increased by asbestos 2, 22, 23 (see also 1.6.1). 
Asbestos induces proto-oncogenes c-fos and c-jun, which are subunits of AP-1, in bronchial 
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epithelial and in pleural mesothelial cells and contributes to their proliferative responses to the 
fibers. Furthermore, AP-1 proteins are phosphorylated and activated also by MAPkinases 2.  
Activation of NF-κB is critical in upregulation of various genes linked to inflammation, 
proliferation and apoptosis, as well as chemokine and cytokine production 23. Asbestos induced 
inflammatory response activates NF-κB in tracheal epithelial cells in vitro and in vivo leading to 
transcriptional activation of a number of NF-κB- dependent genes, including the proto-oncogene c-
myc 23-25. Cell survival promoting NF-κB can also be activated via the EGFR-(PI3-K)/AKT 
pathway 23. Furthermore, asbestos fibers have been reported to directly bind and activate the 
epidermal growth factor receptor (EGFR) 26 . 
Lung epithelial cells communicate with the underlying fibroblasts and smooth muscle cells through 
paracrine signaling 1. Epithelial cells produce various factors, including ligands for EGFR. This 
signaling through EGFR plays an important role in asbestos induced fibrosis by promoting 
fibroblast proliferation. Also ROS mediate part of their signaling effects through EGFR on 
fibroblasts and epithelial cells, as well as other cell types. Importantly, asbestos fibers or ROS 
initiated signaling cascades are significantly different in duration of the signal compared to the 
endogenous ligand stimulated responses 1. The components of the downstream signaling cascade 
can also be different. Accumulating evidence suggests that the EGFR-MEK-MAPK/ERK cascade is 
an important target for therapeutic intervention in asbestos related lung diseases.  
Mutations and altered expression of the tumor suppressor p53 are found in lung cancer and in lung 
fibrosis 1, 6, 17, whereas in mesothelioma p53 mutations are rare (see below). After asbestos exposure 
p53 mediates mitochondria-regulated apoptosis in lung epithelial cells 6. Wild type p53 also 
promotes cell cycle arrest by transcriptionally activating p21(Cip1/Waf1) 27.     
1.2.5 Mesothelioma 
Malignant mesothelioma (MM) is a relatively rare tumor but it is among the most aggressive ones 
28. Detection of MM can be difficult 29 and often takes place in late stages of the disease, which in 
part affects the poor prognosis of the patients 28. In Finland, 60-80 new mesotheliomas are 
diagnosed each year (the Finnish Institute of Occupational Health). Majority of mesotheliomas 
associate with previous, usually work related asbestos exposure but 20-25% of mesotheliomas 
occur in individuals no apparent exposure, suggesting that there is a genetic susceptibility to 
mesothelioma or an additional causative agent, or both 28, 30. Majority of the exposed individuals 
never develop mesothelioma 17.      
Mesothelioma arises from mesothelial cells lining pleura, peritoneum or, in rare cases, pericardium. 
Histologically mesotheliomas are divided into three subgroups: epithelioid, sarcomatoid and 
biphasic 29. Epithelioid mesotheliomas compose of polygonal, oval or cuboidal cells that can 
resemble non-neoplastic reactive mesothelial cells. Sarcomatoid mesotheliomas generally consist of 
spindle shaped cells. Biphasic mesotheliomas contain both epithelioid and sarcomatoid areas within 
the same tumor. Epithelioid mesothelioma is the most frequent subtype, more amenable to 
treatment and has better prognosis compared to the sarcomatoid or biphasic forms. However, better 
prognosis means only longer survival with the disease. Unfortunately, mesothelioma is currently 
incurable. Compared to pleural mesothelioma, the sarcomatoid and biphasic subtypes are rare in 
peritoneal mesothelioma 31, 32.      
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Early stage tumors may be surgically removed, but this rarely results in complete resection 28. 
Surgery is usually combined with chemotherapy, sometimes also radiotherapy. Inoperable tumors 
are treated with chemotherapy. Current standard of care for first line chemotherapy is platinium 
compound (cisplatin or carboplatin) combined with a folate inhibitor (pemetrexed). However, 
response rates are low and reoccurrences common. The pattern of spread surrounding the lung in 
the proximity of vital organs (heart, spinal cord), together with usually large surface area of the 
tumor, limits the delivery of effective therapeutic doses of radiation without significant toxic 
effects. Clinical trials of new therapeutics have found histone deacetylases and acetyltransferases as 
well as anti-angionetic agents ineffective 28. Surprisingly, although EGFR is highly overexpressed 
in mesothelioma tumors and MAPK/ERKs are strongly implicated in MM, also small molecule 
EGFR tyrosine kinase inhibitors gefitinib and erlotinib have failed to show clinical effect in MM 
patients 33, 34. The overexpression of rather specific proteins and the involvement of chronic 
inflammation in MM have driven clinical trials that are evaluating the potency of immunotherapies 
alone or combined with chemotherapies in the treatment of MM. These include dendritic cell 
(DC)35 and WT-1 36 analog peptide vaccines and antibodies targeting mesothelin 37. 
1.2.6 Molecular mechanisms in mesothelioma  
Suggested mechanisms through which asbestos fibers cause mesothelioma overlap the ones 
suggested to underlie the pathogenesis of asbestosis and lung cancer. Interestingly, the same signal 
transduction pathways activated by asbestos are also important in survival and chemoresistance of 
mesotheliomas and lung cancer 23. Some of the asbestos activated pathways and mechanisms 
through which asbestos induces fibrosis and malignant diseases are presented in Figure 1.  
 
Similarly to other asbestos exposure related diseases, ROS likely play a central role also in the 
pathogenesis of mesothelioma 5, 23. ROS are produced when macrophages and mesothelial cells 
engulf asbestos fibers. Asbestos fibers can tangle with the chromosomes and the mitotic spindle, 
leading to chromosomal abnormalities and aneuploidy of mesothelial and other cells. In addition, 
asbestos fibers can absorb various proteins and chemicals. This can lead to deprivation of important 
cellular proteins or to the accumulation of toxic and carcinogenic compounds, or both. Finally, 
macrophages and mesothelial cells release a variety of growth factors and cytokines in response to 
asbestos exposure. These include TNF-α, IL-1β, TGF-β and PDGF isoforms. Asbestos exposure 
also induces necrotic cell death and release of high mobility group box 1 protein (HMGB-1) from 
mesothelial cells into the extracellular space in vitro and in vivo 38. HMGB-1 is a nuclear protein, 
and its release initiates persistent inflammatory response, secretion of TNF-α, which activates NF-
κB. NF-κB can then promote the survival of the mesothelial cells that have accumulated genetic 
damage due to the asbestos exposure. Based on in vitro data and analysis of patient material, high 
HMGB-1 expression has been suggested to act as prognostic marker for mesothelioma 39 and to 
support mesothelioma progression 40. High expression of another high-mobility group A protein 
with similar functions, HMGA2, is associated with poor prognosis in MM 41.  
 
The most frequently mutated tumor suppressor genes in mesothelioma include cyclin –dependent 
kinase inhibitor 2A/alternative reading frame (CDKN2A/ARF) (homozygous deletion in ~70% of 
epithelioid and in ~100% of sarcomatoid type), neurofibromatosis type 2 (NF2) (mutation or 
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homozygous deletion in 40-50%, not subtype defined) and tumor suppressor BRCA1-associated 
protein-1 (BAP1) (somatic mutation in ~23 %, not subtype defined) 5, 41, 42. Furthermore, germ line 
mutations of BAP1 have also been suggested to genetically predispose to mesothelioma 
development 43, 44. Genetic variants of the DNA repair enzyme genes, as well as epigenetic-related 
genes, may also contribute to the susceptibility difference to mesothelioma 5.  
 
Mesotheliomas display some of the hallmarks of most cancers 28. Mesothelioma tumors suppress 
apoptosis, become self-sufficient in mitogenic signaling and capable to cell replication and tissue 
invasion. However, some oncogenic events commonly seen in other solid tumors are rarely seen in 
mesothelioma. These include activation of the RAS oncogene, commonly seen in lung cancer, and 
inactivation of the tumor suppressor gene TP53 5, 45.  
 
Mesothelioma frequently exhibits localized intracavitary growth and aggressive invasion instead of 
distal metastasis 28. Mesotheliomas exhibit various defects in mitogenic signaling pathways as well 
as disruption of cell cycle control. Furthermore, similarly to other solid tumors, persistent activation 
of the canonical receptor tyrosine kinase (RTK) Ras/ERK1/2 and the phosphaditylinositol-3-
kinase/AKT pathways are common in human mesothelioma and frequently recapitulated in mouse 
models of MM 28, 46-48. However, despite constitutive and simultaneous activation of several RTKs, 
activating mutations of the oncogenes involved in these cascades, such as K-Ras and epidermal 
growth factor receptor families, are rare in mesothelioma 5.  
1.2.7 Complexity and multiplicity of asbestos induced diseases 
Although asbestos initiated responses in different cell types clearly overlap, the mechanism by 
which asbestos induces asbestosis, lung cancer or mesothelioma appears to differ to some extent 1, 6, 
29, 30. In addition to the disease itself, these differences can result from the tissue as well as from the 
genetic background of the individual.  
 
Historically, chrysotile has been the most commonly used type of asbestos 3, 28 but it has been 
suggested to be less potent in inducing mesothelioma than amphibole fibers, whereas in lung cancer 
this trend was reported to be less clear 49. Crocidolite asbestos has been suggested to be the asbestos 
type most frequently associated with mesothelioma in humans 50 and to be the most carcinogenic 
type of asbestos 5. Interestingly, mesothelioma can also result from exposure to naturally occurring 
non-asbestos fibers, such as erionite or vermiculite ore 51, 52.  However, no confirmative link 
between certain fiber type and specific disease has been established 17, 28. 
 
In most studies on asbestos exposure related diseases, majority of the patients are men. One 
significant reason for this is likely, that most of the jobs with a high risk of exposure, such as car 
mechanics, working at the construction sites and ship yards have traditionally been occupied by 
men, not so much by women. There is not enough evidence to firmly link any predisposing factors, 
such as age, gender or genetics to asbestos exposure related lung cancer 11. However, in 
mesothelioma male sex, non-epitheloid cell type and poor performance status indicate poor 
prognosis 53. Intriguingly, smoking increases the risk for lung cancer in asbestos exposed 
individuals 11 but not the risk for mesothelioma 54. 
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Physical properties of the fiber can affect biopersistence and clearance of the fiber as well as 
generation of reactive species and initiated cellular signaling responses 5, 23, 28. However, all types of 
asbestos fibers induce malignant and nonmalignant diseases 3. Different doses and exposure times 
may also have different effect 17. Asbestos dose can be crucial determinant for triggered 
inflammation type 6. Low dose exposure for prolonged time can elicit different type of 
inflammatory response than high dose exposure for a short period of time. There is likely no safe 
level of asbestos exposure and the exposure- response relationship appears to be linear 4, 11.  
 
The pathogenesis of asbestos exposure related lung diseases involves various cell types 5, 6. 
Extensive research has revealed various pathways and molecular mechanisms underlying asbestos 
induced lung diseases, but the precise mechanisms and the crosstalk between the implicated 
pathways in each separate disease are not yet fully understood. The notable difference between 
mesothelioma and lung cancer in the activation of the Ras- oncogene and in the inactivation of the 
tumor suppressor p53 emphasizes the complexity of the mechanisms leading from asbestos 
exposure to the disease 28.   
Inside the histological subtypes, mesothelioma exhibits further heterogeneity between and within 
the tumors 28. For instance, a recent report 41 identified two subgroups in mesothelioma: C1 with a 
better prognosis and C2 with a worse prognosis. This was irrespective of the histological subtype. 
The C2 group was characterized by mesenchymal phenotype (see 1.3). This subgrouping was able 
to divide epithelioid mesotheliomas into groups of better and worse prognosis. Consistent with their 
two-component nature, biphasic mesotheliomas were also included in both subgroups. As could be 
expected, sarcomatoid tumors were all included into the C2 group.  
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Figure 1. Some of the asbestos evoked disease related responses. Phosphorylation cascades are not 
shown. Asbestos has pleiotropic effects on epithelial and mesothelial cells as well as other cell types.  
Asbestos can activate cell signaling pathways through direct interactions with receptors or by inducing 
generation of reactive oxygen species (ROS) and bioactive molecules. ROS are also generated at the 
surfaces of asbestos fibers. ROS and growth factors (e.g. TGF-β) and cytokines (e.g. TNF-α) are released 
by macrophages as a result of unsuccessful phagocytosis of large fibers. TGF-β and TNF-α mediate 
inflammatory and anti-apoptotic signals through their receptors, TGF-β type 2 (TβR2) and type 1 (ALK5) 
receptors and TNF-α receptor (TNFR). Asbestos induced oxidative stress and bioactive molecules promote 
pulmonary inflammation and matrix remodeling and degradation as well as fibrosis. Asbestos also induces 
activation of nuclear factor- κB (NF-κB), which promotes cell survival and inflammation as well as chemokine 
and cytokine production. Direct interaction of the fibers with the epidermal growth factor receptor (EGFR) 
activates the Ras-Raf-extracellular signal–regulated kinase (ERK) pathway, which by stimulating and/or 
regulating proliferation, differentiation, survival and migration will promote disease progression. Activated 
EGFR also activates the phosphoinositol-3 kinase (PI3K)/AKT pathway, which promotes cell survival through 
NF-kB. Adapted and modified from 1, 6, 23, 55. 
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1.3 Epithelial-to-mesenchymal transition 
Epithelial cells can downregulate their epithelial characteristics and acquire mesenchymal traits. 
Epithelial-to-mesenchymal transition (EMT) is a reprogramming of the cells’ gene expression, as 
well as non-transcriptional changes induced and regulated by extracellular cues 56. Endothelial and 
mesothelial cells can also undergo transition to mesenchymal phenotype.  
1.3.1  Introduction to EMT  
The epithelia has a recognized role as a permeability barrier outlining tissues and organs as a single 
cell layers or as multilayer tissues 57. On the contrary, mesenchymal cells are loosely organized in a 
three dimensional extracellular matrix comprising connective tissues next to the epithelia 58. During 
EMT, E-cadherin in adherens junctions, ZO-1 in tight junctions and other intercellular junction 
proteins are dissoluted, which leads to the loss of apical-basal polarity 56, 59. The cells reorganize 
their cytoskeleton and gene expression, and begin to express mesenchymal genes such as N-
cadherin, vimentin, fibronectin and α-SMA 58, 60. During EMT, the Rho GTPases regulate actin 
dynamics and actin reorganization to stress fibers 56. The loss of apical-basal polarity and 
reorganization of the cytoskeletal architecture result in changes in the cell shape; the cells become 
elongated and they gain front-rear polarity, which enable directional movement.  
Depending on the tissue and signaling context, EMT can also be partial 56. This means that an 
epithelial cell loses some of its epithelial characteristics while retaining some and simultaneously 
acquires some mesenchymal traits. Furthermore EMT can be transient in nature and cells that have 
gone through EMT can revert to their original state by mesenchymal-to-epithelial transition (MET) 
58, 61. Thus, epithelial plasticity covers a wide range of changes in cell behavior and the plasticity of 
the epithelial phenotype enables the cells to undergo multiple rounds of EMT and MET.  
During development, EMT represents an initial differentiation event in the generation of the three 
germ layers from pluripotent cells 56, 59. In addition to its crucial role in the formation of the body 
plan and in the differentiation of various tissues and organs, EMT also contributes to tissue repair 
and wound healing 58. Depending on the physical context, EMT can be categorized into three types 
56 : type 1 EMT occurs in embryogenesis and development, type 2 EMT is an important contributor 
in tissue repair and in organ fibrosis and type 3 EMT associates with cancer progression.   
1.3.2 Inducers and transcription factors 
EMT is crucial for tissue remodeling during embryogenesis and responsible for the formation of 
various structures in vertebrates, including the cardiac valves, the craniofacial structures, the 
vertebrate and the lungs 60, 62. Various signaling pathways have been reported to regulate numerous 
transcription factors during EMT. TGF-β-Smad3, WNT-β-catenin, PI3-K/AKT and MAPK/ERK 
cascades and Notch, NF-κB, epidermal growth factor (EGF), fibroblast growth factor (FGF) and 
bone morphogenetic proteins (BMPs) can initiate EMT 56, 59, 62, 63. These pathways frequently, but 
not necessarily, regulate transcription factors snail and slug (see section 1.3.3), which downregulate 
the expression of epithelial E-cadherin and other cell junction proteins in the initiation of EMT 
which eventually is accompanied by upregulation of mesenchymal gene expression.  
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In EMT processes, other activated transcription factors include AP-1 transcription factors, TWIST, 
zink-finger E-box-binding (ZEB) 1 and ZEB2, which can downregulate epithelial and upregulate 
mesenchymal gene expression 60, 62. During EMT processes, it is likely that several transcription 
factors are activated simultaneously or in a hierarchical manner.  
In addition to the direct effects of growth factors and transcription factors on gene expression, 
numerous splicing and translation factors regulate EMT/MET 62. Alternative splicing generates 
proteins with structural and functional differences and can generate isoforms of the same gene with 
opposing effects on EMT 58. In addition, non-coding miRNAs that selectively bind mRNA regulate 
EMT 56, 62. Binding of a miRNA to mRNA can inhibit mRNA translation or promote mRNA 
degradation. Furthermore, chromatin regulators control EMT processes epigenetically 62.          
1.3.3 Snail family transcription factors 
Snail family zink-finger transcription factors are the key inducers of EMT but act also as survival 
factors and as inducers of cell movement during developmental as well as pathological EMT 63. In 
humans, there are three members in the family: snail (SNAI1), slug (SNAI2) and smuc (SNAI3). All 
three genes are located in different chromosomes in human, SNAI1 in chromosome 20, SNAI2 in 8 
and SNAI3 in 16 (http://www.ncbi.nlm.nih.gov/gene accessed 17.10.2014). Although discovered 
over a decade ago 64, not much is known of about smuc, and it will not be discussed further here. 
Co-operation between different transcription factors is central in EMT induction 58. There is 
increasing evidence of a hierarchy in controlling the expression of the transcription factors snail and 
slug, which are induced by TGF-β superfamily members. For instance, snail upregulates slug 
expression in fibrosis 58. Furthermore, in both developmental as well as in cancer progression 
associated EMT, snail has been suggested to be expressed at the onset of the transition, whereas 
slug together with other transcription factors would be subsequently induced to maintain the 
mesenchymal phenotype 65. Snail family transcription factors act as repressors for genes supporting 
epithelial phenotype, the major gene being E-cadherin (CDH1) 66. They also induce genes of 
mesenchymal phenotype, including vimentin and fibronectin.         
1.3.4 Mesothelial-to-mesenchymal transition 
The mesothelium has multifaceted functions. It resembles the epithelia as it maintains a protective 
barrier. However, the components of extracellular matrix, hyaluronan and other lubricants, as well 
as chemokines and cytokines that mesothelium produces differ from those produced by the 
epithelium 28. Mesothelial cells originate from the mesoderm and are histologically different from 
the cells of true epithelium. Mesotheial cells can undergo an EMT like transition, mesothelial-to-
mesenchymal transition (MMT). In peritoneal mesothelial cells, EMT has been reported to be 
mediated by the ERK/NF-κB/snail cascade 67.   
1.3.5  Pathological EMT  
Aberrant EMT contributes to organ fibrosis and cancer progression through various mechanisms 58, 
61. EMT provides cells with migratory and invasive properties and pathological EMT prevents 
apoptosis and senescence, and contributes to immunosuppression and chemoresistance. In addition, 
EMT also promotes cancer cell dissemination and metastasis 61. At distant site MET may contribute 
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to the establishment of the metastasis. Many of the same growth factors, extracellular cues and 
pathways that co-operate to orchestrate EMT during development and normal tissue repair operate 
also in pathological EMT 58. Some features of EMT and its contribution to pathological conditions 
are presented in Figure 2.  
During tissue fibrosis, myofibroblasts accumulate and secrete excess amounts of the altered 
extracellular matrix (ECM) 58, 68. This compromises organ function and leads to its failure. In mouse 
models of fibrosis, part of these myofibroblasts has been shown to originate through pathological 
activation of interstitial fibroblasts, but a significant part was shown to arise from the epithelial cells 
through EMT processes 69. Furthermore, high levels of recognized EMT inducer TGF-β have been 
found in the fibrotic tissues of patients. Altered ECM can initiate and support EMT and promote the 
progression of fibrosis and cancer 61.  
Cancer invasion can be a synchronized action of both EMT dependent as well as EMT independent 
mechanisms 61. EMT is observed in the invasive front of colon carcinoma 70, 71 as well as in other 
solid tumors 58, 61. Furthermore, many important EMT drivers, including snail and slug, have been 
found to correlate with disease relapse and survival in various cancers, indicating that EMT leads to 
worse prognosis and clinical outcome 58. In lung cancer and mesothelioma, EMT phenotype and 
expression of snail or slug, or both, has also been linked to worse prognosis 41, 72, 73.   
Constitutive expression of EMT inducers can maintain the mesenchymal phenotype and because 
this suppresses senescence and apoptosis, the two safeguard mechanism against cancer, it ensures 
an invasive phenotype and promotes survival of metastatic cells 58. Tumors with EMT phenotype 
can resist chemotherapy. In addition, EMT can induce 59, 74 and be induced by the expression of 
matrix metalloproteinases (MMPs) which degrade the ECM 75 and promote tumor invasion as well 
as fibrosis. Degradation of ECM can release more EMT driving growth factors and cytokines, 
which can create a self-amplifying vicious cycle.        
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Figure 2. Characteristics of pathological EMT (epithelial-to-mesenchymal transition). During fibrosis or 
cancer progression, epithelial cells can undergo complete or partial EMT, which can be reversible. Various 
effectors are able to induce EMT, including growth factors (e.g. TGF-β, Wnt, EGF, FGF), cytokines (e.g. IL-6 
and TNF-α) and ECM components. Although not all events in EMT require transcriptional changes, these 
inducers will also activate transcription factors (including snail, slug and NF-κB) which are responsible for 
transcriptional reprogramming of the cell undergoing EMT. Some of these transcription factors are also used 
as markers for mesenchymal phenotype (e.g. snail and slug).  During EMT, the cells downregulate epithelial 
proteins of cellular junctions (e.g. E-cadherin and ZO-1) and reorganize their cortical actin to stress fibers. 
The cells lose their apical-basal polarity and gain front-rear polarity. A mesenchymal cell will express 
mesenchymal markers, including N-cadherin and α-smooth muscle actin (α-SMA). During EMT, the cell 
loses its cobblestone like morphology and stationary character and becomes elongated in morphology and 
capable of migration and invasion. In addition to the ability to invade, EMT phenotype can gain resistance to 
senescence and apoptosis, and escape immunosurveillance; thus aberrant cells persist and are not removed 
from the tissues. EMT phenotype can also support chemoresistance. Adapted and modified from 58, 60, 76, 77.  
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1.4 Extracellular matrix 
In multicellular organisms, cells are surrounded by a complex three dimensional extracellular 
matrix (ECM) that provides support and strength to the cells within the tissues but also functions as 
an important regulator of various cellular activities and as a reserve for many growth factors 78. 
1.4.1 Structure and function 
The composition of the ECM differs depending on the tissue and organs, and it defines the rigidity 
of the tissue 78. Therefore, the strength of the bone, flexibility of the skin and other unique 
characteristics of organs and connective tissues are determined by the ECM and by the cells that 
produce it. Collagens, structural glycoproteins, proteoglycans and elastins are components of the 
ECM, and they organize into macromolecular superstructures, such as collagen fibrils, elastic fibrils 
and microfibrils.  
ECM undergoes constant remodeling and reshaping by the cells which degrade and reassemble it 79. 
Thereby the cells actively modulate their surrounding environment which directs their own 
phenotypes. The composition of the ECM is controlled by coordinate and distinct regulation of 
synthesis and turnover of each separate component 80. The ECM interacts and signals through 
cellular receptors 81. Various receptors have been identified that transduce signals from the ECM to 
the cytoskeleton and to the nucleus 82. These include integrins, receptor tyrosine kinases, 
immunoglobulin superfamily receptors, destroglycan and cell surface proteoglycans. Physical 
linkages and biochemical signaling generate a bidirectional flow of information between the 
extracellular and intracellular compartments.  
ECM components are bioactive polymers 80. In addition to its structural role and direct signaling to 
the cells through cell surface receptors, ECM components can also physically interact with 
signaling molecules and their regulators 78. These interactions enable the sequestering of bioactive 
molecules, which modulates the availability, localization and activity of the signaling molecules 
including FGF, WNTs, Hedgehogs, TGF-βs and BMPs (see l.7.3 and 1.7.5). Remodeling of the 
ECM is often a result of cell-matrix crosstalk leading into the release of active ECM components 
and bioactive peptides as well as the growth factors stored into the ECM 79. During cancer 
progression, cancer cells modulate their surroundings, which usually leads to generation of a stiffer 
ECM, that can facilitate tumor progression and invasion 83.         
When tissue is injured, healing processes involve the formation of early remodeling phase of 
provisional ECM 80, 84. This provisional ECM contains for example proteoglycans and hyaluronan 
and it is a loose and highly hydrated environment for cell invasion and repair. During this stage, 
specific ECM components interact with the cells and control cell behavior critical to the wound 
healing. In many diseases, something goes wrong after this early repair phase leading to generation 
of fibrotic ECM. Like cancer ECM, fibrotic ECM is stiffer and altered in composition, compared to 
the ECM of a heathy tissue 85. Fibrotic ECM can also contain increased amounts of profibrotic 
growth factors.  
 
By eliciting structural changes and releasing growth factors and cytokines sequestered into the 
ECM, the cells and the ECM sustain a reciprocal communication important in normal tissue 
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development, homeostasis and wound healing 79, but is also a crucial factor in cancer progression 86 
and in lung fibrosis (IPF) 8. Tumor cells and cancer associated fibroblasts modify their surrounding 
ECM to promote angiogenesis, chemoresistance and metastasis 86. In lung fibrosis, aberrant wound 
healing processes lead to deposition of excess and altered ECM 8.  Modification of the altered ECM 
and release of stored signaling molecules supports inflammation and fibrosis promoting 
environment.       
Basement membrane is a specialized ECM lining the basal face of epithelium and endothelium, and 
surrounding muscle and fat cells 87. Basement membrane is mainly comprised of laminins and 
collagen IV but contains also nidogen and heparin sulfate proteoglycans.  
 
1.4.2 Microfibrils  
Fibrillins are large cysteine rich glycoproteins 78, 88, 89. In human, three fibrillin genes have been 
identified: FBN1 (fibrillin-1), FBN2 (fibrillin-2) and FBN3 (fibrillin-3) 90, which are scattered in 
different chromosomes, FBN1 in chromosome 15, FBN2 in 5 and FBN3 in 19 
(http://www.ncbi.nlm.nih.gov/gene, accessed on 17.10.2014). Fibrillins-1 and- 2 are ECM proteins, 
structurally related to fibulins and latent TGF-β binding proteins (LTBPs) 88-90. LTBPs and fibrillins 
form a fibrillin-LTBP family of extracellular matrix proteins 91. This family contains the fibrillins 
and four different LTBPs 92.  These proteins typically have repeated domain structure that consists 
of EGF-like repeats and characteristic eight cysteines.   
 
Fibrillin -2 is generally expressed during development and tissue remodeling but consistently in 
lower amounts than fibrillin-1 89, 90. Fibrillin-1 production continues in adult organisms. Fibrillins-1 
and -2 have both unique as well as overlapping functions 90, 93. Fibrillins exert structural functions 
through the temporal and hierarchical assembly of microfibrils and elastic fibers 90. The fibrillin 
monomers organize into microfibrils. The microfibrils are essential for elastic fiber formation.  
In addition to their structural role, fibrillins exert indispensable regulatory function to biochemical 
signaling by sequestering TGF-βs and BMPs, thereby concentrating, targeting and regulating 
bioavailability of these growth factors. Perturbation of either structural or regulatory function will 
lead to a disease. Elastic fibers that contain fibrillins are key architectural components of connective 
tissues, although microfibrils containing fibrillins can also exist without being associated with 
elastic fibers 90, 94. The fundamental roles of fibrillins in connective tissues are emphasized by the 
manifestations of the microfibrillopathies, a group of diseases resulting from abnormalities in the 
microfibrillar network 95. Two recognized examples are Marfan syndrome caused by a mutation in 
fibrillin-1 96, and congenital contractual arachnotactyly (CCA), which results from fibrillin-2 
mutations 97. Fibrillin mutations lead to disintegration and fragmentation of connective tissues. 
Some syndrome manifestations can result directly from these structural abnormalities. Due to the 
indispensable role of the fibrillins in sequestering and in regulation of various growth factors, parts 
of the manifestations are likely to result from aberrant growth factor activation and signaling. In 
Marfan syndrome, the extracellular TGF-β protein levels and patient serum TGF-β levels are 
significantly elevated 98. Fibrillin-1 mutation impairs the delivery of the large latent complexes to 
ECM, and abnormal ECM can stimulate aberrant activation of TGF-βs. Considering that also BMPs 
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are targeted to microfibrils, which contain fibrillins 94, 99,  it is likely that the balance of also BMP 
activities might be disturbed in fibrillin mutation induced syndromes.         
1.5 Nuclear factor-κB   
The nuclear factor-κB transcription factor family is central in regulating several cellular functions, 
including inflammation, apoptosis, cell survival and proliferation 100. NF-κB transcription factors 
also play a key role in innate and acquired immunity.   
1.5.1 NF-κB mechanism of activation 
NF-κB signaling occurs via two independent yet interlinked pathways 100, 101 of which only the 
canonical pathway is discussed here. The NF-κB transcription factor family consists of five 
subunits: RelA (p65), RelB, c-Rel (Rel), p50 (processed from NF-κB1) and p52 (processed from 
NF-κB2) 100. All subunits share the same homologous element the Rel homology region (RHR), 
which is responsible for dimerization, inhibitor binding, nuclear localization and DNA binding. The 
genes RELA, RELB, REL, NFKB1 and NFKB2 are all located in different chromosomes in human 
genome (http://www.ncbi.nlm.nih.gov/gene, accessed 1.9.2014). These five subunits form homo- 
and heterodimers which in most quiescent cells are bound to inhibitory molecules, the IκB 
(inhibitors of NF-κB) family proteins 101. Association with the inhibitory proteins sequesters the 
NF-κB-IκB complexes in the cytoplasm, and because the binding takes place through the DNA 
binding domains of NF-κBs, it makes them transcriptionally inactive. The activation of NF-κB 
occurs by release from the IκB molecules. This can be achieved by degradation of the inhibitor. IκB 
is targeted to proteosomal degradation by polyubiquitination, which requires a specific double 
phosphorylation of the IκB 102. This is mediated by an enzyme complex that contains IκB kinases 
IKK1 (IKKα) or IKK2 (IKKβ) and accessory proteins. IKKs are phosphorylated and activated by 
NIK (NF-κB inducing kinase) and MAPK3K family kinases (see 1.6) MEKK1, MEKK2 and 
MEKK3 as well as by TAK1 (TGF-β activating kinase 1). Extracellular signals that can activate 
NF-κB pathway include LPS (lipopolysaccharides), TNF-α and IL-1 (interleukin-1).   
1.5.2 NF-κB in inflammation and cancer 
Inflammation, a process of innate immunity, is a response to physical injury, oxidative stress, or 
other harmful substance, and it is associated with activation of the canonical NF-κB pathway 101. 
Inflammation and NF-κB have a dual role in cancer. NF-κB activation is part of the immune 
defense targeted to eliminate transformed cells.  However, this immune defense is not always tight 
enough or capable to eliminate all aberrant cells. Most malignancies exhibit constitutive activation 
of NF-κB 100, which enables it to exert various pro-tumorigenic functions. NF-κB can do this 
because it regulates the expression of pro-inflammatory cytokines (IL-1, IL6), chemokines, growth 
factors, cell cycle regulators, adhesion molecules, matrix degrading proteases and anti-apoptotic 
molecules (e.g. B-cell lymphoma 2 gene, Bcl-2) 87. Importantly, NF-κB can antagonize the 
apoptotic pathway of the tumor suppressor p53. Tumors can establish elevated NF-κB activity by 
obtaining mutations that target NF-κB genes (the five subunits) or oncogenes that activate the NF-
κB pathway; increased NF-κB activity can also be achieved by increasing the release of activating 
cytokines, such as TNF-α, into the tumor microenvironment.  
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1.6 Mitogen activated protein kinases 
The mitogen activated protein kinase (MAPK) pathways transduce signals from the cell membrane 
into the cell and into the nucleus 103. In response to many different stimuli, MAPK cascades control 
a range of cellular processes, including growth, differentiation and stress responses.    
1.6.1 MAPK cascades 
The MAPK family contains extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase 
(JNK, often referred to also as the stress activated protein kinase, SAPK) and p38 MAPK 103. The 
ERK pathway is activated by mitogenic stimuli by growth factors and cytokines, whereas JNK and 
p38 MAPKs respond less robustly to growth factor stimulation but are readily activated by stress 
signals, including TNF-α, IL-1. Whereas the ERK pathway is a central regulator of cell growth, 
survival and differentiation, the JNK and p38 MAPK pathways contribute to the regulation of stress 
response and apoptotic cell death. Majority of the MAPK pathways become activated, along with 
the NF-κB pathway, in response to stress and inflammation 104.  The MAPkinase signaling is highly 
complex. A core triple kinase cascade is a defining feature of the MAPKs. This means that the 
phosphorylation, i.e. activation of a MAPK/ERK, JNK or p38 is a result of a sequential, three-
membered kinase cascade. The kinase closest to the cell membrane receptor in the cascade is a 
member of a vast group of kinases called MAPK kinase kinase (MAP3K) 104. These kinases 
phosphorylate serines and threonines in a conserved motif in MAPK kinases (MAP2Ks, MKK or 
MEKs) and induce their activation. MAP2Ks having a dual specificity will phosphorylate threonine 
and tyrosine residues in a distinct conserved motif in MAPKs, which leads to their activation. 
MAPK p38 is phosphorylated by MAP2Ks MKK3, MKK4 and MKK6, and JNK is phosphorylated 
by MKK4 and MKK7. These MAP2Ks, on the other hand, are phosphorylated by a vast group of 
different MAP3Ks. The most well-known triple phosphorylation signaling cascade for ERK is 
Ras/Raf/MEK/ERK cascade. It starts from activated cell membrane tyrosine kinase receptor (e.g. 
EGFR) and a G-protein Ras (Ras oncoprotein), which activates Raf family of MAP3Ks. Raf 
phosphorylates ERK-spesific MAP2Ks: MEK1 (MAP2K1) and MEK2 (MAP2K2), which 
phosphorylate and activate ERKs 104, 105. MEK1 and MEK2 can, however, be activated also by 
various other MAP3Ks 104. ERKs can also be activated independently of Ras. Separate MAPKs 
have distinct but also overlapping targets. They phosphorylate membrane proteins and cytoplasmic 
proteins, which can act as downstream kinases, and on cytoskeletal proteins 105. MAPKs 
phosphorylate and activate transcription factors that upregulate AP-1 (see 1.2.4) component genes 
104. JNKs and p38 are the predominate MAPKs responsible for the recruitment of the AP-1, but also 
ERKs can regulate AP-1. AP-1 in turn controls a number of cellular processes, including 
differentiation, proliferation and apoptosis.  
 
The duration and amplitude of the MAPK cascades are regulated by controlling the intracellular 
localization of the kinases as well as removing the activating phosphorylations 105. The activated 
MAPKs can be concentrated in a different intracellular localizations, cellular structures and 
compartments in the cell which can affect downstream cascades and cellular responses. 
Furthermore, substantial number of dual specific phosphatases, MAPkinase phosphatases (MKPs), 
specifically removes one or both phosphorylations. Activities of the MAP kinases are also regulated 
by targeting them for degradation by ubiquitin proteasome system 106.    
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1.6.2  Extracellular signal-regulated kinases (ERKs) 
There are at least seven ERK genes in human (ERK1, ERK2, ERK3, ERK4, ERK5, ERK6 and 
ERK7=ERK8, http://www.ncbi.nlm.nih.gov/gene, accessed on 1.9.2014). The most well studied 
MAPK/EKRs are encoded by the genes ERK1 and ERK2 104, which are located in the chromosomes 
16 and 22, respectively (http://www.ncbi.nlm.nih.gov/gene, accessed on 15.10.2014). The 
Ras/Raf/MEK/ERK is the best studied MAPK pathway 107. There are more than 160 substrates 
which ERK1/2 can phosphorylate 108. In addition, ERKs have also functions that do not depend on 
kinase activity. For instance, kinase deficient ERK1/2 could upregulate p21 levels and induce cell 
cycle arrest in response to Raf/MEK activation 109. Activation by growth factors, hormones and 
cytokines has been shown to stimulate and regulate proliferation, differentiation, survival, 
senescence and migration 107, 108. External stimulus will eventually activate the membrane bound 
GTPase Ras. Ras, when GTP-bound recruits Raf to the plasma membrane and enables it to 
phosphorylate MEK1 and MEK2, which are the two only substrates for Rafs. MEKs will further 
phosphorylate ERKs. Three isoforms of Raf are expressed in mammals (A-, B- and C-Raf) with 
distinct differences in affinities for both the upstream activator Ras as well as for the target MEKs. 
As discussed above, ERKs require dual (tyrosine and threonine) phosphorylation in their activation 
loop to become active. Both ERKs are expressed ubiquitously, but the relative levels of ERK1 and 
ERK2 in tissues differ 105.  In various cases, the ERKs can also be activated in Ras-independent 
manner by proinflammatory stimuli, such as cytokines of the TNF-family 104. This Ras-independent 
mode of ERK activation plays a significant role in innate immunity and inflammation as well as in 
cell proliferation. MAPK/ERKs are well recognized activators of cyclin D1 gene transcription 110. 
Cyclin D1 functions in a rate limiting role in cell cycle progression through G1. Subsequently, 
cyclin D1 is overexpressed in various cancers. However, sustained activity of Raf/MEK/ERK 
pathway can also induce growth inhibitory signaling in many different cell types 108. MAPK/ERK 
signaling can induce cell death and cell cycle arrest in response to various signals. A model has 
been suggested where not only too low but also too high MAPK/ERK activity leads to growth arrest 
108. The thresholds are likely to be different in different cell types.     
 
1.6.3 ERKs and EGFR in pathological conditions 
Epidermal growth factor receptor (EGFR, also known as HER1, ERBB1, 
http://www.ncbi.nlm.nih.gov/gene, accessed on 15.10.2014) is one of the major cell membrane 
tyrosine kinase receptor activating ERKs. Therefore, changes in MAPK/ERK regulation can result 
from EGFR overexpression or activating mutations of Ras or Raf 103, 105, 107. This is frequently 
observed in human cancers. However, EGFR and Ras mutations may be mutually exclusive 55. 
Mouse knockout experiments show that in B-Raf deficient cells growth factor stimulated ERK 
activation decreases, but this is not the case in A-Raf or C-Raf deficient cells 111-113. This suggestion 
of B-Raf as a dominant MAP3K is supported by the observation that B-Raf mutations are far more 
frequent in human cancers compared to A-Raf or C-Raf mutations 114, 115.    
 
EGFR family tyrosine kinase receptors are frequently upregulated in human cancers 55. 
Dimerization of these receptors after ligand (for example EGF) binding will eventually activate the 
Raf/MEK/ERK or PI3K/AKT pathway, or both. These pathways promote cell cycle progression and 
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cell proliferation as well as anti-apoptotic signals and survival pathways. ERK activation will also 
promote transcription of inflammatory cytokine TNF-α and angiogenesis stimulating VEGF 
(vascular endothelial growth factor). MAPK/ERKs are strongly implicated in the development of 
radio- and chemoresistance 103, 116.  
 
In addition to these two well characterized mechanisms (hyperactivation of EGFR or Raf), 
MAPK/ERK may contribute to cancer progression and treatment resistance also through regulating 
other cascades. MAPK pathways play a central role in regulating the key mediators of fibrosis, 
namely TGF-β and Smad pathways (see 1.7). There is also significant cross-talk between these 
pathways. MAPKs are also strongly implicated in EMT processes (see 1.3.2). In addition, MAPK 
cascades contribute to the development of fibrotic diseases. ERK activation is implicated in EMT in 
chronic hypoxia-induced renal fibrosis in vitro and in rodent models as well as in the samples from 
patients suffering from chronic kidney disease 117. In TGF-α mouse model of pulmonary fibrosis, 
MEK inhibition prevents the progression of established fibrosis 118. Furthermore, upregulation of 
EGFR in IPF lungs has been reported 119 and EGFR activation has been suggested to be an 
important event in the development of pulmonary fibrosis 120. However, MAPK/ERK activation can 
also occur independently of EGFR and promote fibrosis. Activation of the MAPK/ERK pathway 
occur in cancer cells not only by growth factors but also by activating mutations which promote 
EMT 56.        
 
EGFR also activates PI3-K/AKT pathway which promotes cell survival through NF-κB 23. PI3-
K/AKT activity is frequently elevated in mesothelioma, and this reduces sensitivity to 
chemotherapeutic drugs  46, 121. Also hepatocyte growth factor (HGF)/Met receptor and other growth 
factors (e.g. insulin) can activate the PI3-K/AKT pathway. Activation of AKT increases tumor 
invasion, antagonizes cell cycle arrest and activates mTOR (mammalian target of rapamycin), a 
serine/threonine protein kinase that regulates numerous cellular functions, including proliferation, 
cell survival, transcription and protein synthesis. PRAS40 (proline-rich AKT substrate of 40-kDa) 
is a substrate for AKT and a regulator of mTOR 122. mTOR is found in cellular complexes referred 
as mTOR complex 1 and 2 (mTORC1 and mTORC2). The core component of mTORC1 is the 
Raptor (regulatory associated protein of mTOR) but also other regulatory proteins are found bound 
in these complexes, including Rag GTPases, RalA GTPase and PRAS40. PRAS40 associates with 
the mTOR complex 1 and regulates its activity. PI3-K/AKT phosphorylates PRAS40 and modulates 
is regulatory effect on mTOR complex 1.   
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1.7 Transforming growth factor-β superfamily 
The transforming growth factor-β superfamily consists of over 30 members in mammals 123. 
Members of this superfamily have fundamental roles in the development as well as in the 
homeostasis of adult organisms. The TGF-β superfamily members are found broadly in both 
vertebrates and in invertebrates.     
1.7.1 Introduction to the TGF-β superfamily 
The transforming growth factor (TGF)-β superfamily includes TGF-βs, activins, nodals, BMPs, 
growth differentiation factors (GDFs) and anti-Müllerian hormone 123. The TGF-β superfamily 
members have from 66% to 80% sequence identity and nine strictly conserved cysteines 124. 
Ubiquitous expression of these secreted factors starts at development and continues into the 
adulthood of the organism 123. TGF-β superfamily members participate in determining the body axis 
formation and patterning. At cellular level, TGF-β superfamily members control fundamental 
cellular processes including proliferation, differentiation cell death, cytoskeletal organization, 
adhesion and migration. Consistent with their fundamental role in normal physiology, aberrant 
TGF-β superfamily signaling activity is strongly implicated in pathologic conditions such as fibrotic 
and malignant diseases.  
The ligands of the TGF-β superfamily are synthetized as precursor proteins and they are processed 
and secreted as proproteins where the N-terminal prodomain associates non-covalently with the C-
terminal mature active ligand 125. Within the superfamily the C- terminal active growth factor 
domains resemble each other but the N-terminal prodomains appear dissimilar. Prodomains differ 
between TGF-βs and BMPs, whereas activin-A proregion resembles more that of TGF-β 126, 127. The 
prodomains facilitate proper folding, dimerization and secretion 126. Mature ligands are 
characterized by a structure called the cysteine knot that results from the formation of the three 
intramolecular disulfide bonds between six highly conserved cysteines 128. Also a seventh cysteine, 
that mediates dimerization is conserved in most members 123. Schematic structures of TGF-βs, 
BMPs and activin-A are pictured in Figure 3. 
 
TGF-β superfamily members can be divided into two functional groups, the TGF-β-like group 
contains TGF-βs, activins, nodals and some GDFs; whereas the BMP-like group contains BMPs, 
most GDFs and anti-Müllerian hormone 123. Intracellular Smad responses also follow this division 
so that the TGF-β-like group binding receptors activate receptor Smads (R-Smads) Smad2 and 
Smad3 and the BMP-like group binding receptors activate R-Smads Smad1, Smad5 and Smad8. 
The ligand binding and activated Smads (canonical pathways) of some of the TGF-β superfamily 
members are presented in Figure 4. Some of the reported non-canonical signaling cascades for those 
growth factors are also shown, as well as some of the extracellular regulators, which will be 
discussed in sections 1.7.4 and 1.8.   
1.7.2 Receptors and signaling through Smads 
TGF-β superfamily members transmit their signals through heteromeric complexes of type 1 and 
type 2 serine/threonine receptors  123, 129-132. Generally the activated receptor complex is formed 
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when the ligand dimer binds to two type 2 receptor kinases. Two type 1 receptors are recruited to 
the complex and phosphorylated after which the Smad cascade is initiated133-135. However, the 
BMPs have higher affinity to type 1 receptors than to type 2 receptors, and BMPs can form receptor 
complexes also by binding first to the type 1 receptors 136-138. Typically, the type 1 receptor defines 
the specificity of the Smad signal 130. In vertebrates, there are five type 2 and seven type 1 receptors 
123. This relatively small group of receptors can pair up in various combinations to mediate signals 
for all the members of the TGF-β superfamily. Remarkably, the diversity of over 30 ligands and 
numerous combinations of receptor signals are mainly funneled to only two intracellular Smad-
pathways.  
Both the TGF-β-like group and BMP-like group activated R-Smads share the same common partner 
Smad (co-Smad), Smad4 123. Heteromeric partnering with Smad4 is not needed for nuclear 
localization, but it is essential for initiation of transcriptional regulation 139. After localization to the 
nucleus, the R-Smad likely determines target gene specificity and the co-Smad acts to promote 
transcriptional activity 123. However, although these Smads bind directly to DNA, the binding is of 
low affinity, and Smads generally need to recruit binding partners, specific transcription factors and 
co-activators. In the C- and N- termini of the R-Smads are highly conserved domains called Mad 
Homology (MH) 1 and MH2 140. The MH domains are separated by a linker region of variable 
length. The MH1 domain mediates DNA binding and MH2 mediates oligomerisation.  
 
In transcription complexes, depending on the interacting transcription factors, different 
stoichiometries of R-Smads can be found 141. Smad heterodimers, containing for instance Smad2 
and Smad4, or heterotrimers containing two Smad2s and one Smad4, can be found in transcription 
complexes associated with FAST-1 or FAST-3 transcription factors, respectively. It has been 
suggested that TGF-β induced transcriptional responses would be primarily mediated by 
Smad3/Smad4 complexes, whereas activin responses would be mainly mediated by Smad2/Smad4 
complexes 139. 
Various TGF-β family members induce transcription of inhibitory Smads (I-Smads) 139, 140, 142. 
These Smads, Smad6 and Smad7, associate with type 1 receptors, but they lack the MH1 domain 
and the phosphorylation site (SXS motif) at their C-terminus, which in R-Smad is phosphorylated 
by type 1 receptors during signal transduction 139, 140. Thus I-Smads act as inhibitors of the Smad 
pathways. Whereas R-Smads and Smad4 are expressed in most if not all cells, the expression of the 
inhibitory Smads is strictly controlled by extracellular signals, which include TGF-β and BMP 143. 
Inhibitory Smad, Smad7, besides inhibiting canonical Smad activation induced by TGF-β, also 
functions as an adaptor protein that facilitates the activation of the non-canonical, non-Smad 
signaling pathways 144. Smad6 has been suggested to be specifically induced by BMP signaling and 
Smad7 by TGF-β and activin signals with similar regulatory distinction 145.        
Although the phosphorylation of the SXS motif in R-Smads is the key event in signal transduction, 
Smad signaling is also fine-tuned through post-translational modifications such as phosphorylation, 
ubiquitination, SUMOylation (Small-Ubiquitinrelated Modifier) and acetylation 146. Post-
translational modifications of the signaling components control their subcellular localization, 
activity and duration of the signal. Type 1 receptor phosphorylated R-Smad can be 
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dephosphorylated or ubiquitinated and targeted to degradation 146. R-Smads can also be 
phosphorylated to alternative locations (linker region) by MAPKs and cyclin-dependent kinases 
(CDKs) which can regulate Smad activity positively or negatively. Interestingly, linker region 
phosphorylation by MAPKs can have a dual role in the regulation of Smad2 and Smad3 in different 
contexts. Mitogens and hyperactive Ras stimulated ERK-mediated phosphorylation of Smad3 and 
Smad2 have been reported to inhibit the nuclear localization of both Smad2 and Smad3 in epithelial 
cells 147, whereas ERK dependent Smad2 phosphorylation was suggested to enhance Smad2 
transcriptional activity in COS7 and in mink lung epithelial cells 148. MAPK/ERK, p38 and JNK 
can phosphorylate Smad1, which leads to its cytoplasmic retention 149. Smad proteins are frequently 
inactivated in cancer 146.  
 
An additional layer of complexity is brought by the ability of TGF-β superfamily members to bind 
co-receptors which can regulate ligand/receptor activation, and pseudoreceptors, which lack the 
kinase domain and inhibit signaling by forming inactive complexes with type 2 receptors 123. 
BAMBI (BMP and Activin membrane bound inhibitor) is an example of a pseudoreceptor for TGF-
β, BMPs and activins 123, 150. TGF-β co-receptors betaglycan and endolgin can enhance ligand 
binding to the receptor complexes when they are membrane bound. However, when the cytoplasmic 
tail is cleaved, the co-receptor is released to the extracellular space and the soluble co-receptor 
sequesters the ligands, thus leading to negative regulation 123, 129. In addition, the access of the 
ligands of the TGF-β superfamily members to their receptors is controlled by numerous 
extracellular binding factors. Of these, extracellular regulators of the activins and BMPs will be 
discussed later.  
1.7.3 TGF-βs 
There are three isoforms of TGF-β, TGF-β1, TGF-β2 and TGF-β3, which are structurally and 
functionally very similar (reviewed in 151). The genes TGFB1, TGFB2 and TGFB3 are all located in 
different chromosomes, in the chromosomes 19, 1 and in 14 (http://www.ncbi.nlm.nih.gov/gene, 
accessed on 15.10.2014). Latent TGF-βs complexes are targeted to fibronectin and fibrillin 
containing fibers in the ECM 152, 153. In the three dimensional structure of TGF-β, two monomers 
are arranged in antiparallel manner and the bioactive dimer is established by a disulfide bond 142, 154.  
 
TGF-βs have various functions in normal physiology. In general, they modulate inflammatory cell 
function, inhibit cell growth, regulate differentiation and control extracellular matrix production 155. 
TGF-βs regulate also development, organogenesis and wound healing 151. Massive inflammatory 
response and early death in TGF-β1 null mice emphasizes the critical role of this growth factor in 
normal tissue homeostasis 156. However, the amount and activation of TGF-βs must be in delicate 
balance. Disturbances in this balance can result in a disease but may also be a result of a disease.       
Fibrillin rich microfibers enable temporal and spatial extracellular regulation of TGF-β and BMP 
signaling in a context specific manner (reviewed in 90). TGF-βs (TGF-β1, TGF-β2 and TGF-β3) are 
secreted as a small latent complex that contains the bioactive homodimer, which is non-covalently 
associated with its pro-peptide called small latency associated protein (LAP). This association 
blocks interaction with the receptors, but the small latent complex can associate covalently with 
latent TGF-β binding proteins (LTBPs) through specific interactions 153. LTPBs target TGF-βs to 
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fibronectin and fibrillin-1 and -2 containing ECM structures 152 where the growth factor can be 
activated by various mechanisms. LAP associated TGF-β1 can be cleaved by furin endoproteinase 
in the RXRR sequence 157, 158 while LAP remains associated with TGF-β dimer via non covalent 
interactions. This is referred as small latent TGF-β. In most cultured cells TGF-βs are secreted as 
large latent complexes (reviewed in 92). In large latent complex small latent TGF-βs are covalently 
associated with one of the four latent TGF-β binding proteins (LTBPs). LTBPs likely have a central 
role in the processing and secretion of TGF-βs.  
Activation of TGF-β can take place through various mechanisms. During activation the non -
covalent interactions between TGF-β and LAP need to be disrupted. In vitro activation can take 
place through proteolysis, enzymatic deglucosylation, acid treatment (reviewed in 92), by ROS 159 
and by plasmin 160. Young thrombospondin-1 null and TGF-β1 null mice exhibit many similarities 
in their phenotypes 161. Thrombospondin-1 can activate latent TGF-β in vivo, and this likely occurs 
through binding induced conformational change in LAP which enables TGF- β to bind its receptors 
161. Furthermore, human LTBP-1 and the LAP isoforms of TGF-β1 and 3 contain an integrin 
binding sequence arginine-glycine-aspartic acid (RGD) 155, 162 which has been shown to bind 
integrins α5β1, α5β5, α5β6 and α5β8 155, 163. Of these integrins αvβ6 155 and αvβ8 can activate the 
latent forms of TGF-β1 in in vivo mouse models. The mechanisms suggested by the in vitro studies 
are, however, different: activation by αvβ6 involves cell traction 155, whereas αvβ8 functions 
through proteolytic cleavage by membrane bound metalloproteinase 163. Activation of the growth 
factor on the cell surface offers means to spatially restricted activation 155. Also active TGF-β can 
bind to many ECM components 92. 
TGF-βs signal through type 2 TGF-β receptors (TβR2), and partnering with ALK5 (TβR1) leads to 
activation of Smad2 and Smad3 139. TβR2 can, however, also partner with ALK1 and activate 
Smad1 and Smad5. In addition to Smad mediated transcription, TGF-βs can activate also other 
signaling cascades, including MAPK/ERK, JNK and p38 139, 144. Part of these pathways can regulate 
Smad activation as described for ERKs above but others can also induce responses unrelated to 
transcription. The mechanism of TGF-β induced ERK activation has been suggested to rely on the 
dual specificity of the receptors acting as serine/threonine kinases but also as tyrosine kinases 144. 
Phosphorylated tyrosine residues can recruit adaptor proteins that facilitate ERK activation. PI3K 
and mTOR are other non-canonical pathways activated by TGF-β and which have been linked to 
TGF-β induced EMT.      
1.7.3.1 TGF-βs in pathological conditions 
Especially TGF-β1 is implicated in EMT and in fibrotic and malignant diseases. This is at least 
partially due to its capacity to upregulate the production of ECM components and suppress the 
immune system 153, 164. Whereas immunostaning of TGF-βs is present but low in normal lung, all 
TGF-β isoforms are found abundantly expressed in the tissue samples of patients suffering from 
asbestosis 165. TGF-βs localize into the extracellular matrix in fibrotic areas. Immunoreactivity was 
reported to increase as the fibrosis progressed. Due to mutation in the fibrillin-1 gene and 
impairment of the extracellular sequestering of latent TGF-βs, the extracellular TGF-β protein and 
serum TGF-β levels are significantly elevated in patients with Marfan syndrome 98. Elevated levels 
of TGF-β are also found in the lung tissues of IPF patients 119, 166. LTBP-1 is also overexpressed and 
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associates with fibrillin fibers and fibronectin in IPF lungs 167. Some TGF-β1 polymorphisms have 
been reported to be associated with increased risk of asbestos induced fibrosis with simultaneous 
decreased risk to lung cancer 168. This appears controversial with the established view that lung 
fibrosis increases the risk for lung cancer 6, 11, 12 (and 1.2).  In asthmatic patients serum, TGF-β1 
levels are elevated irrespective of the disease severity and glucocorticoid treatment 169.      
 
TGF-β overexpression is a general phenomenon in cancer cells and suggests poor prognosis 151. 
TGF-β inhibits the growth of benign cells. During cancer progression, cancer cells lose 
responsiveness to the growth inhibitory signals of TGF-β and become susceptible to TGF-β induced 
EMT 142. One proposed model to explain this paradox suggests that TGF-β induces differential 
ERK activation in benign and cancer cells through differential recruitment of the tumor suppressor 
PP2A-B56α (subunit B56α of protein phosphatase2A) 151. This model suggests that the initial 
triggering factor would be downregulation of type 1 TGF-β receptor TBR1 (ALK5) in early 
carcinogenesis, which would also lead to attenuation of Smad2/3 responses and increase the 
activation of the MAPK/ERK pathway. Activated ERK is a key regulator of cell proliferation as 
discussed above (1.6.2). Hyperactive Ras induced ERK activation and subsequent phosphorylation 
of Smad2/3 linker region by MAPK/ERK, which leads to decreased nuclear translocation of the 
Smads, has also been suggested as one mechanism by which TGF-β induced growth inhibition 
could be overcome in Ras mutated cancers 147.        
Due to the diverse regulatory functions that TGF-βs have in normal physiology, the contribution of 
TGF-βs in cancer progression is likely more complex than merely the impact on cell proliferation. 
As a potent inducer of EMT (see 1.3), TGF-β also contributes to migration and invasion of the 
cancer cells, but TGF-β is also an important regulator of apoptosis. The mechanisms through which 
TGF-β induces apoptosis are complex, differ between the cells, can be Smad-dependent or 
independent, and often involve specific transcription factors, such as p53 (reviewed in 142). As 
mentioned, I-Smads are transcriptionally regulated by the TGF-β family members, including TGF-
β, and induced by Smad signaling 142 (and 1.7.2). Smad7 is essential to TGF-β induced apoptosis in 
human prostate cancer cell lines, human keratinocytes, human embryonic kidney (HEK) cells and in 
apoptosis of hepatocellular carcinoma cancer cells 170-173, as well as in the mouse model 173. The 
transmitting signaling cascades appear to differ although apoptosis depends on Smad7. Different 
pathways in Smad7 dependent apoptosis include TGF-β induced p38 activation with subsequent 
p53 or β-catenin activation 170-172 and suppression of TGF-β and NF-kB activity by Smad7 173. In 
many occasions, TGF-β induced Smad7 appears to function as a common scaffold for recruited 
apoptosis inducing factors.   
1.7.3.2 TGF-βs in mesothelioma 
TGF-β1 and TGF-β2 are overexpressed in human mesothelioma 164, 165, 174. The levels of 
phosphorylated Smad2, which indicate TGF-β activity, have been found to be elevated in human 
mesothelioma tumors 164. Activated Smads localize into the nucleus and were found mainly in the 
tumor and associated with worse survival. It has been suggested that TGF-β1 localizes 
predominantly into the stroma and TGF-β2 more into the mesothelioma cells 165. TGF-βs can 
promote tumor growth and invasion through regulation of immune functions and angiogenesis, as 
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well as production of stromal components. In a murine model soluble TGF-β receptor combined 
with treatment with monoclonal antibodies targeted to regulatory T-cells and cytotoxic T-
lymphocytes were effective in clearing the tumors 175. Inhibitor of TGF-β receptor ALK5 was found 
to efficiently inhibit growth of the tumors and their reoccurrence after surgical resection in another 
murine model of mesothelioma 176. Various clinical trials targeting TGF-β pathway in numerous 
different cancers are ongoing (reviewed in 140).  A clinical trial for monoclonal antibody targeted to 
TGF-β in relapsed pleural mesothelioma has been completed 2012, but no publications of the 
outcome is yet available. (http://clinicaltrials.gov/ct2/show/NCT01112293?term=TGF-
beta+mesothelioma&rank=1, accessed on 1.9.2014). A study on a TGF-β blocking antibody on a 
small patient group (n=13) has been reported 177. The treatment was well tolerated, but 
unfortunately not very efficient. 
1.7.4 Activins 
Activins consist of two β-subunits, which they share with the inhibins 178. The activin β-subunits are 
coded by the genes INHBA and INHBB, and these β-units form homodimers to generate activin-A 
(two activin-A β-units) or activin-B (two activin-B β-units). Activin-A and –B β-subunits share 
only 65% sequence homology 179. Formation of a heterodimer, activin-AB, has also been reported, 
and this activin would have binding and signaling capacities of both activins. Other activin β-units, 
βC, βD and βE, have been found, but their biological roles are not very well known 180, 181. Activin-
C and heterodimers activin-AC and -BC have been detected at least in vitro and have been 
suggested to form non-signal transducing receptor complexes and to inhibit or regulate activin 
signaling by competing for the receptors 182. Activin Eβ subunit appears to be liver specific 183. Like 
the other members of the TGF-β superfamily, activins are homodimers linked with intramolecular 
disulphide bonds that form the cysteine knot motif 124. Following the characteristics of the 
superfamily, activins are synthesized as disulfide linked dimers, which are processed from the 
mature cytokine by proteolysis or acid hydrolysis 126, 180, 184. However, unlike many members of the 
TGF-β superfamily, the activin propepitide sequence has relatively low affinity for the mature 
dimer and does not interfere with receptor binding 185.    
Inhibins antagonize activins by forming a stable inactive complex with the type 2 activin receptors 
(ActR2A and ActR2B) 181, 186. This interaction requires betaglycan for sufficient affinity, but when 
the complex is formed it efficiently sequesters the type 2 receptors and excludes the type 1 
receptors. As mentioned earlier (1.7.2) betaglycan participates also in the regulation of TGF-β- 
signals 129. Inhibins form when the activin-A and activin-B β-subunits form a heterodimer with an 
α-subunit (INHA), generating inhibin-A (activin-A β-unit+ α-subunit) or inhibin-B (activin-B β-
unit+ α-subunit).  Inhibins resemble TGF-β superfamily members structurally 181. The INHA and 
INHBB genes are both located in the chromosome 2, whereas INHBA is located in chromosome 7 
(http://www.ncbi.nlm.nih.gov/gene, accessed on 1.9.2014). 
Activins and inhibins were originally discovered because of their ability to stimulate and inhibit the 
secretion of the follicle stimulating hormone (FSH) from the pituitary 186, 187. Activins-A and-B are 
expressed in most, if not all, tissues but especially in the female and male reproductive tracks under 
normal conditions 180. In addition to their role in the reproductive track, activins are now recognized 
as multifunctional regulators of inflammation, immunity, hematopoiesis and angiogenesis 180, 186. 
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Activins regulate differentiation and proliferation of various cell types and are central in the control 
of wound healing 180, 186, 188. Mouse knockout experiments have demonstrated that although 
activins-A and –B do have some overlapping functions, they do have distinct physiological roles 
and cannot replace each other 189.  
Activin-A gene expression is stimulated by various pro-inflammatory and immunoregulatory 
pathways, such as TNF-α, IL-1 and MAPKs 180, 190. The INHBA promoter contains one or more 
binding sites for the stress/inflammatory transcription factor, AP-1 191, 192. The INHBB promoter 
also contains similar binding sites suggesting similarities in the regulation 192.  In vitro TGF-β1 can 
induce activin-A expression and reciprocally activin-A can stimulate the expression of TGF-β, but 
in lesser extent 169. 
Activin action starts when activins bind their type 2 receptors ActR2A (ACVR2A) or ActR2B 
(ACVR2B) 193. ALK4 (ActR1B) is the major type 1 receptor for activins through which they 
activate Smad2 and Smad3 130, 194 . However, activin-B has been reported to activate these Smads 
also through ALK7 (ActR1C) 195, 196 and Smad1/5/8 through ALK3 (BMPR1A) 197. Similar to TGF-
β, activins also activate MAP kinases. Activin-A has been reported to induce phosphorylation, i.e., 
activation of MAPK/ERK and p38 198. Activin-B induced activation of SAPK/JNK and 
MAPK/ERK are strongly linked to cell migration and wound healing 199-201. 
Follistatin (FST) and follistatin like-3 (FSTL-3) bind activins with high affinity 202 and this binding 
renders activins unable to bind their receptors 203. Different sized splice variants are produced from 
a single follistatin gene (FST) 181, 203. The most common splice variants of follistatin are (FS)-315 
and FS-288, which undergo further multiple levels of modifications, including proteolytic 
processing and glycosylation 203. Follistatin does not structurally relate to the TGF-β superfamily 
181. FST binds and antagonizes activins but also myostatin and some BMPs 202. FST does not bind 
TGF-β or block its effects (reviewed in 180). FSTL-3 resembles FST and acts as an inhibitory 
binding protein for activins and BMP-2 203.  
1.7.4.1 Activins in pathological conditions 
Aberrant activin activity is implicated in tissue fibrosis. Compared to normal lung, where activin-A 
expression is relatively low and localized in the bronchiolar epithelium, strong immuostaning of 
activin-A is found in the tissue samples of patients suffering from lung fibrosis 204. Activin-A is 
found in alveolar macrophages, in fibrotic lesions and in hyperplastic smooth muscle cells. Activin-
A can stimulate fibroblast proliferation 205, 206 and induce differentiation of lung and renal 
fibroblasts to myofibroblasts 206, 207 in vitro. Activin expression is stimulated in vitro by various 
inflammatory cytokines, such as TNF-α and IL-1 190. This together with reciprocal co-operation 
with TGF- β 169 implies that activin-A and possibly also –B have important roles in the progression 
of fibrotic diseases. In asthmatic patients with mild asthma and no anti-inflammatory medication, 
serum activin-A levels are elevated, whereas this is not the case in patents on anti-inflammatory 
glucocorticoid medication 169. 
 
Activins can be tumor suppressive or tumor promoting depending on the tumor and tissue type 181 . 
Activin-A has been reported frequently to have a tumor suppressive role in breast and liver cancer 
183, 208. In vitro activin-A inhibits growth and induces apoptosis in low grade prostate cancer cell 
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lines, whereas high grade metastatic prostate cancer cell lines are insensitive to these effects 209. 
However, in thoracic cancers activin-A is frequently overexpressed in tumor samples and associated 
with poor outcome 210, 211. Activins can contribute to cancer progression also indirectly by 
modifying the tumor microenvironment through their regulatory action on inflammatory and 
immune responses and by regulating angiogenesis 188. 
1.7.4.2 Activins in mesothelioma 
Activin-A is highly overexpressed in human mesothelioma tumors 212. In vitro data suggest that 
activin-A stimulates mesothelioma cell migration and growth via cyclin D. 
1.7.5 Bone morphogenetic proteins   
Human BMP genes (BMP2, BMP3, BMP4, BMP5, BMP6, BMP6, BMP7 and BMP10) are scattered 
in different chromosomes in the human genome (http://www.ncbi.nlm.nih.gov/gene, accessed on 
1.9.2014). Similar to the other members of the TGF-β superfamily, the C-terminal disulfide linked 
bioactive dimer of BMPs remains non-covalently associated with its N-terminal prodomain 94, 127.  
These prodomains (pds) target the BMPs to the microfibrils in the ECM.  BMP prodomains, 
however, do not likely confer latency to the associated dimers 94. Quite little is known about the 
activation of BMPs and the role of the prodomains during BMP activation. BMP-2, -4, -7 and -10 
bind to the N-terminal end of both fibrillin-1 and fibrillin-2 99. In addition, fibrillins also have 
alternative binding sites for different BMPs and other growth factors with weaker affinity than the 
N-terminal universal binding site. The extracellular regulation of BMP bioavailability is less well 
understood, but it is known to differ from the extracellular regulation of TGF-β signaling 90. Unlike 
TGF-βs, BMPs can be directly targeted to the microfibrils through non-covalent interactions 
between their prodomains and the fibrillins. The type 2 receptors can compete for the binding site 
and displace the prodomain 94.  
 
BMPs, despite the name, actually differ significantly in their ability to induce bone formation 213. 
Different BMPs have various unique functions during development and are expressed in tightly 
regulated temporal and spatial manner. Mouse knockout studies have shown that knockout of BMP-
2, -4 or -7 is lethal due to severe defects in the development of the heart, limb patterning and 
kidney, respectively (reviewed in 213). Also neural and cartilage development depends on BMPs 214. 
In addition to their indispensable role in embryonic development, BMPs and the signaling cascades 
they generate are central in maintaining homeostasis and proper functionality in the tissues of adult 
organisms 215. BMPs also play an important role in bone formation in adult organisms 214. 
BMPs can signal through ActR2A/B+ALK3 as well as ActR2A/B+ALK6 and activate Smad1/5/8 
137, 139, 193. BMPs activate Smad1/5/8 also when BMP-R2 combines with ALK3, ALK2 or ALK6. 
Anti-Müllerian hormone type 2 receptor partners with ALK3, ALK2 and ALK6 and induces 
Smad1/5/8 activation 139. In development, anti-Müllerian hormone mediates EMT in coleomic 
epithelium (the epithelium lining the surfaces of body wall and abdominal organs) during Müllerian 
duct regression 56. As mentioned (1.7.2) BMPs have higher affinity to type 1 receptors than type 2 
receptors and can therefore bind first the type 1 receptor. There are also differences between 
affinities of distinct BMPs to different receptors 137.  
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In addition to the canonical Smad1/5/8 response, BMPR2 has been reported to bind and regulate 
LIM kinase 1 (LIMK1), a downstream effector of GTPase Rho, in a Smad independent manner 216. 
Binding and activation of JNKs by BMPR2 has also been reported 217. In addition, BMP type 1 and 
type 2 receptors can form complexes with TGF-β-activated kinase 1 (TAK1) via binding partner 
TAB1, which eventually leads to Smad independent activation of p38/MAPK 213, 218. Interestingly, 
TAK-1 mediated p38 and MAPK/JNK activation is also implicated in TGF-β induced growth 
arrest, apoptosis and EMT 219, 220. Furthermore, activated ALK3 (BMPR1A) complexes can initiate 
downstream signaling also through MAPK/ERK, p38 and JNK as well as NF-κB, although the 
mechanisms are not yet known 150.    
As mentioned earlier (1.7.4), inhibins sequester type 2 activin receptors with betaglycan 186. 
Considering that, in addition to BMPR2, BMPs can bind and signal through ActR2A and ActR2B, 
there is a possibility that inhibins contribute to the regulation of the BMP-cascades as well as the 
activin cascades. BMP and BMP-R1 binding with ActR2A/ActR2B induces Smad1/5/8 activation, 
whereas activin-A or -B and activin type 1 receptor (ALK4 or ALK7) will induce activation of 
Smad2/3. This emphasizes the diversity of the system and, that the type I receptor specifies the 
Smad signal 130.  
The receptor binding and activities of the BMPs are regulated by numerous extracellular regulators 
123. These binding factors include noggin, chordin and twisted gastrulation (TSG) as well as DAN 
(differential screening selected gene aberrative in neuroblastoma) family members NBL1 (Dan), 
cerbus 1 and gremlin-1 and -2. 
1.7.5.1 BMPs in pathological conditions 
In agreement with the drastic developmental defects, caused by BMP knockout, abnormal BMP 
signaling activity has been associated with several pathological conditions. Aberrant BMP signaling 
activity can result from overproduction and/or activity of BMP antagonists, or from mutation of the 
components in the BMP signaling pathway. In agreement with its role in bone development, BMP-2 
has also been implicated in osteoporosis and in osteoarthritis 215. 
Mutations in the BMPR2 gene are frequently found in patients with familiar pulmonary 
hypertension 221. Mutations in BMPR1A and SMAD4 genes are linked to hereditary juvenile 
polyposis syndrome which increases the risk of colon cancer 222.  
BMP cascades are strongly implicated in fibrotic diseases. Upregulation of TGF-β and 
downregulation of BMP expression and signaling is strongly implicated in chronic renal diseases, 
including fibrosis 223 and in liver fibrosis 224. BMP-4 signaling is severely impaired in the lungs of 
IPF patients due to the overexpression of BMP antagonist gremlin 225. In a mouse model, asbestos 
induced lung fibrosis is reduced by BMP-7 treatment 226. Considering this evidence, a drug that 
could restore the balance between TGF-β and BMP signaling pathways would have a therapeutic 
potential 227.         
BMP-7 and BMP-4 are frequently overexpressed in human cancer samples 228, 229. In vitro data 
suggests that, for instance in breast cancer cells, BMPs have a complex role in the regulation of 
proliferation, migration and invasion 228, 230. It has been reported that BMP-2 serum levels are 
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elevated in non-small-cell lung cancer (NSCLC) patients, and BMP-2 levels are more elevated in 
the patients with more progressed disease and correlated with poor prognosis 231. Whereas BMP-2 
is only moderately expressed in normal lung, it is strongly overexpressed in NSCLC patient tumor 
samples and localizes specifically in the cancer cells 232. In vitro data and mouse experiments have 
suggested that BMP-2 functions in a cancer promoting manner in NSCLC. Clearly, different BMPs 
have distinct functions in different cancer types.  The role of the BMPs in cancer is likely 
complicated and ligand and context dependent. In pathological context, BMPs have been linked to 
both EMT and MET 56. Not surprisingly, increased cancer risk is one of the reported serious side 
effects of clinically approved and applied human recombinant BMPs-2 and -7 149.        
1.7.5.2 BMPs in mesothelioma 
The data on BMPs in malignant mesothelioma are very restricted. The genes BMP6 and BMP3b 
have been found to be silenced by promoter methylation in mesothelioma tumor samples 233. The 
BMP inhibitor gremlin-1 is overexpressed in mesothelioma 234. 
 
 
 
 
 
Figure 3. Schematic presentation of the structure of the TGF-β superfamily members. TGF-βs, BMPs and 
activins are synthetized as precursor proteins with a N-terminal prodomain and a C-terminal mature active 
disulfide bond linked ligand dimer. The propepide is cleaved by furin or other proprotein convertase (PC) 
endopeptidases. After this, LAP in TGF-β and prodomains (pds) in BMPs and activin-A remain non-
covalently associated with the active peptide. LAP renders latency in small latent complex of TGF-β.  This is 
likely not the case in BMPs and activin-A. TGF- β is targeted to ECM fibronectin and fibrillin microfibrils via 
association with latent TGF- β binding proteins (LTBPs). BMPs are targeted to microfibrills through their 
prodomains, whereas activins remain soluble. Adapted from 92, 94, 126, 127, 157, 158, 185, 235, 236. 
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1.8 Inhibitors of bone morphogenetic proteins  
Of the plethora of BMP binding regulators, many share the cysteine–knots of the TGF-β 
superfamily 123. These extracellular regulators bind and sequester ligands and have an indispensable 
role in the control of BMP signals by restricting their access to the receptors.   
1.8.1 Introduction to the BMP antagonists   
Although the BMP expression levels are strictly regulated, the bioavailability is the integral way of 
controlling BMP action 150. The bioavailability is controlled by targeting the mature BMPs to the 
ECM structures, as discussed earlier (1.7.5) and by extracellular regulators that bind distinct BMPs 
with different affinities. Over 15 BMP antagonists are currently known, and they are classified into 
three subgroups according to the size of the cysteine-knot. The DAN family has an eight-membered 
ring in the knot, and it includes Dan (NO3/Nbl1, neuroblastoma suppression of tumorigenesity1), 
gremlin-1 (DRM, downregulated by v-mos / IHG-2, induced in high glucose-2), gremlin-2 (PRDC, 
protein related to Dan and cerberus), cerberus (Cer1), coco (Dan5), USAG-1 (uterine sensitization-
associated gene-1/ Sostdc1, sclerostin domain containing 1), sclerostin and some others. Twisted 
gastrulation (Tsg) has a nine-membered ring, and the chordin family, noggin, FST and FSTL3 ten-
membered rings. These antagonists are a disparate group. They vary in size, sequence and the way 
they interact with the BMPs. FST and FSTL3 were discussed above. Only Gremlin-1 from the 
DAN-family will be discussed here in more detail.         
1.8.2 Gremlin-1      
Gremlin-1 (DRM) was initially found as a novel gene downregulated in mos-transformed cells and 
suggested to play a role in cell growth control or viability, and tissue specific differentiation 237. 
Gremlin gene GREM1 is located in chromosome 15 in human (http://www.ncbi.nlm.nih.gov/gene, 
accessed on 1.9.2014). Gremlin-1 was predicted to have a molecular weight of 20.682, potential 
nuclear localization signals near the C-terminus, potential N-linked glycosylation sites, and multiple 
potential sites for phosphorylation 237. Gremlin is a secreted glycosylated and phosphorylated 
protein 238. 
Gremlin-1 acts as a homodimer and binds and inhibits BMPs-2, -4 and -7 238, 239, which are all 
osteogenic BMPs, meaning they can all initiate bone formation 149. Gremlin-1 exerts its most 
important functions during development; gremlin-1 mediated BMP antagonism regulates limb, 
kidney and lung development 221, 240, 241. Gremlin-1 null mice often die before birth due to lung 
septation defects and lack of kidneys 240. In addition to lung, kidney and limb development, 
gremlin-1 is also central in skeletal development, as well as in postnatal skeletal homeostasis 242.   
Gremlin-1 expression in majority of adult tissues is low, but moderate expression levels have been 
reported in some healthy adult tissues such as kidneys, skin and bone marrow suggesting a specific 
function also in adult tissues 243. Analysis of human samples and in vitro data suggests that gremlin-
1 can support the stem cell niche in human intestinal epithelial cells and in human hepatocellular 
carcinoma 244, 245. TGF-β can induce gremlin-1 expression in vitro 225, 246, and in serial sections of 
biopsies in patients with chronic allograft nephropathy gremlin-1 and TGF-β mRNAs have been 
found co-expressed, suggesting that this is also the case in vivo 247. 
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1.8.3 Gremlin-1 in pathological conditions  
Emerging evidence links gremlin-1 to fibrosis and more specifically to fibrosis related EMT. 
Gremlin-1 has been reported to be downstream mediator of TGF-β1 induced EMT in human tubular 
epithelial cells 248, 249 and gremlin-1 has been suggested to function in a similar manner in patients 
with chronic allograft nephropathy 247. In this study, gremlin-1 expression localized in the areas of 
interstitial fibrosis and expression correlated with tubulointerstitial fibrosis. In vitro data by 
Rodrigues-Diez (2014) 249 suggests positive feedback-loop: gremlin-1 was reported to act as a 
downstream mediator of TGF-β1 but, intriguingly, silencing gremlin-1 was reported to inhibit TGF-
β1-mediated matrix production and EMT in cultured human tubular epithelial cells. Furthermore, 
gremlin-1 was reported to activate Smad3 and increase nuclear localization of both Smad3 and 
Smad2 together with Smad4 directly and independently of TGF-β 249. Gremlin-1 induced EMT also 
in retinal pigment epithelial cells 250. In addition, gremlin-1 overexpressing lung carcinoma (A549) 
cells downregulate E-cadherin and exhibit increased migration and invasion 251.  
Gremlin-1 is highly expressed in the IPF lungs, upregulated in mouse hypoxic lungs and plays a 
central role in lung fibrosis as well as in the pathophysiology of pulmonary hypertension 221, 225, 226 . 
In non-ischemic heart failure, gremlin-1 expression correlates with the degree of myocardial 
fibrosis and is a predictor of adverse outcome 252.   
Gremlin-1 is frequently found expressed by the stromal cells in the microenvironment of human 
carcinomas 253. However, in sarcoma and in lung, colon, cervical and pancreatic cancer, as well as 
in carcinomas of ovary, kidney and breast, gremlin-1 has been found highly expressed and localized 
into the tumor tissue 254. Gremlin-1 has been reported to co-operate with other BMP inhibitors, 
including FST, in human colorectal cancer and to promote cancer progression in invasive fronts 255. 
It is likely that gremlin-1 has an oncogenic role in thoracic malignancies as it is overexpressed in 
lung adenocarcinoma and in malignant mesothelioma 234, 256. In contrast, in pancreatic 
neuroendocrine tumors gremlin-1 has been suggested to have a tumor suppressive role 257. In report 
from Chen (2002)258, gremlin-1 inhibited neoplastic transformation through transcriptional 
activation of the cell cycle inhibitor p21Cip1 and by reducing activated levels of MAPK/ERK1/2. 
Although gremlin-1 was originally suggested to have a tumor suppressive role 237, it is nowadays 
more frequently reported to be tumor promoting. It appears that the function of gremlin-1 in 
carcinogenesis is complex and context dependent; it differs between the tissue, cell and cancer type. 
Gremlin-1 interacts with the YWHAH (14-3-3η) protein 254. YWHAH belongs to the family of 
conserved 14-3-3 proteins with a multitude of binding properties and which are crucial in variety of 
cellular processes such as cell cycle progression, the control of the DNA damage check point and 
apoptosis 254, 259. However, no report on the function of the interaction of YWHAH with gremlin-1 
is yet available. Gremlin-1 may contribute to cancer progression also through BMP independent 
mechanisms 251, 256. Gremlin-1 can bind to VEGFR2 (vascular endothelial growth factor receptor 2) 
in a BMP independent manner and induce angiogenesis in vivo 260. Gremlin-1 may also modulate 
inflammatory cell responses by inhibiting monocyte migration through interaction with cell surface 
slit proteins 261.  
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Figure 4. Signaling cascades of some of the TGF-β superfamily members. Ligand binding recruits type 2 and 
type 1 receptors. Type 1 receptor specifies the receptor-Smad (R-Smad) identity. All receptor Smads share 
the same common-partner Smad (co-Smad, Smad4). The canonical Smad- signaling pathways as well as 
non-canonical non-Smad pathways induced by TGF-βs are presented with light gray arrows. In addition to 
ALK5 mediated Smad2/3 and ALK1 mediated Smad1/5 responses, TGF-βs can activate MAPkinases ERK, 
JNK and p38. The canonical as well as non-canonical pathways induced by activin-A are represented with 
black arrows. In addition to ALK4 mediated Smad2/3 activation, activin-A can activate MAPkinases ERK and 
p38. Activin-B induced pathways are shown with white arrows. Activin-B can induce the same ALK4 
mediated Smad2/3 cascade as activin-A but, in addition, activin-B can induce Smad2/3 through ALK7 and 
Smad1/5/8 through ALK3. Activin-B can also activate MAPkinases ERK and JNK. BMPs-2, -4 and -7 
induced pathways are shown with dark grey arrows. BMPs can recruit first the type 1 receptors. The BMPs 
activate Smad1/5/8 through ALK3, ALK2 and ALK6. In addition, BMPs can activate MAPkinases ERK, JNK 
and p38 and NF-κB pathways.  Inhibitory binding is shown with red bars. Follistatin (FST) binds and inhibits 
activin-A and –B and BMPs. Follistatin like 3 (FSTL3) binds and inhibits activin-A and –B and BMP-2. 
Gremlin-1 binds and inhibits BMPs-2, -4 and -7. Inhibin-A and inhibin-B bind activin type 2 receptors (ACVRA 
and ACVR2B) and prevent activins and BMPs from recruiting them to active receptor complexes. Adapted 
and modified from 139, 150, 193.  
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2. Aims of the study  
The main aim of this study was to extend the understanding of molecular mechanisms of asbestos 
exposure related diseases.  In the first study, we set out to find out pathways and mechanisms 
through which asbestos induces cancer and fibrosis in lung epithelial cells. Because EMT is 
implicated in both fibrosis and cancer, we tested whether asbestos fibers were able to induce EMT 
in vitro. In the next two studies we focused on mesothelioma. Mesothelioma is characterized by 
resistance to chemotherapy and local invasion, and it lacks efficient treatment. In these last two 
studies, we aimed to specify novel potential therapeutic target molecules and pathways from the 
TGF-β superfamily members and their extracellular regulators. In more detail, we aimed to 
characterize the role of these molecules as well as implicated intracellular signaling cascades in 
mesothelioma cell chemoresistance, migration and invasion. The specific aims of this study were: 
1. To investigate the ability of asbestos to induce EMT  
2. To find novel gremlin-1 interacting proteins and to characterize the function of gremlin-1 in 
mesothelioma tumors  
3. To characterize how gremlin-1 contributes to mesothelioma progression  
4. To investigate the expression and function of activin-A and activin-B in mesothelioma 
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3. Materials and methods  
3.1 Cell lines and human primary cells  
Human primary mesothelioma cells were harvested from pleural effusion samples of mesothelioma 
patients. Cells were centrifuged, washed and seeded on plastic culture dishes. At the early stages of 
primary mesothelioma (JP) cell cultures serum level was 20%. BEAS-2B cells were maintained in 
LHC-9 medium (Invitrogen). Primary human lung bronchial epithelial cells (NHBE) were 
maintained in BEGM (Bronchial Epithelial Cell Growth Medium) and small airway epithelial cells 
(SAEC) in SAGM (Small Airway Epithelial Cell Growth Medium) according to the manufactures 
(Lonza) instructions. The other cells and cell lines were maintained as follows: A549 in minimum 
essential medium (MEM), Met5A, H2052, 211H, H28, H2452 cells and primary mesothelioma cells 
in Roswell Park Memorial Institute medium (RPMI) supplemented with 10% (v/v) fetal bovine 
serum and 100 units/ml penicillin, 100 μg/ml Streptomycin and 2mM L-glutamine (Gibco). 
Table 1. Primary cells 
Primary cells Description  Source  Used in study 
SAEC human small airway epithelial cells Lonza   I 
NHBE human bronchial epithelial cells Lonza   I 
JP1 human mesothelioma cells pleural effusion II, III 
JP3 human mesothelioma cells pleural effusion II, III 
JP4 human mesothelioma cells pleural effusion II, III 
JP5 human mesothelioma cells pleural effusion II, III 
 
Table 2. Immortalized cells or cancer cell lines 
Cell line Description  Reference Used in study 
A549 human lung carcinoma cells ATCC, CCL-185   I 
BEAS-2B immortalized human bronchial epithelial cells ATCC, CRL-9609   I 
Met5A immortalized human mesothelial cells Ke (1989) 272 II, III 
211H biphasic human mesothelioma cell line ATCC, CRL-2081 II, III 
H2452 human mesothelioma cell line ATCC, CRL-5946 II, III 
H2052 human mesothelioma cell line ATCC, CRL-5915 II, III 
H28 human mesothelioma cell line ATCC, CRL-5820 II, III 
 
3.2 Three dimensional cultures 
3.2.1 Lung epithelial cells (I)  
Three dimensional (3D) cultures of lung epithelial cells (A549 and SAEC) were generated using 
Matrigel basement membrane matrix (BD Bioscience). Ice cold Matrigel was laid to chambered 
cover glasses (Nunc) on ice and allowed to solidify at 37°C. The cells were seeded on top of the 
Matrigel. Normal complete culture medium was used on the 3D cultures to produce the polarized 
structures. New medium was added every 2-3 days. Asbestos and TGF-β1 treatments were started 
on 3-7 days old cultures and continued for one week. 3D cultures in Matrigel were fixed with 4% 
paraformaldehyde/PBS for overnight at room temperature. After fixation the 
paraformaldehyde/PBS was removed and the gels were embedded in paraffin and cut into 4 μm 
sections.  
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3.2.2 Mesothelioma cells (III)   
In the invasive growth assay, two layers of Matrigel gel were used. The lower layer on 96-well plate 
was allowed to solidify at 37˚C for 45 minutes. Next, cells were seeded. The cells were allowed to 
attach for 1 hour after which the media was carefully removed and replaced with the top gel. The 
cells were pre-treated with sActR2B-Fc, sAMHR2-Fc, DMSO or PD98059 for 15 minutes before 
seeding where indicated. The top gel was added and allowed to solidify for 30 minutes after which 
media was added on top of the culture. Inhibitors were also added to the both layers of Matrigel and 
to the cell culture media on top of the gel. The cells were imaged 36 hours after seeding, and 
sprouting from the cell clusters indicated invasive growth. 
3.3 Reagents 
Table 3. Reagents and growth factors  
Name Description Used 
concentration 
Reference Used  
in study 
TNF-α tumor necrosis factor-α, 
human recombinant 
5 ng/ml R&D Systems   I 
TGF-β transforming growth 
factor-β, human 
recombinant 
0.5 and 2 ng/ml R&D Systems   I 
crocidolite 
asbestos 
amphibole asbestos 
fibers in PBS 
0.5, 1 and 5  
μg/ cm² 
Finnish Institute 
of Occupational 
Health 
  I 
SB431542 inhibitor of ALK5, 4 
and 7 
6 μM Sigma   I 
PD98059 inhibitor of MEK 30 μM Calbiochem   I, III 
SP600125 inhibitor of JNK 10 μM Calbiochem   I 
JSH-23 inhibitor of nuclear 
localization of NF-κB  
20 μM Calbiochem   I 
activin-A human recombinant 25 ng/ml R&D Systems   III 
activin-B human recombinant 25 ng/ml R&D Systems   III 
sActR2B-Fc recombinant Fc-fusion 
protein containing the 
ectodomain of human 
ActR2B. Sequesters 
ligands and inhibits 
their binding to cell 
surface receptors 
 200 or 650 ng/ml 
(2D) or 10 μg/ml 
(3D)  
Hulmi (2013) 262   III 
sAMHR2-Fc recombinant fusion 
protein containing the 
ectodomain of human 
AMHR2 
 200 or 650 ng/ml 
(2D) or 10 μg/ml 
(3D)  
Hulmi (2013) 262    III 
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Table 4. Antibodies   
List of the antibodies used in the study. IF, immunofluorescence; IHC, immunohistochemistry; IB, 
immunoblotting; PLA, in situ proximity ligation assay. 
Name Source Application Reference Used in study 
E-cadherin mouse IB, IF BD Transduction 
Laboratories 
  I 
α-SMA mouse monoclonal IB NeoMarkers   I 
α-SMA mouse/1A4 IB Sigma   II 
NF-κB 
(p65,RelA) 
rabbit polyclonal IF Calbiochem   I 
phospho-
Smad2 
rabbit polyclonal IB Professor Peter 
ten Dijke 
  I 
Smad2/3 mouse IB BD Transduction 
Laboratories 
  I 
phospho-
ERK1/2 
rabbit monoclonal 
/D1314.4E 
IB Cell Signaling    I, II, III 
total ERK mouse (3A7) IB Cell Signaling   I, II, III 
ZO-1 rabbit polyclonal IF BD Transduction 
Laboratories 
  I 
SP-D rabbit polyclonal IHC Santa Cruz   I 
β-tubulin rabbit polyclonal IB Santa Cruz   I,  II, III 
calretinin mouse/DAK-
Calret1 
IF, IHC DAKO   II 
cytokeratin-7 rabbit /EP16204 IF Novus Biological   II 
vimentin mouse/V9 IF, IB Santa Cruz   II 
N-cadherin mouse/32 IB BD Biosciences   II 
HA mouse/16B12 IB Covance   II 
fibrillin-1 mouse/2499 IF Millipore   II 
fibrillin-1 rabbit/ pAb9543 IHC, IF Professor Lynn 
Sakai  
  II 
fibrillin-2 mouse/48 IHC, PLA Millipore   II 
gremlin-1 rabbit pAb IHC Abcam   II 
gremlin-1 goat  pAb IHC, PLA Santa Cruz   II 
gremlin-1 rabbit pAb IF Santa Cruz   II 
Slug rabbit pAb IB, IHC Sigma   II 
WT1 mouse/WT49 IHC Novocastra    II 
phospho-AKT 
(S473) 
rabbit polyclonal IB Cell Signaling   II 
phospho-AKT 
(T308) 
rabbit polyclonal IB Cell Signaling   II 
total AKT rabbit polyclonal IB Cell Signaling   II 
V5 mouse monoclonal IB Invitrogen   II 
activin-A mouse monoclonal 
(18/26A) 
IHC, IB AnshLabs LLC   III 
48 
 
activin-B mouse monoclonal 
(12/9A) 
IHC AnshLabs LLC   III 
activin-B mouse monoclonal 
(46A/F) 
IB AnshLabs LLC   III 
FST mouse monoclonal 
4/73C 
IHC AnshLabs LLC   III 
FST mouse monoclonal 
4/208 
IB AnshLabs LLC   III 
                                         
3.4 Generation of IκB 32/36A expressing stable cell line (I) 
Retroviruses containing the vector pBabePuro (Addgene) and the construct pBabePuro IкB32/36A 
that express a dominant-negative mutant of IкB (kindly provided by Juha Klefström, University of 
Helsinki) were produced in 293GPG packaging cell line 263. The dominant negative function is 
described in Traenckner (1995) 102. The producer cells were transfected overnight using Fugene 
transfection reagent (Roche), followed by collection of cell conditioned medium, which was then 
used to transduce A549 cells. Puromycin (5 μg/ml) selection was started two days after 
transduction.  
3.5 Transient transfection and reporter assay (I, II, III) 
Table 5. Promoter and expression constructs 
Name Description Reference Used in study 
(CAGA)12???? Smad3 responsive  Prof. Peter ten Dijke   I, III 
ARE-luc  Smad2 responsive  Prof. Peter ten Dijke   I, III 
FAST-1 Smad2 required 
transcription factor 
Prof. Peter ten Dijke   I, III 
(Bre)2-luc Smad1/5 responsive  Prof. Peter ten Dijke   II, III 
pRL-TK Renilla luciferase 
control 
Promega   I, II, III 
 
3.5.1 Smad responsive promoters (I, II, III) 
The cells to be transfected were seeded in 6-well or 96-well plates.  The next day the cells were co-
transfected with a total of 2 μg of promoter constructs (1 well on 6 well plate or 40 wells on 96 well 
plate) (CAGA)12-luc (Smad3 responsive) or ARE-luc (Smad2 responsive) and Fast-1 or (Bre)2-luc 
(Smad1/5 responsive) together with pRL-TK plasmid using Fugene HD transfection reagent 
(Roche). The pRL-TK plasmid contains the Renilla luciferase gene under control of the 
constitutively expressed thymidine kinase promoter, and it was used in dual luciferase assays to 
normalize the transfection efficiency. The next day the stimulation by asbestos, TGF-β1 or activins 
was started in serum free media. After overnight stimulation the cells were lysed and subjected to 
luciferase activity measurements by Dual Luciferase Reporter Assay (Promega) and DCR-1 
luminometer (MGM Instruments Digene Diagnostics Inc.). 
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3.5.2 10-pathway Cancer reporter array (I) 
Dual luciferase based Cignal Finder 10-Pathway Cancer Reporter Array (SABioscience) was used 
according to manufacturer’s instructions. Briefly, the cells were transfected during plating on 24-
well plate using Fugene transfection reagent (Roche). The cells were allowed to recover overnight. 
The cells were lysed and subjected to luciferase activity measurements by Dual Luciferase Reporter 
Assay and DCR-1 luminometer. Unspesific reporter responses to TGF-β1 or asbestos were tested 
but none was observed. 
3.6 Analysis of the mesothelioma tumor tissue  
Table 6. Mesothelioma tumor tissues 
 
3.6.1 Immunohistochemical analysis (II, III) 
Paraffin-embedded tissues from mesothelioma tumor samples were cut into 2.5 μm sections, which 
were then deparaffinized in xylene and rehydrated in graded alcohol. Antigens were retrieved by 
heating in 10 mM citrate buffer (pH 6.0). For immunostaining, the Novolink Polymer Detection 
System (Novocastra, Leica Biosystems Newcastle Ltd.), Histostain Plus Broad Spectrum Kit 
(Zymed), or ImmPRESS reagent kit (Vector Laboratories,) was used according to the respective 
manufacturer’s protocol. The sections were incubated with the primary antibody at 4°C overnight. 
The bound antibodies were visualized by using peroxidase substrates 9-ethyl-3-aminocarbozole 
(AEC; Zymed) or 3-,3-diaminobenzidine (DAB; Leica). The sections were counterstained with 
Mayer’s hematoxylin and mounted on glass slides. Control sections were treated with isotype 
controls for mouse (Zymed), rabbit (Invitrogen), or goat (Jackson Immunoresearch Laboratories) to 
determine the specificity of the staining. For follistatin staining, the formalin-fixed, paraffin 
embedded specimens were stained according to the manufacturer’s staining protocol [with the Leica 
Bond Polymer Refine Detection-kit, Bond Epitope Retrievel Solution 2 for 20 mins, R.T.U. Normal 
Patient Type Location Age at 
diagnosis 
Gender Smoker Exposure Used in 
study 
JP1 epithelioid pleura 53 male yes yes   II, III 
JP2 biphasic pleura 71 male no no   II, III 
JP3 epithelioid pleura 63 male yes yes   II, III 
JP4 biphasic peritoneum 72 female ? ?   II, III 
JP5 epithelioid pleura 69 female yes no   II, III 
JP6 biphasic pleura 71 female no no   II, III 
JP7 epithelioid pleura 62 male yes yes   II, III 
JP8 epithelioid pleura 63 male yes ?   III 
JP9 epithelioid pleura 54 male yes yes   III 
JP10 epithelioid pleura 75 male no yes   III 
JP11 epithelioid pleura 65 male no yes   III 
JP12 epithelioid pleura 60 male yes yes   III 
NP1 normal 
pleura 
pleura 32 male yes no   II 
NP2 normal 
pleura 
pleura 34 male yes ?   II 
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Horse serum 2,5% (Vector Laboratories) blocking] on Leica BOND-MAX fully automated staining 
system. The sections were incubated with the primary antibodies at room temperature for 1 h. The 
bound antibodies were visualized by DAB (Vector Laboratories). The sections were counterstained 
with Mayer’s hematoxylin and mounted on glass slides. Images were captured with Nikon DS-Fi1 
or with Axio Imager with ApoTome (Zeiss, Göttingen, Germany) by using Axio Vison 4.8 software 
(Zeiss). From H&E and SP-D stained sections, images were captured with Olympus BX51 and 
Artray Artcam 300 MI. 
 
3.6.2 In situ proximity ligation assay (II)   
Gremlin-1 and fibrillin protein interactions were studied by proximity ligation assay (Olink 
Bioscience) 264. First, acetone-fixed frozen sections of mesothelioma tumor samples were incubated 
overnight with primary antibodies: anti-gremlin-1 antibody together with anti-fibrillin-2 antibody. 
Secondary antibodies (α-goat and α-mouse) conjugated with DNA probes which, when in close 
proximity, formed a closed circle with the added oligonucleotides and ligase enzyme. This closed 
circle was amplified by rolling-circle amplification reaction.  Fluorescently labeled oligonucleotides 
complementary to the circle were hybridized in the reaction, resulting in spot-like positive signals 
indicating that the two primary antibodies are bound in close proximity. Cell nuclei were visualized 
with 2,4-diamidino-2-phenylindole (DAPI). Images were captured with Axioplan 2 epifluorescence 
microscope (Zeiss) and AxioCam HRm 14-bit grayscale CCD camera Axiovision 4.6 software 
(Zeiss). 
3.7 RNA analysis 
3.7.1 RNA isolation and cDNA synthesis (I, II, III) 
Total cellular RNA was isolated using RNeasy Mini kit (Qiagen) and reverse transcribed to cDNA 
using Random hexamer primers (Invitrogen) and Superscript III reverse transcriptase (I) (Life 
Technologies) or iScript cDNA synthesis Kit (Bio-Rad) (II, III) according to manufacturer's 
instructions.     
3.7.2 Quantitative RT-PCR (I, II, III) 
The cDNAs were amplified using TaqMan Assays-on-Demand gene expression products (Applied 
Biosystems) and CFX96 real-time PCR detection system (BioRad). The levels of gene expression 
were determined using the ΔΔCt method, and the results have been expressed as mRNA expression 
levels normalized to the levels of a gene with a constant expression (TBP, TATA binding protein). 
3.7.3 siRNA transfection (II) 
The cells were seeded on a 6-well plate. The next day the cells were transfected with either gremlin-
1 siRNAs (gremlin-1 siRNA1, siRNA2 and siRNA3 (Ambion) or control siRNA (Ambion), for 6 
hours in the absence of antibiotics by using Lipofectamine 2000 transfection reagent (Invitrogen). 
The cells were collected from the 6-well plates three days after transfection and the RNA was 
extracted.  
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3.8 Protein analysis 
3.8.1 Immunofluorescence analysis (I, II) 
The cells were grown on glass coverslips and cultured for the indicated times. The cells were fixed 
with 4% paraformaldehyde/PBS at room temperature for 10-20 minutes or with methanol at -20°C 
for 15 minutes  or overnight. Nonspecific binding of the antibodies was prevented by blocking with 
5% BSA/PBS for 30 minutes. During blocking, 0.3% Triton X-100 was added when 
permeabilization of cells was needed. All antibody dilutions and washing steps were made in 
Dulbecco’s PBS containing 0.5% BSA. The cells on coverslips were incubated with the primary 
antibodies for 1-2 hours at room temperature and then washed. The bound primary antibodies were 
detected using AlexaFluor secondary antibodies (Molecular Probes). TRITC-conjugated phalloidin 
(Sigma) was used for the detection of F-actin (I). Finally, the coverslips were washed with water 
and mounted on glass slides with Vectashield mounting medium containing DAPI (Vector 
laboratories). Images were captured with Axioplan 2 epifluorescence microscope and Axio Cam 
HR camera using Axiovision 4.5 software (Zeiss) at the Biomedicum Imaging Unit of the 
University of Helsinki. 
Fixed 3D cultures in Matrigel were embedded in paraffin and cut into 4 μm sections. These sections 
were then deparaffinized in xylene and rehydrated in graded alcohol. Antigens were retrieved by 
heating in 10 mM citrate buffer (pH 6.0). The sections were blocked with 5% non-fat dry milk/PBS, 
which contained normal goat serum (Jackson Immuno Reseach) at room temperature for 30 minutes 
followed by incubation with primary antibodies diluted in blocking buffer at 4°C overnight. The 
sections were then incubated with AlexaFluor secondary antibodies at room temperature for 1 h, 
washed several times and mounted using Vectashield Hard Set mounting medium. The nuclei were 
visualized with DAPI. The images were captured as described above. Digital morphometry was 
conducted using Image Pro Plus 7.0 program.  
3.8.2 Cell conditioned media (III) 
Conditioned media from mesothelioma cell cultures were collected for two days, concentrated using 
Amicon Ultra 10K centrifugal filters (Millipore) and analyzed with SDS-PAGE and 
immunoblotting. 
3.8.3 SDS-PAGE and immunoblotting (Western blotting) (I, II, III) 
The cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1mM EDTA, 1% 
NP-40, 0.2% Na deoxycholate) containing protease and phosphatase inhibitors (Roche Diagnostics) 
for 15 minutes on ice. Protein concentrations were measured using a BCA Protein Assay Kit 
(Pierce). Equal amounts of protein were separated by SDS-PAGE using 4-20% gradient Tris-
glycine gels (Bio-Rad). Proteins were transferred to Protran nitrocellulose membranes (Whatman) 
by using a semi-dry blotting system (Bio-Rad). Membranes were first blocked with 5% non-fat dry 
milk in TBS/0.05% Tween-20 to prevent non-specific binding of the antibodies and incubated with 
the primary antibodies diluted in 5% BSA in TBS/0.05% Tween-20 at 4˚C overnight and then with 
biotin-conjugated secondary antibodies (DAKO) at room temperature for 1 h. After several washing 
steps, the final detection was performed using HRP-conjugated streptavidin and an enhanced 
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chemiluminescence Western blotting detection system (Amersham). Immunoblot band intensities 
were analyzed by the Scion Image (Scion Corporation) (I, II) and by ImageJ (III) software.  
3.8.4 Human phospho-kinase array (II) 
Control and gremlin-1 siRNA treated cells were lysed and alterations in phospho-kinase levels were 
analyzed using a Proteome profiler array (ARY003b, R&D Systems) according to manufacturer’s 
instructions. Quantity One version 4.6 (BioRad) was used for quantification. The kinase array was 
performed twice. 
3.9 Gremlin-1 interaction studies (II)  
3.9.1 Expression constructs and stable transfection  
C-terminally tagged whole length gremlin-1 construct was generated by Gateway-cloning the 
gremlin-1 construct from the Human Orfeome Collection (Thermo Scientific) to a pTO-SHc-GW-
FRT plasmid with c-terminal Strep-tag III and human influenza hemagglutinin (HA)-tag 265. Flip-In 
human embryonic kidney (HEK) 293 cells (Life Technologies) were grown as recommended. 
Stable transfection of cells was carried out as described by Glatter (2009) 266. After two weeks of 
culture, hygromycin B resistant clones were tested for tetracycline (Sigma) inducible gremlin-1 
expression 
3.9.2 Affinity purification  
Transfected Flip-In HEK293 cells were stimulated with tetracycline (25 ng/ml) to induce gremlin-1 
expression. After a 24-hour stimulation, cells were lysed in HNN-lysis buffer [50 mM HEPES pH 
8, 150 mM NaCl, 50 mM NaF, 1 mM PMSF, 1.5 mM Na-vanadate, 0.5% NP-40 and protease 
inhibitors (Sigma)] followed by double affinity purification 266. Briefly, cell lysates were passed 
through Strep-Tactin columns (IBA GmbH) followed by elution of bound proteins with 2.5 mM 
biotin. Next, the eluate was immunoprecipitated using anti-HA agarose (Sigma). Proteins were 
finally eluted using 0.2 M glycine and neutralized. 
3.9.3 Protein digestion  
Protein amount from the elution fractions was precipitated using trichloroacetic acid (TCA). First, 
TCA was added to the elution fractions to a final concentration of 25%, followed by incubation for 
30 minutes on ice. The precipitates were centrifuged, washed once with ice cold 0.1M HCl in 
acetone and once with acetone. The pellets were then allowed to dry. For trypsin digestion the 
precipitated proteins were dissolved in 50 mM ammonium bicarbonate, pH 8.9, containing 0.1% 
Rapigest detergent (Waters). Proteins were reduced using DTT for 30 minutes at 60ºC followed by 
alkylation using iodoacetamide for 30 minutes at room temperature in the dark. Proteins were 
digested with trypsin (Promega, Madison, WI) for 18 hours at 37°C and then the Rapigest detergent 
was hydrolyzed with HCl for 45 minutes at 37°C. Peptides were purified with PepClean C18 Spin 
Columns (Thermo Fisher) according to the manufacturer’s protocol. Finally the purified peptides 
were dissolved in 0.1% formic acid for mass spectrometric analysis. 
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3.9.4 LS-MS/MS analysis 
Mass spectrometric analysis was performed using nanoAcquity UPLC – liquid chromatography 
system on-line with Waters Synapt G2 mass spectrometer (Waters). Waters nanoAcquity UPLC 
Trap Column (Symmetry C18, 180μm x 20mm, 5μm) was used as trapping and Waters 
nanoAcquity UPLC Column (BEH130 C18, 75μm x 150mm, 1.7μm) as analytical column. Four μl 
of sample was injected and run using 90 minutes gradient from 3% to 40% mobile phase B (0.1% 
formic acid in acetonitrile). As mobile phase A 0.1% formic acid in water was used. 
Data was collected in a data dependent acquisition manner by collecting eight fragmentation spectra 
simultaneously. Switch limit from MS to MS/MS was set to peak intensity of 200. Fragmentation 
data for detected peaks was collected for 5 seconds and then excluded from fragmentation for 120 
seconds. Scan time for both MS and MS/MS was one second. No lockmass correction was used. 
The raw data was processed with Mascot Distiller software (version 2.3.1.0, Matrix Science), and a 
database search was performed using the Mascot search engine (version 2.2.04) against Swiss-Prot 
human database (dated 16.6.2010). MudPIT scoring and Ion score cut-off limit of 20 were used to 
identify peptides. Require bold red-specification was used to limit the results to those proteins 
which have at least one unique peptide. Carbamidomethylated cysteine was set as fixed 
modification and oxidation of methionine as variable modification. Peptide mass tolerance for 
search was 0.2 Daltons and 0.1Da for fragment ion search. A maximum of two missed trypsin 
cleavages was allowed. The Mascot Distiller processed data was also searched using GPM 
X!Tandem search engine51 using same the parameters. 
3.9.5 Expression and purification of recombinant gremlin-1 
 The expression construct pGremlin-1_V5/HIS in pEF-IRES-P contains cDNA encoding human 
gremlin-1 with C-terminal tags (V5 and 6HIS). H2052 and H28 cells were transiently transfected 
with this construct or the expression vector using Fugene HD transfection reagent (Promega).  CHO 
cells were stably transfected, and gremlin-containing cell culture supernatants produced as 
described by Hulmi (2013) 262. The media was then dialyzed against 50 mM sodium phosphate 
buffer, pH 7.2, and 1 M NaCl (buffer A) and loaded on a 1 ml HiTrap column (GE Health Care, 
Waukesha, WI) previously charged with CoCl? and equilibrated with buffer A. The loaded column 
was washed with 40 column volumes of buffer A, and subjected to a fast protein liquid 
chromatography (GEHC) gradient run starting with buffer A containing 0-100% buffer B (buffer A 
with 250mM imidazole).  Fractions were analyzed by SDS-PAGE for their purity and molecular 
mass, and imidazole in these fractions was removed by dialysis against buffer A.  For further 
concentration and purification, gremlin-1 containing fractions were dialyzed against TBS and 
subjected to affinity chromatography using a 1 ml HiTrap heparin column (GEHC). Bound gremlin-
1 was eluted in a 0 to 1 M NaCl gradient. 
3.9.6 Surface plasmon resonance 
Binding analyses were performed using a BIAcore2000 (GEHC). First, 2000 RUs of gremlin-1 
were covalently coupled to carboxymethyldextran hydrogel 500M sensor chips (XanTec) using the 
amine coupling kit following the manufacturer's instructions (GEHC). Binding assays with N-
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terminal fibrillin-1 (rF11) and -2 peptides (rF86) as analytes were performed as described by Sengle 
(2008a)99.  Kinetic constants were calculated by nonlinear fitting of association and dissociation 
curves (BIAevaluation 4.1 software). 
3.10 Measurement of cell viability and apoptosis (II)  
Cell viability was assessed by MTT assay (R&D Systems). Briefly, cells were seeded on 96-well 
plates (10,000/well), and the next day the cells were treated with different concentrations of 
paclitaxel (Hospira). The metabolic activity of the cells was measured after 48 hours according to 
the manufacturer’s instructions. Apoptosis was assayed with TUNEL technology using In Situ cell 
death detection kit (Roche). Cells were seeded on glass coverslips, cultured overnight and 
transfected with siRNAs as described above. Cells were then fixed and stained according to the 
manufacturer’s instructions three days after transfection. 
3.11 Measurement of cell proliferation (II) 
To a measure cell proliferation, the cells were seeded on 12-well plates and counted 1, 2 and 3 days 
after transfection using TC10 automated cell counter (BioRad).      
3.12  Measurement of cell migration (III) 
3.12.1 Live cell imaging 
Incucyte ZOOM 2013A kinetic live cell imaging system (Essen Bioscience) was used according to 
the manufacturer’s instructions to monitor the cell migration. Briefly, the cells were plated on 96-
well plates, and the next day a wound was applied on confluent monolayer using a woundmaker 
(Essen Bioscience). The media was replaced with serum-free media supplemented with the activin 
blocker (sActR2B-Fc) when indicated. Two distinct pictures were captured of each well every 2 
hours for 48 hours. Data was analyzed with Incucyte ZOOM 2013A software, and the relative 
wound density was used as a measure of the wound closure. 
3.12.2 Scratch wound assay 
For conventional scratch wound assay, the cells were seeded on 12-well plates, and the wounds 
were made on confluent monolayers using a P200 pipette tip. The media was replaced with serum-
free media supplemented with DMSO, PD98059 or sActR2B-Fc where indicated. Two pictures 
were captured of each well after 0, 6, 24 and 48 hours using Nikon Eclipse TS 100 and Digital Sight 
DS-L2. The quantification of the wound density was done using Image ProPlus 7.0 software. The 
percentage of area occupied by the cells relative to percentage of wound area was defined, and that 
area was normalized to wound density data at 0 hour time point. The control treated wound density 
was set to one. 
3.13 A statement for the use of patients samples (II,III) 
A statement for the use of human mesothelioma tissue and pleural effusion materials was received 
from the Ethics Committee of the Helsinki University Hospital, Helsinki, Finland (number 
308/13/0301/2010). All patients gave informed consent to participate in the study. Tissue biopsies 
and pleural effusion samples were obtained from patients undergoing diagnostic procedures and had 
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a clinical and/or radiological suspicion of malignant mesothelioma. All patients included in the 
study were later diagnosed to have mesothelioma. Control pleural samples were obtained from two 
male smokers who were operated for pneumothorax. 
 
3.14 Statistical analysis (I, II, III) 
Data were analyzed using PASW Statistics 18 (I, II) and 21 (III) programs for Windows (SPSS). 
Statistical difference between two independent groups was evaluated using nonparametric Mann-
Whitney U-test. Statistical difference between more than two independent groups was evaluated 
using nonparametric Kruskal-Wallis test. A p-value of less than 0.05 was considered statistically 
significant. 
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4. Results and discussion    
 
4.1    The ability of crocidolite asbestos to induce EMT in vitro (I) 
Asbestosis and IPF are both fibrotic diseases of the lung. Although in asbestosis the initiating 
component is known, whereas in IPF it remains unknown, these diseases share many features 
including histopathology of usual interstitial pneumonia (UIP). EMT is implicated in IPF and other 
fibrotic diseases (see 1.3.5). EMT is also implicated in lung cancer 267, both asbestos related and no-
asbestos related, and mesenchymal characteristics are associated with worse patient prognosis. 
EMT is associated with local invasion and distal metastasis, and contributes to drug resistance and 
anti-apoptotic phenotypes of cancer cells 61. In addition, asbestos exposure can induce signaling 
pathways linked to EMT (see review of the literature). Therefore, we set out to investigate the 
ability of crocidolite asbestos to induce EMT in lung epithelial cells in vitro. 
4.1.1 Exposure to crocidolite asbestos leads to loss of epithelial characteristics in lung 
epithelial cells  
The loss of cell junctions is a hallmark of EMT 58. We found that in 3D cultures of both A549 
carcinoma cells and small airway epithelial cells (SAEC) asbestos exposure led to downregulation 
of E-cadherin protein levels. This indicates the loss of epithelial phenotype. In 2D environment, 
A549 cells were the only cell type in which asbestos exposure downregulated E-cadherin and tight 
junction protein ZO-1 (I; Figures 1 and 2). A549 cells are widely used because they retain many 
characteristics of the type II lung epithelial cells. Primary human small airway (SAECs) or 
bronchial (NHBE) epithelial cells, as well as immortalized bronchial epithelial cells (BEAS-2B), 
most likely lose their type II characteristics in 2D cultures. These cells did not show signs of EMT 
in 2D even when stimulated with TGF-β1, which is a known inducer of EMT. When SAECs were 
placed in 3D environment, they retained type II characteristics, indicated by the production of 
surfactant protein –D (SP-D), and the cells downregulated E-cadherin in response to asbestos and 
TGF-β1 exposure (I; Figure 8). This suggests that only the type II lung epithelial cell phenotype has 
enough plasticity to initiate EMT processes. This seems logical, since the alveolar type II epithelial 
cells do exhibit more plasticity. They are the proliferative lung epithelial cell population and 
progenitor cells for the type I cells 18, 19. As majority of the alveolar surface area is composed of 
type I cells 6, it is plausible that the cells that are exposed to an oxidative stress would not be 
susceptible to EMT. However, considering the fundamental role that the small type II cell 
population has, EMT in this population would have detrimental impact.  
Transcriptional downregulation of E-cadherin has been reported to be a late event in EMT 56, 57. 
However, we saw TGF-β1 induced downregulation of E-cadherin mRNA in A549 cells already 
after three days, and it persisted after six days (I; Figure 1). Even after six days, asbestos exposure 
did not lead to downregulation of E-cadherin mRNA in A549 cells. Transcriptional changes, such 
as upregulation of snail and slug, can also occur at a later state of EMT 57. We found that TGF-β1 
induced snail and especially slug expression already after one hour stimulation, and the levels were 
further elevated up to three and six days. Asbestos was able to induce snail and slug expression in 
A549 cells after six days, and late upregulation of these transcription factors could later lead to 
transcriptional repression of E-cadherin to establish the loss of epithelial junctions and complete 
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EMT. TGF-β1 is a potent biological inducer of EMT (see 1.3). In contrast, asbestos induced EMT 
may not have all the same characteristics as a growth factor induced EMT. For instance, the time 
scale of EMT events, the expression profile of the mesenchymal markers and the effector pathways 
were different to what has been reported for TGF-β1 induced EMT in A549 cells 268.  
4.1.2 Pathway activities differ between normal and cancer cells  
TGF-β1 induced EMT in A549 cells has been suggested to be Smad2 mediated 268. Initially, we 
hypothesized that asbestos exposure could stimulate endogenous TGF-β activity, possibly by ROS 
mediated activation of latent TGF-βs, and this would induce Smad mediated EMT. However, 
whereas TGF-β1 induced robust Smad2 and Smad3 activation in A549 cells, asbestos failed to do 
so (I; Figure 5). Consistent with this, blocking TGF-β type 1 receptors with SB431542 could not 
prevent decrease in E-cadherin in asbestos exposed cells, whereas it did so in TGF-β1 exposed 
cells. In order to characterize the underlying pathway(s) of asbestos induced loss of epithelial 
phenotype, cancer associated pathway array was used to compare the basal activity of different 
pathways in SAECs and A549 cells grown in 2D (I; Figure 6). This array indicated three pathways, 
MAPK/JNK, NF-κB and MAPK/ERK, which all have been implicated in EMT (see 1.3). MAPKs 
ERK and JNK are also non-canonical pathways for TGF-β (1.7.3 and Figure 4 in thesis).  
4.1.3 MAPK/ERK pathway contributes to asbestos induced epithelial plasticity   
We found that asbestos induced ERK activation in A549 cells (I; Figure 7). Furthermore, the loss of 
epithelial phenotype and reorganization of the actin cytoskeleton induced by asbestos in 2D could 
be prevented by the inhibition of MAPK/ERK phosphorylating kinase MEK by PD98059. Asbestos 
has been reported to induce ERK activation 26. MAPK/ERK pathway has been linked to EMT (see 
1.3) and is implicated in fibrotic and malignant diseases (see 1.6.3). Interestingly, also radiation 
induced EMT in A549 and in rat alveolar type II epithelial cells (RLE-6TN) has been reported to be 
ERK mediated 269. Our findings are in concord with the literature and emphasize targeting 
MAPK/ERK pathway in the treatment of asbestos induced lung cancer and asbestosis. However, 
much more research is needed, and the future treatments are likely to target multiple pathways. The 
inhibition of MAPK/ERK (PD98059), MAPK/JNK (SP600125) or NF-κB (dominant negative 
mutant IκB32/36A) pathways had no effect on asbestos induced α-SMA induction. Consistent with 
the recognized role of NF-κB in cell survival and in stress responses (see 1.5) inhibition of the NF-
κB pathway in A549 cancer cell line led to significantly decreased cell survival, particularly when 
exposed to asbestos.  
Cytoplasmic protein β-catenin interacts with E-cadherin in adherens junctions 56. When E-cadherin 
is cleaved or removed from the membrane, β-catenin is released and either degraded or it can enter 
the nucleus and regulate transcription. Nuclear localization of β-catenin is implicated in EMT and 
has been reported to contribute to the activation of the α-SMA promoter (reviewed in 270). This 
would be interesting to study in more detail in the future. 
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4.2 Localization and function of gremlin-1 in mesothelioma ECM in vitro and in tumor tissue 
(II) 
Gremlin-1 was originally suggested to have a tumor suppressive role 237, but nowadays it is more 
frequently reported to be tumor promoting 254. Gremlin-1 is overexpressed in lung adenocarcinoma 
and in malignant mesothelioma 234, 256. We set out to analyze whether gremlin-1 overexpression 
contributed to mesothelioma development and progression. We started by searching for new 
gremlin-1 interacting proteins in vitro after which the results were validated in mesothelioma tumor 
samples. We also confirmed the key findings of the in vitro functional studies in the mesothelioma 
patient samples. 
4.2.1 Characterization of primary mesothelioma cells 
In order to best recapitulate the phenotypic characteristics of mesothelioma tumors in vitro, primary 
mesothelioma cells from the clinical pleural effusion samples of mesothelioma patients were 
collected. Majority of the harvested cells (JP-cells) were found to be able to proliferate on a cell 
culture dish and were positive for mesothelial markers calretinin and cytokeratin-7 (CK-7) as well 
as for vimentin, which is frequently expressed in cancer cells. Calretinin and CK-7 expression 
confirmed the mesothelial origin of the cells, whereas May-Grünwald-Giemsa (MGG) and 
Papanicolaou (PAPA) stainings (unpublished observation) of the cytospin samples, together with 
the characteristic vacuolated cytoplasm 271 (see Figure 4 in II) and vimentin expression, confirmed 
their malignant characteristics. These primary cells, especially at early passages, represent 
mesothelioma much better than established cell lines, which during passaging and culturing may 
have lost or altered the gene expression of phenotypic proteins, sometimes even the expression of 
calretinin or CK-7, or both (unpublished observation). This loss of initial phenotype will also 
happen to JP cells during prolonged culturing (unpublished observation, thesis Figure 5). Therefore, 
for mechanistic studies it is critical to choose cell lines that faithfully recapitulate the investigated 
characteristics of primary tumor cells, as has been done in II and III. Representative cell lines are a 
necessity because primary cells will eventually lose their original characteristics, after which they 
alter their primary gene expression profile and phenotype. During studies II and III, we have found 
H2052 cells to resemble primary mesothelioma cells closely in respect of the proteins and 
characteristics analyzed in these studies.  
We used non-malignant Met5A cells as a control cell line. These cells are normal human 
mesothelial cells immortalized with SV (simian virus) 40 early region DNA 272. These cells are 
widely used, and alternative control cells are limited. SV40 virus is frequently found in MM and 
also in other malignancies, but its contribution to the development of the malignancy has remained 
controversial 30, 273.  
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Figure 5. Primary mesothelioma cells lose phenotypic gene expression during prolonged culture. (A) Early 
passages of the primary mesothelioma cells (JP4 and JP5) recapitulate tumor characteristics and express 
calretinin and CK-7, diagnostic marker proteins for mesothelioma. (B) JP4 cells lose the expression of these 
markers at later passages. JP5 cells retain mesothelial marker expression. (C) Irrespective of the marker 
expression, both JP cells lose the expression of gremlin-1 and transcription factor slug, key molecules of the 
second study, during passaging. Gremlin-1 and slug were highly expressed in early passages of primary 
cells as well as in the mesothelioma tumors. The characteristics that are beneficial in tumor progression in 
vivo are not necessary beneficial in adaption to cell culture in vitro and are therefore not maintained. Instead, 
cell culture selects for fast proliferating cells.        
 
4.2.2 Fibrillin-1 and -2 are novel gremlin-1 interacting proteins 
The search for new gremlin-1 interacting proteins was done using systematic affinity purification 
coupled with mass spectrometry identification (AP-MS). Fibrillin-2 was identified in all three 
replicate experiments. This interaction was further confirmed by testing for direct interactions 
between purified gremlin-1 and recombinant N-terminal fragments of fibrillin-2 and fibrillin-1 
using surface plasmon resonance technology. High affinity interaction between gremlin-1 and the 
N-terminal peptides were observed (II; Figure 1, Table 1). Interestingly, also BMPs-2, -4, -7 and -
10 bind to the N-terminal end of both fibrillin-1 and fibrillin-2 99(and 1.7.5).  
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4.2.3 Gremlin-1 and fibrillin-2 and/or fibrillin-1 are concomitantly overexpressed and co-localize 
in mesothelioma tumor tissue and in vitro 
Validation of the in vitro interactions was done by immunohistochemical staining and by in situ 
proximity ligation assay (PLA) in mesothelioma tumor samples. In immunohistochemical staining 
gremlin-1 and fibrillin-2 expression was low and fibrillin-1 absent in normal mesothelium (II; 
Figure 2). In reactive mesothelium, both gremlin-1 and fibrillin-2 expression were moderately 
elevated whereas in mesothelioma tumor samples both gremlin-1 and fibrillin-2 were highly 
expressed. Fibrillin-1 was detected only in the stroma of one tumor sample. Gremlin-1 and fibrillin-
2 exhibited strikingly similar staining patterns, which was not surprising considering that the two 
had been found to interact in vitro. The interaction in the mesothelioma tumors was further 
validated with proximity ligation assay, which showed clear co-localization of gremlin-1 and 
fibrillin-2 in mesothelioma tumors with intermolecular distance being less than 40 nm, which is the 
theoretical maximum distance achieved by this method. Unlike the tumors, primary mesothelioma 
cells expressed both fibrillin-1 and -2, and gremlin-1 was found to co-localize with fibrillin-1 (II; 
Figure 5) in culture. As mentioned earlier, gremlin-1 interacted in vitro with both fibrillin-1 and -2, 
but fibrillin-1 was mainly absent from the tumors.  
Previously, Seddon et al. (2006) 253 reported gremlin-1 expression in the stromal cells in 
carcinomas, whereas we found gremlin-1 expression in mesothelioma tumor cells. Carcinomas are 
highly complex tumors and likely differ in organization from mesotheliomas, which are reasonably 
unique tumors in nature.   
The cells remodel the ECM and the ECM interacts with the cells and influences cell adhesion, 
proliferation, migration and survival 80. Furthermore, altered ECM can initiate and support EMT 61  
and promote the progression of fibrosis and cancer. We showed that mesothelioma cells remodel 
the surrounding ECM by producing excess fibrillin-2. Fibrillin-2 is normally expressed during 
development, and the expression in healthy adult pleura is low (1.4.2 and II; Figure 2). Re-
expression of developmental programs is associated with cancer progression 274. Consistently, also 
gremlin-1 is a developmental protein (1.8.2). Efficient deposition of gremlin-1 into fibrillin-2 
containing fibers in mesothelioma ECM may enable production of larger amounts of gremlin-1. 
This could also partially explain the concomitant overexpression of fibrillin-2 and gremlin-1. This 
resembles what has been reported for TGF-βs and LTBP-1 in mesothelioma. TGF-β expression and 
activity are high in mesothelioma tumors 164, 165, 174. LTBPs are required for targeting TGF-β into 
ECM (see 1.7.3). Interestingly, LTBP-1 is found abundantly expressed in the stroma of 
mesothelioma patient samples 164, suggesting that it might function as a reservoir for increased 
TGF-β levels. It is important to note, that those BMPs which gremlin antagonizes, BMPs -2, -4 and 
-7 are also targeted to microfibrills 94, 99. Thus, gremlin-1 appears to be deposited close to its 
biological targets, and this might have functional importance. However, experiments on mice and 
on cultured mouse osteoblasts suggest that although both fibrillins-1 and -2 bind and store both 
TGF-βs and BMPs, the distinct fibrillins may modulate the bioavailability of TGF-βs and BMPs 
differentially 93. Depletion of fibrillin-2 led to increased activation of TGF-β, whereas both TGF-β 
and BMP signaling were elevated in fibrillin-1 depleted cells.  
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4.2.4 Intracellular signaling is affected by gremlin-1  
In mechanistic studies, we found that silencing gremlin-1 severely impaired H2052 cell 
proliferation and led to significant alterations in cell signaling pathways (II; Figures 6 and 7). Parts 
of the observed alterations were clearly attributable to increased BMP activity. Silencing gremlin-1 
with siRNA interference lead to significant increase in the MAPK/ERK phosphorylation levels. 
This could also be due to increased BMP activity because MAPK/ERK is one of the non-canonical 
pathways for BMPs (see 1.7.5 and thesis Figure 4). H2052 and primary mesothelioma cells do 
express endogenous BMPs, especially high levels of BMP-2. BMP-2 has also been reported to 
promote cancer cell migration and invasiveness via Smad1 and via MAPK/ERK pathways 275, 276. 
As expected, when gremlin-1 was silenced, BMP activity in H2052 cells increased, demonstrated 
by increased activity of Smad1/5 pathway and increased expression of Id1.  
High MAPK/ERK activity can also lead to growth arrest by elevating the levels of p21108. Our 
finding that silencing gremlin-1 led to severe reduction in cell proliferation (II; Figure 6) with 
concomitant upregulation of ERK activity and p21 expression (II; Figure 7) is in agreement with 
proposed model that both too low as well as too high MAPK/ERK activity levels promote cell cycle 
arrest via p21 108.       
In H2052 mesothelioma cells, the AKT phosphorylation levels (S473) were high (II; Figure 7). 
AKT, and particularly this phosphosite, is frequently phosphorylated in MM and contributes to 
chemoresistance 46, 121. Our data supports this. Although after silencing gremlin-1 we saw no change 
in the AKT (S473) phosphorylation levels, the phosphorylation of AKT target and regulator of 
mTOR, PRAS40, was increased in gremlin silenced cells. Furthermore, gremlin-1 binds directly to 
the 14-3-3 protein 254, which also binds and regulates PRAS40 and other PI3-K/AKT/mTor 
pathway proteins 122.  
As mentioned, the majority of mesotheliomas (see 1.2) have wild type functional p53. We found 
that silencing gremlin-1 in H2052 mesothelioma cells increased phosphorylation of p53 (S46 and 
S392) and the expression of p53 target gene p21(Cip1/Waf1) (II; Figure 7), which promotes cell 
cycle arrest in G1 277. Accordingly, forced gremlin-1 overexpression in H2052 and H28 cells (of 
which the latter has minor endogenous expression levels, see Figure 4 in II) reduced the p21 mRNA 
levels. These results propose gremlin-1 a role in cell proliferation and survival. This is also 
supported by our finding that silencing gremlin-1 severely impaired cell proliferation in H2052 
mesothelioma cells (II; Figure 6). Clearly, gremlin-1 is involved in a more complex network of 
pathways than solely BMP inhibition, and the distinction between BMP-dependent and BMP-
independent mechanisms may prove challenging.    
4.2.5 Gremlin-1 sustains chemoresistant EMT phenotype through slug  
Slug functions as a potent EMT inducer, regulating the expression of many genes repressing the 
epithelial and promoting the mesenchymal state 58. We found high gremlin-1 and high slug 
expression strongly associated (II; Figure 8). They were co-expressed in the MM tumor samples 
and in the cells and cell lines exhibiting high gremlin-1 expression (JP cells and H2052). Instead, 
cell lines exhibiting low gremlin-1expression exhibited also low slug expression levels but, when 
forced to overexpress gremlin-1, increased also slug expression levels (II; Figure 8). Furthermore, 
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when gremlin-1 expression was silenced, slug expression levels decreased. Concomitant 
downregulation was also observed in primary mesothelioma cells during prolonged culture (thesis 
Figure 5). Simultaneously with slug expression levels in H2052 cells, expression levels of 
mesenchymal markers N-cadherin, vimentin, α-SMA and fibronectin decreased and epithelial 
marker E-cadherin increased (II; Figure 8). We have also observed similar upregulation of E-
cadherin in late passages of JP-cells (our unpublished observation, not shown) suggesting that the 
mesenchymal phenotype of the JP-cells is at least partially lost together with gremlin-1 and slug 
expression. Our results suggest that gremlin-1 supports mesenchymal phenotype in mesothelioma 
cells through transcription factor slug. Snail expression levels in primary mesothelioma cells did not 
differ from the expression levels in Met5A cells. This is in agreement with the suggested hierarchy 
in snail and slug expression. In this hypothesis, snail is expressed at the onset of the transition, 
whereas slug and other transcription factors are subsequently induced to maintain the mesenchymal 
phenotype 65. Mesothelioma invades surrounding tissues aggressively. During EMT, a switch from 
E- to N-cadherin leads to the loosening of intercellular contacts and facilitates migration 56.  
Gremlin-1 induces and supports EMT, and EMT is associated with elevated expression of matrix 
metalloproteinases (MMPs), which degrade the extracellular matrix (ECM) (see 1.3.5). ECM 
degradation can release more fibrillin bound gremlin-1 and TGF-β bound to fibrillin and fibronectin 
and they can further promote cancer progression.  
A recent report by de Reynies (2014) 41 identified two subgroups in mesothelioma, which 
associated with better (C1) or worse (C2) prognosis irrespective of the histological subtype. 
Interestingly, the C2 subgroup exhibited mesenchymal (EMT) phenotype. In agreement with what 
is known of the prognosis of the sarcomatoid mesothelioma, all sarcomatoid mesotheliomas fell 
into the C2 subgroup. Importantly, this subgrouping was able to differentiate mesotheliomas to 
better (C1) and worse (C2) prognosis subgroups within the epithelioid histological subtype. In the 
C2 subgroup also slug and gremlin-1, in addition to other mesenchymal markers, were upregulated 
and E-cadherin was downregulated compared to the C1 group whereas in the C1 group gremlin-1 
and slug were expressed less and E-cadherin more compared to the C2 group. This is in agreement 
with our findings and suggests that gremlin-1 could be the key factor promoting the mesenchymal 
phenotype and it might hold potential not just as therapeutic target but also as prognostic marker in 
mesothelioma.        
EMT phenotype is implicated in chemoresistance (1.3.5). Chemoresistance is a major problem in 
the management of MM (see 1.2.5.). We found that the mesothelioma cells expressing high 
gremlin-1 tolerated chemotherapeutic drug paclitaxel better compared to the cells with low gremlin-
1 expression. Furthermore, silencing gremlin-1 expression led to sensitization to the cytotoxic 
effects of the chemotherapeutic drugs paclitaxel and pemetrexed. This together, with what was 
discussed of the potential role of gremlin-1 in the regulation of PI3-K/AKT cascades and its 
contribution to chemoresistance on MM, strongly proposes a central role for gremlin-1 in 
mesothelioma chemoresistance and possibly a way to overcome this problem. Targeting EMT in 
cancer is challenging 61. The cells can switch between epithelial and mesenchymal states or retain 
characteristics of both phenotypes. Therefore specific targets such as gremlin-1 are needed. No 
chemical inhibitor for gremlin-1 is yet available, but a small interfering RNA targeting human 
gremlin-1 has been patented (http://www.lens.org/lens/patent/US_7741470_B2, accessed on 
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1.9.2014). Gene expression can efficiently be silenced with siRNAs in mouse models using cationic 
liposome-siRNA complex or other vehicles in infusion 278, 279. Intriguingly, encouraging results in 
mesothelioma have been reported using fully humanized monoclonal antibodies for targeting T-cell 
receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4) 280. Studying efficacy of a 
specific antibody targeting gremlin-1 could be worthwhile in mesothelioma. Due to its specific and 
consistent overexpression in mesothelioma 234 (and II) and low expression in most normal adult 
tissues 243, gremlin-1 would make potential therapeutic target.  
 
4.3 Role of activins in mesothelioma cell migration and invasion in vitro (III) 
Activins function as multifaceted regulators of inflammation, immunity and angiogenesis 180, 186. 
They regulate differentiation and proliferation of various cell types and are central in wound healing 
188. Activins can be tumor suppressive or tumor promoting depending on the tumor and tissue type 
181. Activin-A has been reported to be overexpressed and to promote growth in mesothelioma 212. 
This study was conducted to characterize the expression and signaling pathways of activin-A and -B 
in mesothelioma and the contribution of activin- dependent signaling cascades in mesothelioma 
progression. 
4.3.1 Activin-A and activin-B are overexpressed in mesothelioma tumors and in cultured 
mesothelioma cells  
We found activin-A and activin-B highly expressed in mesothelioma tumors and in primary 
mesothelioma cells (III; Figure 1). Predominant expression of activin-A in biphasic mesothelioma 
cells (JP4 and 211H) was an interesting finding. The mesothelioma cell lines were very variable in 
their activin expression, and the cell lines used in the mechanistic studies were selected based on 
their high activin expression resembling primary cells (H2052 and 211H). Also FST was found 
abundantly expressed in the tumors and in the representative cell lines. The primary mesothelioma 
cells, however, expressed high levels of FSTL-3 instead of FST.  
FSTL-3 resembles FST and binds and inhibits activins and BMP-2 203. Interestingly, in primary 
mesothelioma cells BMP inhibitor gremlin-1 and BMP-2 (II) as well as FSTL3 and activins-A and -
B (III) were upregulated compared to the Met5A control cells. Gremlin-1, FST and activin 
expressions were abundant also in the tumor tissues. These observations emphasize the role of the 
TGF-β superfamily members and their extracellular regulators in mesothelioma. In study II, we 
found that BMP-2 is highly expressed in mesothelioma cell lines and especially in primary 
mesothelioma cells. The high FST/FSTL3 expression in mesothelioma cells may therefore not only 
counteract high activin levels but also BMP-2 activity. Co-operation of BMP inhibitors, including 
gremlin-1 and FST, in cancer progression has been reported previously in colorectal cancer 
desmoplastic invasion fronts 255. We found high activin-A and FST expression in mesothelioma 
tumor samples, as well as in H2052 and 211H cell lines. In cell culture of rodent pituitary and 
granulosa cells, activin-A induces FST expression 281, 282. Furthermore, recombinant BMP-2 can 
induce activin-A and FST expression in mouse prechondroblastic cell line 283. Together with our 
findings, this suggests a complex network of regulation.   
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We also found ACVR2A and ALK7 overexpression in mesothelioma cells (III; Figure 2). The 
contribution of ALK7 overexpression remains to be elucidated, as well as its predominant ligand in 
mesothelioma. In addition to activin-B, also Nodal, a developmental morphogen implicated in 
cancer progression 284, 285, is a ligand for ALK7. Intriguingly activin-A has been reported to induce 
Nodal and maintain self-renewal and pluripotency in human embryonic stem cells in vitro 286. In 
this setting, activin-A was also reported to suppress BMP expression and signals.  
Interestingly, the attenuation of the canonical Smad2/3 response and switch to non-canonical 
MAPK/ERK signaling (see 4.3.2) was also associated with a switch of the predominant type 2 
receptor from ACVR2B to ACVR2A. The ACVR2A overexpression possibly serves to enhance 
activin induced MAPK/ERK signals, which promote cell migration and invasion (see 4.3.3). Type 1 
receptor specifies the R-Smad response 130, but it would be interesting to investigate whether type 2 
receptors could contribute to the specification of the non-canonical signals or selection between 
canonical and non-canonical signals.   
4.3.2 Attenuation of canonical Smad3 response to activins associates with migratory and 
invasive phenotype 
We found that majority of the mesothelioma cells had attenuated Smad3 response to activins, and 
this was associated with a migratory and invasive phenotype (III; Figures 3, 4 and 5). Interestingly, 
the mesothelioma cell lines with attenuated Smad3 response to activins (211H and H2052) did 
activate Smad3 in response to TGF-β1 stimulation (unpublished observation, thesis Figure 6) 
suggesting that the attenuation of the Smad3 response was activin specific. Smad2 response was 
attenuated in H2052 and in JP5 cells expressing both activin-A and -B but activated in 211H cells, 
expressing practically only activin-A (III; Figure 1 and 3). Furthermore, JP5 and H2052 activated 
MAPK/ERK also in response to exogenous human recombinant activin-A and –B (III; Figure 6). 
Smad2 and Smad3 differ in their ability to bind DNA as well as their cellular targets 145. Whereas 
the MH1 domain of Smad3 and Smad4 can directly bind DNA, MH1 domain of Smad2 cannot. 
Smad2 and Smad3 activation can also have distinct effects on cell migration 287. In this study, 
however, attenuation of the Smad3 response to activins was consistently associated with a 
migratory and invasive phenotype.  
We found invasive and migratory characteristics to depend on activin mediated signals. Migration 
and invasion could be abolished by inhibiting activin signaling by sequestering extracellular 
activins by soluble type 2 receptor (sActR2B-Fc) (III; Figure 4 and 5). For therapeutic point of view 
this is interesting. In mouse model, soluble type 2 activin receptor has been used 288. In this model, 
inhibition of activin-A by soluble receptor was shown to inhibit cancer associated muscle wasting 
and cachexia efficiently and to prolong survival of the tumor bearing animals.  
It has been suggested that TGF-β induced transcriptional responses would be primarily mediated by 
Smad3/Smad4 complexes, whereas activin responses would be mainly mediated by Smad2/Smad4 
complexes 139. This, however, is likely not the case in mesothelioma cells. In H2052 and JP5 cells 
also Smad2 response to activins was attenuated (III; Figure 3). Furthermore, in control Met5A and 
in H28 mesothelioma cells activins did induce robust Smad3 activation.    
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FST and FSTL3 bind soluble activins and prevent their binding to the receptors 202, 203. In the cells 
exhibiting high FST/FSTL-3 expression and attenuation of the Smad3 response, activins did, 
however, elicit responses, explicitly the MAPK/ERK cascade. If high FST/FSTL3 levels would 
explain attenuation of the Smad3 response, no alternative signaling cascades in response to activins 
should be detected as activins could not bind their cell surface receptors. Thus, high expression of 
FST/FSTL-3 cannot account for the attenuation of the Smad3 response in mesothelioma cells. 
4.3.3 Activin stimulated MAPK/ERK phosphorylation supports mesothelioma cell 
migration and invasion   
We found MAPK/ERK pathway to be the major pathway mediating the activin stimulated 
migration and invasion in mesothelioma cells. Consistently in all cells (H2052, JP5 and in 211H), 
sequestering of extracellular activins by soluble type 2 receptor (sActR2B-Fc) led to significant 
reduction in ERK phosphorylation levels (III; Figure 6) concurrently with the impairment of 
migration and invasion (III; Figure 4 and 5). Furthermore, inhibiting ERK phosphorylating kinase 
MEK caused similar impairment of cell migration and invasion (III; Figure 6) as observed with 
sActR2B-Fc.  
The MAPK/ERK pathway is known to promote EMT (see 1.3.2). Migration and invasion are 
characteristics of cells of the mesenchymal phenotype. It is therefore possible, that like many other 
members of the TGF-β superfamily, also activin-A, and possibly also activin-B, could be able to 
support mesenchymal phenotype. We found a switch of activin signaling from the Smad3 pathway 
to the MAPK/ERK pathway and this switch promoted migration and invasion. This agrees with the 
concept that pathological EMT is an important mechanism in the progression of mesothelioma and 
agrees with reported importance of MAPK/ERK pathway in mesothelioma (1.2.6 and 1.6.3).  
We did not clearly differentiate which activin, –A or –B, was the major factor in the MAPK/ERK 
mediated cell migration and invasion. However, the migratory and invasive 211H cells expressed 
almost exclusively activin-A, and this speaks for the major role for activin-A. Likely in vivo 
mesothelioma cell invasion requires co-operation of both activins-A and –B mediated ERK and 
other cascades, as well as numerous other factors and pathways.     
The well-studied growth factor of the same family, TFG-β, has a dual function during 
carcinogenesis. At first TFG-β acts as a tumor suppressor but eventually it switches to a tumor 
promoting role 140, 145, and this has been suggest to occur by suppressing the Smad2/3 activity with 
concomitant increase in ERK activation 151 (see also 1.7.3.1). Our results suggest that activins could 
act in a similar manner. Another proposed mechanism to explain how TGF-β induced growth 
inhibitory signals could be overcome suggests increased inhibitory phosphorylation of Smad2/3 in 
the linker region by elevated ERK activity 147. Our results are consistent also with this mechanism. 
Interestingly, in vitro data suggest that in also prostate cancer cells, a loss of sensitivity to activin-A 
mediated growth inhibitory and apoptotic signals takes place during cancer progression 209. 
  
Figure 6. TGF-β induced Smad3 response in 211H and H2052 cells. The 
mesothelioma cell lines exhibiting attenuated Smad3 response to activins do 
activate Smad3 in response to TGF-β (2 ng/ml) stimulation.   
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The key findings of this thesis are gathered in Figure 7.  
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Figure 7. Synthesis of the work. Asbestos exposure of lung epithelial cells can induce EMT like processes 
which promote fibrosis and cancer progression. Asbestos fibers can induce MAPK/ERK activation. 
MAPK/ERK pathway initiated epithelial plasticity in type II lung epithelial cells leads to downregulation of E-
cadherin and ZO-1 and to dissolution of epithelial junctions and reorganization of cortical actin to stress 
fibers. EMT in the lung type II epithelial cells likely results from co-operation of various signaling pathways 
and transcription factors, which induce mesenchymal markers (such as α-SMA) and complete EMT. In 
mesothelioma, BMP inhibitor gremlin-1 and ECM protein fibrillin-2 are highly overexpressed. Concomitant 
upregulation of gremlin-1 and fibrillin-2 enables gremlin-1 deposition into mesothelioma ECM. Gremlin-1 
supports chemoresistant EMT phenotype through transcription factor slug. Slug downregulates epithelial E-
cadherin and upregulates mesenchymal proteins N-cadherin, vimentin and α-SMA. EMT phenotype can also 
promote invasion. Activin-A and activin–B are overexpressed in mesothelioma. Attenuation of the canonical 
Smad2/3 response and switch to non-canonical MAPK/ERK signaling promotes mesothelioma cell migration 
and invasion. Simultaneous switch of the predominant type 2 receptor from ACVR2B to ACVR2A with 
concomitant upregulation of ACVR2A may further enhance the invasion promoting signaling. Inhibiting 
activin activity by sequestering extracellular activins by soluble activin receptor (sActR2B-Fc) or inhibiting 
ERK phosphorylating kinase (PD98059) impairs mesothelioma cell migration and invasion.  
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5. Conclusions and future perspectives  
The understanding of the molecular mechanisms of EMT as well as asbestos elicited physiological 
and cellular responses has increased tremendously in the past years. The work presented in this 
thesis supports the concept of pathological EMT as one key mechanism not only in the pathogenesis 
of fibrosis (asbestosis) and asbestos induced lung cancer, but also in the progression and 
chemoresistance of mesothelioma. Due to the extensive latency preceding the diseases, eventually 
understanding the molecular mechanisms of pathogenesis and progression of asbestosis, lung cancer 
and mesothelioma will, possibly provide an opportunity to prevent the outbreak of disease in the 
exposed individuals, or at least slow down the process.  
Whether gremlin-1 and activin-A play a cancer promoting or cancer suppressing role in 
carcinogenesis is currently under debate and appear to depend on the tissue and cancer type. 
However, we and others 212, 234 have shown that in mesothelioma they have properties that are likely 
to promote tumor development. The situation is, however, complicated by the tight interplay 
between gremlin-1, the other regulators and the other members and of the TGF-β superfamily, not 
to mention the diversity and overlap of the signaling cascades. Nonetheless, gremlin-1 and activin-
A, and possibly also activin-B, have presented themselves as putative candidates for targeted 
therapy in mesothelioma and should be investigated further. 
The finding that gremlin-1 localized into fibrillin-2 containing microfibrills in mesothelioma tumor 
ECM was completely new. Concomitant overexpression of fibrillin-2 and gremlin-1 possibly 
enables the expression and deposition of larger amounts of gremlin-1 compared to if no efficient 
extra cellular deposition was available. We found that high gremlin-1 expression supports the EMT 
phenotype and our results and the literature suggest that EMT is an important process in 
chemoresistance. In mesothelioma, chemoresistance is an enormous problem. Our results suggest 
that gremlin-1 holds potential as a way to target chemoresistance in mesothelioma and should be 
thoroughly investigated. Gremlin-1 overexpression in mesothelioma appears to be consistent and 
high 234(and II). This together with low expression in normal lung and weak or moderate expression 
in majority of tissues in healthy adults 243 suggests that gremlin-1 would also be a very specific 
therapeutic target. No chemical inhibitor for gremlin-1 is available currently. Possible means by 
which gremlin-1 could be targeted in mesothelioma include specific siRNAs and specific 
antibodies.  
Our results of the involvement of the MAPK/ERK pathway in asbestos induced epithelial plasticity 
and in mesothelioma cell migration and invasion are in agreement with the current view on 
molecular pathogenesis of asbestos exposure related diseases. The evidence that implicates 
MAPK/ERK pathway in mesothelioma pathogenesis is strong. However, small molecule EGFR 
tyrosine kinase inhibitors have failed to show clinical efficacy in MM patients 28. Our in vitro data 
suggests an alternative way of ERK activation in MM - through activin receptors. This is an 
important finding since the MEK inhibitor trametinib has proven rather toxic for normal tissues, 
which limits therapeutic use 289and the efficiency of another MEK inhibitor, selumetinib appears to 
be limited to patients with BRAF mutations 290. Targeting Raf/MEK/ERK pathway is complicated 
because it is able to promote cell proliferation but also cell cycle arrest108.       
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We showed that by sequestering activins or by inhibiting ERK activation cell migration and 
invasion were impaired. Mesothelioma progresses predominantly through local invasion. Therefore, 
activins as therapeutic target in mesothelioma invasion in vivo would be important to investigate in 
the future. In mouse model soluble activin receptors have already been found to be efficient in 
inhibiting activin-A activity 288. 
Although mesothelioma has a certain unique characteristics it does share many common features of 
other solid tumors. The understanding of mesothelioma pathogenesis can also benefit the research 
of other cancers. Our finding that gremlin-1 supported chemoresistant EMT phenotype could be a 
mechanism not limited to mesothelioma and should be investigated in other cancer types, 
particularly in those overexpressing gremlin-1. 
How do cancer cells escape from the normal regulatory activin signals and how do activins become 
cancer promoting? Our work suggest that this happened by switching from the canonical Smad 
pathway to the non-canonical MAPK/ERK pathway. This could be a more general mechanisms in 
thoracic cancers, where activin-A is frequently overexpressed and associated with worse outcome 
210, 211.  
Cysteine knot proteins gremlin-1, activin-A, TGF-β and the BMPs likely co-operate through a 
complex network to regulate cell plasticity and proliferation in asbestos exposure related diseases, 
and this is shown in Figure 8.  
                                                                                          
Figure 8. Gremlin-1 and TGF-β superfamily members in cell plasticity in lung and pleural diseases. Gremlin-
1, activin-A and TGF-β are all highly expressed in malignant mesothelioma. Aberrant TGF-β activity, activin-
A and gremlin-1 overexpression are also implicated in other fibrotic and malignant diseases of the lung (see 
review of the literature). TGF-β can induce the expression of gremlin-1 and activin-A 169, 225, 248, 249. Literature 
implies, that activin-A and gremlin-1 could also induce TGF-β expression 169, 249. Gremlin-1 antagonizes 
BMPs -2, -4 and -7. BMP-2 has been reported to induce activin-A expression 283 and respectively, activin-A 
has been reported to suppress BMP expression and signals 286. Through activation of Smad2/3 and 
MAPK/ERK as well as other signaling pathways these bioactive molecules may induce EMT and sustain the 
mesenchymal phenotype, which promote fibrosis, cancer invasion and chemoresistance.   
In future we need to thoroughly investigate the specific contributions of gremlin-1 and activins in 
mesothelioma development, progression and chemoresistance as well as the intermolecular 
signaling networks of gremlin-1 and activins with the other members of the TGF-β superfamily. 
Gremlin-1 and activins can become true therapeutic targets in mesothelioma only after full 
characterization of their specific roles, interactions and the mechanisms through which these 
molecules promote EMT, invasion and chemoresistance.   
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ABSTRACT
The inhalation of asbestos ﬁbers is considered to be highly harmful, and lead to ﬁbrotic and/or malignant disease. Epithelial-to-mesenchymal
transition (EMT) is a common pathogenic mechanism in asbestos associated ﬁbrotic (asbestosis) and malignant lung diseases. The
characterization of molecular pathways contributing to EMT may provide new possibilities for prognostic and therapeutic applications.
The role of asbestos as an inducer of EMT has not been previously characterized. We exposed cultured human lung epithelial cells to
crocidolite asbestos and analyzed alterations in the expression of epithelial and mesenchymal marker proteins and cell morphology. Asbestos
was found to induce downregulation of E-cadherin protein levels in A549 lung carcinoma cells in 2-dimensional (2D) and 3D cultures. Similar
ﬁndings were made in primary small airway epithelial cells cultured in 3D conditions where the cells retained alveolar type II cell phenotype.
A549 cells also exhibited loss of cell–cell contacts, actin reorganization and expression of a-smooth muscle actin (a-SMA) in 2D cultures.
These phenotypic changes were not associated with increased transforming growth factor (TGF)-b signaling activity. MAPK/Erk signaling
pathway was found to mediate asbestos-induced downregulation of E-cadherin and alterations in cell morphology. Our results suggest that
asbestos can induce epithelial plasticity, which can be interfered by blocking theMAPK/Erk kinase activity. J. Cell. Biochem. 113: 2234–2247,
2012.  2012 Wiley Periodicals, Inc.
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A sbestos is a common name for a group of naturallyoccurring hydrated silica ﬁbers. Because of their tensile
strength and resilient structural and chemical properties asbestos
ﬁbers have been used in various construction and insulating
purposes. Asbestos exposure raises the risk for non-malignant
inﬂammatory conditions such as pleural effusions, pleural plaques,
and asbestosis (asbestos-induced lung ﬁbrosis) [Kamp, 2009]. It is a
severe condition in which loss of lung function can lead to death
[Frank, 1980]. Malignant conditions associated with asbestos
exposure include pleural and peritoneal mesothelioma and lung
cancer. Diffuse malignant mesothelioma is a fatal tumor arising
from mesothelial cells or underlying mesenchymal cells in the
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pleura, pericardium, and peritoneum [Mossman et al., 1990].
Asbestos-induced lung cancer is indistinguishable from that caused
by tobacco smoke [Roggli and Sanders, 2000]. Although asbestos
has been banned, the long latency preceding diseases together with
the remaining risk for exposure during renovation and demolition
works are expected to lead to increased incidence of asbestos
exposure-related diseases worldwide [Huuskonen and Rantanen,
2006].
Epithelial-to-mesenchymal transition (EMT), a series of altera-
tions occurring in cell architecture and behavior, is implicated in
ﬁbrotic diseases and in cancer progression. In EMT epithelial cells
lose their epithelial characteristics and gain properties of mesen-
chymal cell [Thiery and Sleeman, 2006]. Cells undergoing EMT lose
epithelial marker proteins such as the adherens junction protein
E-cadherin and tight junction protein zonula occludens (ZO)-1 and
begin to express mesenchymal proteins such as smooth muscle
actin (SMA), collagen, vimentin, and ﬁbronectin. Loss of epithelial
markers and expression of mesenchymal marker proteins correlate
with tumor progression and poor prognosis [Thiery, 2002; Peinado
et al., 2004; Barrallo-Gimeno and Nieto, 2005; Moody et al., 2005;
Thiery and Sleeman, 2006]. Loss of E-cadherin-dependent intercel-
lular adhesion contributes to increased tumor cell motility and
invasion into surrounding tissues [Brabletz et al., 2001; Guarino,
2007]. EMT can give rise to metastasizing cells from the primary
tumors and contribute to metastasis development [Thiery, 2002;
Huber et al., 2005].
After epithelial injury, EMT is likely to have a role in repair and
scar formation [Willis and Borok, 2007]. In organ ﬁbrosis including
lung, kidney, eye, and liver, EMT may contribute to ﬁbroblast
accumulation and parenchyma destruction in advanced ﬁbrosis
[Guarino et al., 2009]. Markers of EMT have been identiﬁed from
epithelial cells of idiopathic pulmonary ﬁbrosis (IPF) patients [Willis
and Borok, 2007]. Asbestosis and IPF exhibit many similarities
including histopathology of usual interstitial pneumonia (UIP).
These diseases may share common pathogenic mechanisms.
Despite active research, understanding of molecular mechanisms
underlying the pathogenesis of asbestos-associated malignancies,
and of ﬁbrotic lung diseases has remained insufﬁcient for the
development of efﬁcient treatments. Increasing evidence has
recognized reactive oxygen species (ROS) and reactive nitrogen
species (RNS) as important mediators of asbestos-induced toxicity
[Mossman and Churg, 1998; Shukla et al., 2003; Kamp, 2009]. These
reactive species oxidate and/or nitrolysate proteins and DNA
[Shukla et al., 2003] and alter cell signal transduction pathways.
Increased levels of ROS as well as endoplasmic reticulum stress have
been implicated in alveolar epithelial cell EMT [Zhong et al., 2011].
In addition, asbestos exposure can lead to increased production and
activation of various growth factors and cytokines [Robledo and
Mossman, 1999; Yin et al., 2007].
Because asbestos exposure can induce signaling pathways
previously linked to epithelial cell plasticity, we hypothesized
that asbestos may initiate EMT processes which contribute to the
pathogenesis of ﬁbrotic and malignant lung diseases. Here, we
found that asbestos-induced EMT-like alterations in human A549
lung carcinoma cells. Primary human lung epithelial cells did not
show similar alterations, which was likely due to loss of alveolar
type II cell phenotype in 2D cultures. However, primary cells
cultured in 3D exhibited abundant cell surface E-cadherin
expression, surfactant protein production and were sensitive to
asbestos-induced loss of E-cadherin protein expression. To identify
possible sites of therapeutic interference, we analyzed in detail the
mechanism of asbestos-induced phenotypic changes in A549
epithelial cells.
MATERIALS AND METHODS
GROWTH FACTORS, ANTIBODIES, AND INHIBITORS
Transforming growth factor (TGF)-b1 and tumor necrosis factor
(TNF)-a were from R&D Systems. Mouse monoclonal anti-E-
cadherin, mouse monoclonal Smad2/3, and rabbit polyclonal anti-
ZO-1 antibodies were from BD Transduction Laboratories and
Invitrogen, respectively. Rabbit polyclonal anti-phospho-42/44
MAP kinase (Thr202/Tyr 204) and mouse monoclonal anti-44/42
MAPK (Erk1/2) (3A7) antibodies were from Cell Signaling
Technology, rabbit polyclonal antibody against NF-kB (p65,
RelA) from Calbiochem. Rabbit polyclonal anti-b-tubulin and
rabbit polyclonal anti-SP-D antibodies were from Santa Cruz
Biotechnology. Rabbit polyclonal anti phospho-Smad2 was
provided by Peter ten Dijke (The Netherlands Cancer Institute,
Amsterdam). Mouse monoclonal a-smooth muscle actin antibody
was from NeoMarkers. The inhibitor of TGF-b superfamily type I
activin receptor-like kinase (ALK) receptors, SB431542, was from
Sigma and used at 6mM concentration. PD98059 [inhibitor of MAP
kinase kinase (MEK), used at 30mM], SP600125 [inhibitor of c-Jun
N-terminal kinase (JNK), used at 10mM], JSH-23 (inhibitor of the
nuclear translocation of NF-kB p65, used at 20mM) were from
Calbiochem.
TWO DIMENSIONAL CELL CULTURES
Primary human bronchial epithelial cells (NHBE) and small airway
epithelial cells (SAEC) were from Lonza and cultured according to
manufacturer’s instructions. One batch of NHBE cells and several
independent batches of SAECs were used in the experiments. Cells
were used between passages 4 and 8. BEAS-2B cells are non-
malignant immortalized human bronchial epithelial cells (ATCC).
They were grown in LHC-9 medium according to manufacturer’s
instructions (Invitrogen). Human A549 lung epithelial cells (ATCC)
originate from carcinoma tissue, but have retained some character-
istics of alveolar type II epithelial cells. These cells were grown in
minimal essential medium (MEM) supplemented with 10% fetal
bovine serum (Gibco) and antibiotics.
For experiments the cells were seeded on six-well plates and
treated with increasing concentrations of crocidolite asbestos
(obtained from the Finnish Institute of Occupational Health) or
TGF-b1 for the indicated times. For longer incubations fresh
culture medium was changed every 2–3 days. The experiments
were performed under standard culture conditions. Only short
stimulations for the analysis of Smad2 phosphorylation were
performed under serum-free conditions. The inhibitors were added
to the medium 1 h prior to stimulation where indicated. Images of
cells were captured using Axiovert 200 inverted epiﬂuorescence
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microscope and Axio-Cam HR camera (Zeiss) at the Biomedicum
Imaging Unit of the University of Helsinki.
THREE DIMENSIONAL CELL CULTURES
Three dimensional (3D) cultures were generated using Matrigel
basement membrane matrix (Beckton-Dickinson). Ice cold Matrigel
was added to chambered coverglasses (Nunc) on ice and allowed
to solidify at 378C for 2 h. Subconﬂuent A549 or SAEC cells were
trypsinized and seeded on top of Matrigel (5 104 cells/chamber).
Normal complete culture medium was used to produce the polarized
3D structures. New medium was added every 2–3 days. Asbestos
and TGF-b1 treatments were started on 3- to 7-day-old cultures
and continued for 1 week.
GENERATION OF IkB 32/36A EXPRESSING STABLE CELL LINES
Retroviral vector pBabePuro was from Addgene and the construct
pBabePuro IkB32/36A expressing a dominant-negative mutant of
IkB was kindly provided by Juha Klefstro¨m (University of Helsinki),
dominant negative function described in [Traenckner et al., 1995].
Retroviruses were produced in 293GPG packaging cell line
[Ory et al., 1996]. Brieﬂy, the producer cells were transfected
overnight using Fugene transfection reagent (Roche) followed by
collection of cell-conditioned medium, which was then used to
transduce A549 cells. Puromycin selection was started 2 days after
transduction.
TRANSIENT TRANSFECTION AND LUCIFERASE ASSAY
Cells to be transfected were seeded in six-well plates. The next day
the cells were co-transfected with a total of 2mg of promoter
constructs (CAGA)12-luc (Smad3 responsive) or ARE-luc (Smad2
responsive) and Fast-1 provided by Peter ten Dijke (The Netherlands
Cancer Institute, Amsterdam) together with pRL-TK (Renilla
Luciferase control, Promega) plasmid using Fugene HD transfection
reagent (Roche). The pRL-TK plasmid contains the Renilla
luciferase gene under the control of a constitutively expressed
thymidine kinase promoter, and was used in dual luciferase assays
to normalize the transfection efﬁciency. Dual luciferase based
Cignal Finder 10-Pathway Cancer Reporter Array (SABioscience)
was used according to manufacturer’s instructions. Cells were
lysed and subjected to luciferase activity measurements by Dual
Luciferase Reporter Assay (Promega) and DCR-1 luminometer (MGM
Instruments Digene Diacnostics Inc.). Treatment with TGF-b or
asbestos was not found to unspeciﬁcally alter luciferase activity of
the promoter constructs.
RNA ISOLATION AND QUANTITATIVE RT-PCR
Total cellular RNA was isolated using RNeasy Mini kit (Qiagen)
and reverse transcribed to cDNA using Random hexamer primers
(Invitrogen) and Superscript III reverse transcriptase (Life Technol-
ogies) according to manufacturer’s instructions. The cDNAs were
ampliﬁed using TaqMan Assays-on-Demand gene expression
products (Applied Biosystems) and CFX96 Real-time PCR detection
system (BioRad). Control ampliﬁcations directly from RNA were
performed in order to rule out DNA contamination. The levels of
gene expression were determined using the Ct method, and the
results have been expressed as mRNA expression levels normalized
to the levels of a gene with a constant expression (TBP, TATA-
binding protein).
SDS–PAGE AND IMMUNOBLOTTING
Cells were lysed in RIPA buffer (50mM Tris–HCl, pH 7.4, 150mM
NaCl, 1mM EDTA, 1% NP-40, 0.2% Na-deoxycholate) containing
protease inhibitors (Roche Diagnostics) on ice for 15min. For the
analysis of Smad2 phosphorylation cells were lysed in lysis buffer
(20mM Tris–HCl, pH 8, 120mM NaCl, 0.5% NP-40, 1mM Na3VO4)
containing protease inhibitors (Roche Diagnostics) on ice for 15min.
Protein concentrations were measured using a BCA Protein Assay
Kit (Pierce). Equal amounts of protein were separated by SDS–PAGE
using 10% or 4–20% gradient Tris–glycine gels (Lonza) and
transferred to Protran nitrocellulose membranes (Whatman) using a
semi-dry blotting system (Bio-Rad). Membranes were ﬁrst blocked
with 5% non-fat milk in TBS/0.05% Tween-20 to prevent non-
speciﬁc binding of the antibodies and then incubated with the
primary or biotin-conjugated secondary antibodies (DAKO) in
TBS/5% BSA-0.05% Tween-20 at room temperature for 1 h.
After several washing steps, the ﬁnal detection was performed
using HRP-conjugated streptavidin and an enhanced chemilumi-
nescence Western blotting detection system (Amersham). Three
independent experiments were included for the analyses of protein
band intensities with the Scion Image analysis program (Scion
Corporation).
IMMUNOFLUORESCENCE ANALYSIS AND MICROSCOPY
Cells were seeded on glass coverslips and cultured for the indicated
times. For the detection of E-cadherin, NF-kB (p65), or F-actin cells
were ﬁxed with 4% paraformaldehyde/PBS at room temperature for
10min. For the detection of ZO-1, the cells were ﬁxed with methanol
at 208C for 15min. Nonspeciﬁc binding of the antibodies was
prevented by blocking with 5% BSA/PBS for 30min. During
blocking 0.3% Tx-100 was added when permeabilization of cells
was needed. All antibody dilutions and washing steps were made in
Dulbecco’s PBS containing 0.5% BSA. The cells on coverslips
were incubated with the primary antibodies for 1 h at room
temperature and washed. The bound primary antibodies were
detected using AlexaFluor secondary antibodies (Molecular Probes).
TRITC-conjugated phalloidin (Sigma) was used for the detection of
F-actin. Finally, the coverslips were washed with water andmounted
on glass slides with Vectashield mounting medium containing
DAPI (Vector Laboratories). Images were captured with Axioplan 2
epiﬂuorescence microscope and Axio-Cam HR camera using
Axiovision 4.5 software (Zeiss) at the Biomedicum Imaging Unit
of the University of Helsinki.
3D cultures in Matrigel were ﬁxed with 4% paraformaldehyde/
PBS for overnight at room temperature. Fixed gels were embedded
in parafﬁn and cut into 4mm sections, which were then
deparafﬁnized in xylene and rehydrated in graded alcohol. Antigens
were retrieved by heating in 10mM citrate buffer (pH 6.0). The
sections were blocked with 5% non-fat milk/PBS containing normal
goat serum (Jackson Immuno Reseach) at room temperature for
30min followed by incubation with primary antibodies diluted in
blocking buffer atþ48C overnight. The sections were then incubated
with AlexaFluor secondary antibodies at room temperature for 1 h,
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washed several times and mounted using Vectashield Hard Set
mounting medium. The nuclei were visualized with DAPI. The
images were captured as described above. Digital morphometry was
conducted using Image Pro Plus 7.0 (Media Cybernetics) program.
A representative picture from the control group was used to generate
a ﬁlter for the detection of E-cadherin ﬂuorescence intensity relative
to unstained area in the 3D structure. Six to 10 independent pictures
of each group were analyzed using this ﬁlter. Images were captured
fromH&E and SP-D stained sections with Olympus BX51 and Artray
Artcam 300 MI.
STATISTICAL ANALYSIS
Data were analyzed using PASW Statistics 18 program forWindows.
Statistical differences in E-cadherin levels in 3D cultures were
evaluated using the nonparametric Kruskal–Wallis test (A549
cultures, all groups) or Mann–Whitney U-test (SAEC cultures,
asbestos-exposed group vs. control group). Differences in mRNA
expression levels (asbestos-exposed group vs. control group) and
E-cadherin immunoblot band intensities (asbestos-exposed group
vs. control group and DMSO treated vs. PD98059 treated group)
were analyzed with Mann–Whitney U-test. A P-value of 0.05 was
considered statistically signiﬁcant.
RESULTS
ASBESTOS EXPOSURE INDUCES DOWNREGULATION OF EPITHELIAL
PROTEINS IN TRANSFORMED LUNG EPITHELIAL CELLS
To test whether asbestos can induce EMT and downregulation of
epithelial proteins we exposed cultured lung epithelial cells to
crocidolite asbestos (0.5–5mg/cm2) under standard culture condi-
tions for 3 days followed by analyses of E-cadherin protein levels by
immunoblotting. TGF-b1, a known inducer of EMT, was used as a
control. In primary human bronchial epithelial cells (NHBE) and
small airway epithelial cells (SAEC) as well as in immortalized but
non-malignant human bronchial epithelial cells (BEAS-2B) neither
asbestos nor TGF-b1 treatment was able to alter E-cadherin protein
levels (Fig. 1A). In contrast, in human lung carcinoma cells (A549)
E-cadherin levels were clearly decreased when treated with asbestos
or TGF-b1. Interestingly, TGF-b1 induced E-cadherin downregula-
tion already after 1 day, while asbestos-induced downregulation
was not detected until after 3 days (Fig. 1B).
Loss of E-cadherin is considered to be a universal marker for
the loss of the epithelial phenotype. In monolayer cultures only in
A549 carcinoma derived cells asbestos seemed to induce alterations
consistent with the initiation of EMT. We addressed the effects of
asbestos on the cell surface localization of epithelial junction
proteins in A549 cells next. Cells grown on glass coverslips were
exposed to asbestos (5mg/cm2) or TGF-b1 (2 ng/ml) for 3 days
after which the cells were ﬁxed and stained with antibodies speciﬁc
for E-cadherin or the tight junction protein ZO-1. Asbestos exposure
induced a signiﬁcant downregulation of cell surface E-cadherin
consistent with the immunoblotting result (Fig. 2). ZO-1 staining
was also decreased or lost from cell contacts in asbestos-treated
cells. As expected, TGF-b1 induced similar alterations in these
epithelial junctional proteins [Kasai et al., 2005].
E-cadherin mRNA levels were examined by quantitative RT-PCR
using speciﬁc primers (Materials and Methods section). Unexpect-
edly, A549 cells exposed to asbestos for 3 or 6 days showed no
downregulation of E-cadherin mRNA levels (Fig. 1C). In contrast,
TGF-b1 treated cells expressed clearly lower levels of E-cadherin
mRNA, suggesting that TGF-b1 and asbestos mediate their effects
via different mechanisms. Transcription factors Snail and Slug have
been implicated in EMT associated downregulation of E-cadherin
transcription, and their mRNA levels were analyzed next. As
expected, TGF-b1 induced dramatically the expression of Snail and
especially of Slug by 3 days (Fig. 1D). The expression was further
increased by 6 days. Unlike TGF-b1, asbestos at 3 days had no effect
and at 6 days induced only a very modest increase in the expression
of these transcription factors, which is consistent with E-cadherin
mRNA expression levels. Further analysis of early time points
revealed induction of both transcription factors by TGF-b1 already
after 1 h stimulation, but no alterations during asbestos exposure
(Supplementary Fig. 1).
The BMP inhibitor gremlin is a TGF-b target gene involved in the
induction of EMT processes [Koli et al., 2006; Lee et al., 2007]. To
analyze whether asbestos exposure can increase gremlin expression
in A549 cells we analyzed gremlin mRNA levels by quantitative RT-
PCR. Gremlin mRNA levels in asbestos exposed A549 cells were
found to be comparable to control levels (Supplementary Fig. 2).
In contrast, TGF-b1 increased gremlin mRNA levels nearly ﬁvefold
at 3 days and over 10-fold at 6 days.
EPITHELIAL PHENOTYPE IS ALTERED BY ASBESTOS ALSO IN THREE
DIMENSIONAL A549 CULTURES
In three-dimensional cultures cells adopt a morphology, which
mimics better in vivo situations. The structural organization of cells
can be protective against exogenous signals [Schmeichel and Bissell,
2003], which prompted us to study asbestos-induced alterations in
A549 cells cultured on Matrigel (Materials and Methods section).
Cells cultured for 2 weeks without stimulatory factors formed well-
organized structures with polarized cells displaying abundant E-
cadherin staining around a central lumen (Fig. 3A). Asbestos or
TGF-b1 treatments were initiated on 1-week-old cultures and
continued for another week. TGF-b1 was found to alter the
appearance of the 3D structures, making them more scattered
and less well organized. In control cultures, cells disappeared
from the centre of the structure, which was less pronounced in the
TGF-b-exposed cultures (Fig. 3A). In addition, the cell surface E-
cadherin levels were signiﬁcantly decreased in asbestos-treated
cultures (from 60% of a total area in the structures to 35%,
Materials and Methods section) and even more in TGF-b1 treated
cultures (from 60% to 15%; Fig. 3B). These results suggest that
the epithelial marker E-cadherin is signiﬁcantly decreased by
asbestos exposure also in three-dimensional cultures consistent with
the initiation of EMT.
INDUCTION OF MESENCHYMAL CHARACTERISTICS IN A549 CELLS
BY ASBESTOS EXPOSURE
We investigated next whether asbestos exposed cells gained
mesenchymal characteristics typical for cells undergoing EMT.
Alterations in cell morphology were ﬁrst analyzed in monolayer
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cultures exposed to asbestos for 3 days. Asbestos exposure
was found to induce the loss of the typical cobblestone-like
appearance of A549 cells, which became scattered and more
elongated (Fig. 4A). Asbestos exposed cells also frequently exhibited
larger intercellular space and less cell–cell contacts. Alterations in
actin organization were visualized by phalloidin staining, which
showed re-organization of actin into longitudinal stress ﬁbers
(Fig. 4A).
The expression of mesenchymal genes associated with EMT was
analyzed next. A549 cells were exposed to asbestos for 3 days,
total cellular RNA was extracted and the expression levels of
vimentin, ﬁbronectin (FN), N-cadherin, collagen 1 (Col1A1), and
a-smooth muscle actin (a-SMA) were measured by quantitative
RT-PCR. Asbestos exposure-induced fourfold increase in a-SMA
and threefold increase in collagen 1mRNA levels (Fig. 4B). However,
only the induction of a-SMA expression reached statistical
signiﬁcance. Vimentin, FN, and N-cadherin mRNA levels were
not altered signiﬁcantly. To analyze alterations in a-SMA protein
levels, cells were exposed to asbestos for 3 or 6 days followed by
immunoblotting analyses. Consistent withmRNA expression results,
asbestos exposure increased a-SMA protein levels (Fig. 4C). The
results suggest that in addition to downregulation of epithelial
proteins, asbestos is able to alter epithelial cell morphology and
induce the expression of certain proﬁbrotic genes as well as proteins
associated with the progression of EMT.
ASBESTOS-INDUCED DOWNREGULATION OF E-CADHERIN IN A549
CELLS IS NOT ASSOCIATED WITH INCREASED TGF-b ACTIVATION
Asbestos has been reported to induce gene transcription of TGF-b
and other cytokines [Yin et al., 2007]. In addition, ROS are generated
during asbestos exposure [Mossman and Marsh, 1989] and asbestos
generated ROS may activate latent forms of TGF-b [Pociask et al.,
2004]. TGF-b signals mainly through Smad2 and Smad3 transcrip-
tion factors, which are phosphorylated and transported into the
nucleus upon ligand binding [Nakao et al., 1997]. To test whether
asbestos increases TGF-b signaling activity in our model, A549 cells
were transiently transfected with constructs containing luciferase
gene under the control of TGF-b responsive promoters (Smad3
Fig. 1. Asbestos exposure leads to downregulation of E-cadherin protein levels in A549 lung carcinoma cells. A: Primary human bronchial epithelial cells (NHBE), small airway
epithelial cells (SAEC), immortalized non-malignant bronchial epithelial cells (BEAS-2B), and lung carcinoma cells (A549) were exposed to asbestos or TGF-b1 for 3 days
followed by analyses of E-cadherin protein levels by immunoblotting. Tubulin was used as a loading control. B: A549 cells were exposed to asbestos or TGF-b1 for the indicated
times followed by analyses of E-cadherin protein levels. C,D: A549 cells were exposed to asbestos as indicated. Total cellular RNA was isolated followed by quantitative RT-PCR
analyses of E-cadherin (C) or Snail and Slug (D) mRNA expression levels. Expression levels were normalized to the expression levels of TBP and are expressed relative to control.
Error bars represent standard deviation of the means (n¼ 2).
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responsive CAGA12-luc or Smad2 responsive ARE-luc, Materials
and Methods section) followed by exposure to asbestos and
measurement of luciferase activity. Exposure to asbestos for 3
days was not able to induce CAGA12-luc (Fig. 5A) or ARE-luc (not
shown) activity in A549 cells, while TGF-b1 induced signaling
activity as expected. To validate these results we analyzed Smad2
phosphorylation, that is, activation at early time points (1, 5, and
24 h) after asbestos or TGF-b1 stimulation. A549 cells were exposed
to asbestos or TGF-b1 for the indicated times followed by
immunoblotting analyses of P-Smad2. TGF-b1 induced phosphor-
ylation of Smad2 peaked at 1 h and decreased thereafter (Fig. 5B).
Asbestos, however, did not induce Smad2 phosphorylation at any
time point.
TGF-b can also signal via Smad-independent pathways, which
may contribute to cell plasticity. To further assess the possible role of
TGF-b in asbestos-induced downregulation of E-cadherin, A549
cells were exposed to asbestos in the presence of SB431542, an
inhibitor of TGF-b type I receptors. Interestingly, SB431542 had
only a moderate effect on asbestos-induced downregulation of
E-cadherin (Fig. 5C). In the presence of SB431542 asbestos was still
able to induce signiﬁcant downregulation of E-cadherin levels,
while TGF-b1-induced downregulation was completely blocked as
expected (Fig. 5D). The result suggests that asbestos-induced EMT-
like phenotype in A549 cells does not depend on Smad2/3 signaling
and is not fully explained by induction of TGF-b-mediated
pathways.
MAPK/JNK, MAPK/Erk, AND NF-kB SIGNALING ACTIVITY DIFFER
BETWEEN NORMAL AND TRANSFORMED CELLS
Cancer cells have typically high activity of cellular signaling
pathways, which are silent or active at low levels in non-malignant
cells. To screen for differences that make A549 cells more
susceptible to asbestos-induced EMT-like alterations than primary
cells (Fig. 1A), we compared the basal activity levels of selected
cancer-associated signaling pathways in A549 cells and those
of normal SAECs using a commercial Cancer Reporter promoter
array (Materials and Methods section). Cells were transiently
transfected with the promoter constructs and cultured for 2 days
under standard culture conditions before the activity measurements.
In addition to the p53 pathway, the signaling activities of
Fig. 2. Epithelial marker proteins decrease from cell junctions of A549 cells after asbestos exposure. A549 cells were seeded on glass coverslips, exposed to asbestos (5mg/
cm2) or TGF-b1 (2 ng/ml) for 3 days, ﬁxed and stained with antibodies speciﬁc for E-cadherin or ZO-1. DAPI staining was used to visualize nuclei. Original magniﬁcations are
indicated on the right.
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mitogen activated protein kinase/c-jun N-terminal kinase (MAPK/
JNK), MAPK/extracellular signal-regulated kinase (Erk), and
Nuclear factor kappa B (NF-kB) pathways were signiﬁcantly
elevated in A549 cells (Fig. 6A). These three pathways have
been previously implicated in EMT and were selected for further
analyses.
BLOCKADE OF NF-kB PATHWAY DOES NOT ALTER CELLULAR
RESPONSES TO ASBESTOS
The role of NF-kB signaling in asbestos-induced responses in A549
cells was analyzed by blocking this pathway using a dominant
negative inhibitor of nuclear factor kappa B (IkB) 32/36A expression
construct. Mutated serines in IkB32/36A render it unsusceptible
to phosphorylation, and therefore prevent its removal from its
inhibitory association with NF-kB [Traenckner et al., 1995]. Stable
A549 cell lines expressing IkB32/36A were generated by retroviral
transduction (Materials and Methods section). Immunoﬂuorescence
analyses of the NF-kB subunit p65 showed that IkB32/36A
expression inhibited TNF-a induced nuclear localization of p65
(Fig. 6B) suggesting efﬁcient blockade of NF-kB pathway activity.
A549 cells stably transduced with the dominant negative IkB
exhibited severely decreased cell proliferation/survival (not shown).
The use of JSH-23, a chemical inhibitor of the NF-kB pathway, also
resulted in reduced number of cells with altered morphology (not
shown) suggesting a role for NF-kB signaling in A549 cell survival.
This may have an effect also on cellular responses to asbestos
treatment. However, expression of IkB32/36A did not alter asbestos-
induced E-cadherin downregulation (Fig. 6C) or a-SMA mRNA
induction (Fig. 6D) in A549 cells.
MAPK/Erk PATHWAY CONTRIBUTES TO ASBESTOS-INDUCED
EMT-LIKE TRANSITION IN A549 CELLS
The role of MAPK/Erk and MAPK/JNK pathways in asbestos-
induced downregulation of E-cadherin was analyzed using chemical
inhibitors of MAP kinase kinase MEK (PD98059, 30mM) and c-Jun
Fig. 3. Epithelial phenotype of A549 cells is altered by asbestos and TGF-b in three dimensional cultures. Cells were grown onMatrigel basement membrane matrix for 1 week
followed by exposure to asbestos (5.0mg/cm2) or TGF-b1 (2.0 ng/ml) for another week. A: The structures were stained with H&E or antibodies speciﬁc for E-cadherin. Asbestos
ﬁbers detectable within the cells are indicated with an arrow. Magniﬁcations are indicated on the right. B: Digital image analysis of the staining intensity of E-cadherin relative
to non-stained cellular area in the structures. The amount of E-cadherin is expressed as percentage relative to non-stained cellular area. Error bars represent SEM of the samples
(n¼ 10). E-cadherin positive area differ signiﬁcantly between the groups (Ctrl, asbestos, TGF-b), P< 0.0001.
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Fig. 4. Asbestos exposed cells gain mesenchymal characteristics. A: A549 cells seeded on culture plates or on glass coverslips, were exposed to asbestos (5mg/cm2) for 3 days.
Live cells were imaged or the cells were ﬁxed and stained with phalloidin to visualize F-actin. DAPI stain was used to visualize the nuclei. Original magniﬁcations are indicated on
the right. B: A549 cells were exposed to asbestos for 3 days. Total cellular RNA was isolated followed by quantitative RT-PCR analyses using speciﬁc primers for vimentin,
ﬁbronectin, N-cadherin, collagen 1A1 or a-smooth muscle actin (a-SMA). Expression levels were normalized to the expression levels of TBP and are expressed relative to
control. Error bars represent standard deviation of the means (n 2). C: A549 cells were exposed to asbestos (5mg/cm2) as indicated followed by analyses of a-SMA protein
levels by immunoblotting. Tubulin was used as a loading control.
Fig. 5. Asbestos-induced downregulation of E-cadherin is not associated with increased TGF-b activity. A: A549 cells transiently transfected with Smad3 responsive
(CAGA)12-luciferase promoter construct were exposed to asbestos (1–10mg/cm2) or TGF-b1 (100 pg/ml) for 3 days and subjected to luciferase activity measurement. The
luciferase activities were normalized to constitutively expressed Renilla luciferase activities, and the results are expressed relative to control. The error bars represent standard
deviation of the means (n¼ 2). A representative experiment of TGF-b induced luciferase activity is shown on the right. B: A549 cells were exposed to asbestos (5mg/cm2) or
TGF-b1 (2 ng/ml) for the indicated times and analyzed for Smad2 phosphorylation (P-Smad2) or total Smad2 by immunoblotting. Tubulin was used as a loading control.
C: A549 cells were exposed to asbestos (5mg/cm2) or TGF-b1 (2 ng/ml) for 3 days in the presence of an inhibitor of TGF-b type I receptors (SB431542, 6mM) or DMSO used as a
control followed by analyses of E-cadherin protein levels by immunoblotting. Tubulin was used as a loading control. D: E-cadherin band intensities were quantiﬁed and
normalized to tubulin. The results are expressed relative to control. Error bars represent standard deviation of the means (n¼ 3). Normalized E-cadherin band intensities differ
signiﬁcantly between the groups (Kruskal–Wallis test), P¼ 0.035.
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N-terminal kinase/stress-activated protein kinase JNK (SP600125,
10mM). A549 cells were pre-treated with the inhibitors for 1 h before
exposure to asbestos (5mg/cm2) under standard culture conditions
for 3 days. Immunoblotting analyses suggested that inhibition
of MAPK/Erk pathway during the exposure signiﬁcantly reversed
E-cadherin downregulation, while inhibition of MAPK/JNK path-
way had no effect (Fig. 7A). Quantiﬁcation of band intensities
(E-cadherin/tubulin) showed statistically signiﬁcant E-cadherin
downregulation by asbestos in control (DMSO)-treated cells, which
was reversed by PD98059 (Fig. 7B). Interestingly, PD98059 also
Fig. 6. The activity of MAP-kinases and NF-kB differ between SAECs and A549 cells but blockade of NF-kB pathway in A549 cells does not interfere with E-cadherin
downregulation or a-SMA induction by asbestos. A: Basal activities of selected pathways were compared between A549 cells and primary human SAECs using a pathway
reporter array. The results are expressed as relative activities and the values are normalized to the positive control. The error bars represent standard deviation of the means
(n¼ 2). B: A549 cells transduced with either control virus or virus containing a dominant negative mutant of IkB (IkB32/36A) were seeded on glass coverslips, exposed to TNF-a
(5 ng/ml) for 2 h, ﬁxed and stained with p65 speciﬁc antibody to analyze NF-kB nuclear localization. Original magniﬁcation is indicated on the right. C: Stably virus transduced
A549 cells were exposed to asbestos (5mg/cm2) for 3 days and analyzed for E-cadherin protein levels. Tubulin was used as a loading control. D: Stably virus transduced A549
cells were exposed to asbestos for 3 days, total cellular RNA was isolated followed by quantitative RT-PCR analyses using speciﬁc primer for a-smooth muscle actin (a-SMA).
Expression levels were normalized to the expression levels of TBP and are expressed relative to control. Error bars represent standard deviation of the means (n¼ 2).
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signiﬁcantly increased the basal levels of E-cadherin (Fig. 7B)
further pointing to a role for MAPK/Erk pathway in the regulation of
E-cadherin levels. In agreement, asbestos exposure further enhanced
Erk1/2 phosphorylation, which could be reduced to basal levels by
the addition of PD98059 (Fig. 7C).
We analyzed next whether the inhibition of MAPK/Erk pathway
could also inhibit asbestos-induced morphological alterations in
A549 cells. PD98059 pre-treated cells were exposed to asbestos
under standard culture conditions for 3 days, ﬁxed and stained
with phalloidin to visualize F-actin. Scattering of cells and loss
Fig. 7. MAPK/Erk1/2 pathway contributes to asbestos induced loss of epithelial phenotype in A549 cells. A: A549 cells were pre-treated with inhibitors of MAP kinase kinase
MEK (PD98059, 30mM) or JNK (SP600125, 10mM) or treated with DMSO only (Ctrl) and exposed to asbestos (5mg/cm2) for 3 days followed by analyses of E-cadherin protein
levels by immunoblotting. Tubulin was used as a loading control. B: E-cadherin band intensities were quantiﬁed and normalized to tubulin. The results are expressed relative to
control. Error bars represent standard deviation of the means (n¼ 3). Normalized E-cadherin band intensities differ signiﬁcantly between the groups (unexposed, asbestos),
P¼ 0.037 and (unexposed Ctrl treated, unexposed PD98059 treated), P¼ 0.037. C: A549 cells were pre-treated with PD98059 or DMSO (Ctrl) and exposed to asbestos for
3 days followed by analyses of ERK1/2 phosphorylation, that is, activation or total ERK1/2 levels by immunoblotting. D: A549 cells were seeded on culture plates or on glass
coverslips, pre-treated and stimulated as above. Live cells were imaged or the cells were ﬁxed and stained with phalloidin to visualize F-actin. DAPI stain was used to visualize
the nuclei. Original magniﬁcations are indicated on the right. E: A549 cells were pre-treated and stimulated as above. Total cellular RNA was isolated followed by quantitative
RT-PCR analyses using speciﬁc primer for a-smooth muscle actin (a-SMA). Expression levels were normalized to the expression levels of TBP and are expressed relative to
control. Error bars represent standard deviation of the means (n¼ 3).
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of cell–cell contacts induced by asbestos were almost completely
blocked by the addition of PD98059 (Fig. 7D). However, a-SMA
mRNA induction by asbestos exposure was not altered by inhibition
of MAPK/Erk activity, suggesting that asbestos-induced mesenchy-
mal gene expression is regulated by other signaling pathways
(Fig. 7E).
PRIMARY SMALL AIRWAY EPITHELIAL CELLS RETAIN TYPE II CELL
PHENOTYPE IN 3D CULTURES AND DOWNREGULATE E-CADHERIN
IN RESPONSE TO ASBESTOS EXPOSURE
Bronchial epithelial cells have been suggested to be less susceptible
to EMT than alveolar epithelial cells [Buckley et al., 2010], which
may explain our results with monolayer cultures of NHBE and
BEAS-2B cells. Furthermore, SAECs in monolayer cultures may
spontaneously differentiate and lose alveolar type II cell phenotype,
which can inﬂuence the sensitivity to EMT. Different interactions
between the cells and with the environment in two and in three
dimensional cultures are also likely to promote different responses
[Schmeichel and Bissell, 2003]. Therefore, we cultured SAEC cells in
3D cultures on Matrigel to investigate the effects of asbestos in 3D
environment. Cells seeded on top of Matrigel formed cell aggregates,
which in 10 days re-organized into saccular-like structures. Cells
facing the lumen were shown to produce surfactant protein D
(Fig. 8A) suggesting that in 3D the alveolar type II cell phenotype
is retained. These saccular-like structures exhibited abundant
E-cadherin staining around the cells (Fig. 8B). Asbestos exposure
was initiated on 3-day-old cultures and continued for 1 week. Cell
surface E-cadherin levels were signiﬁcantly decreased in asbestos-
treated structures (from25% of a total area in saccular structure to
7,5%; Fig. 8B,C). These results suggest that also normal primary
SAEC cells are susceptible to asbestos-induced cell plasticity when
cultured in an environment supporting alveolar type II cell
phenotype.
DISCUSSION
The development of asbestosis is directly associated with the extent
and length of asbestos exposure, but cancer can develop even at
low pulmonary concentrations of asbestos ﬁbers [Kamp, 2009].
Asbestos-related or other forms of pulmonary ﬁbrosis, especially
IPF, signiﬁcantly elevate the risk for lung cancer [Kamp, 2009].
Interestingly, Vancheri et al. [2010] have recently suggested that IPF
could be considered as a neoproliferative disorder of the lung since
there are many similarities between the pathogenic hallmarks of IPF
and cancer. Recapitulation of developmental programs such as EMT
is one common feature which may play an important role in disease
progression [Selman et al., 2008] and the characterization of
molecular mechanisms contributing to EMT may provide new
Fig. 8. SAECs retain alveolar type II cell phenotype in three dimensional cultures and downregulate E-cadherin in response to asbestos exposure. Cells were grown onMatrigel
basement membrane matrix for 3 days followed by exposure to asbestos (5.0mg/cm2) for 1 week. A: Saccular structures were stained with antibodies speciﬁc for SP-D.
B: Saccular structures were stained with antibodies speciﬁc for E-cadherin. Original magniﬁcations are indicated on the right. C: Digital image analysis of the staining intensity
of E-cadherin relative to non-stained cellular area in saccular structures. The amount of E-cadherin is expressed as percentage relative to non-stained cellular area. Error bars
represent SEM of the samples (n 6). E-cadherin positive area differ signiﬁcantly between the groups (Ctrl, asbestos), P¼ 0.01.
2244 ASBESTOS INDUCES EMT JOURNAL OF CELLULAR BIOCHEMISTRY
possibilities for prognostic and therapeutic applications. We found
here that asbestos exposure can lead to downregulation of epithelial
proteins, changes in cell morphology and induction of certain
proﬁbrotic genes consistent with the induction of EMT. These
molecular alterations may contribute to the progression of asbestos-
associated ﬁbrotic and malignant lung diseases.
In the current study, A549 adenocarcinoma cells but not cultured
primary small airway or bronchial epithelial cells were induced
to undergo EMT by exposure to asbestos or TGF-b under normal 2D
culture conditions suggesting that normal cells are not very
sensitive to epithelial transitions. This is in agreement with a
previous report suggesting that normal mammary epithelial cells are
not sensitive to TGF-b mediated EMT unless sensitized by ionizing
radiation [Andarawewa et al., 2007]. However, recent studies have
described TGF-b induced EMT also in primary human cells [Doerner
and Zuraw, 2009; Camara and Jarai, 2010]. Different origin of the
cells and differences in culture conditions may explain some of
the differences between studies [Buckley et al., 2010]. Intracellular
signaling pathways responsible for cell polarity are regulated in
signiﬁcantly different manner in cells depending on whether the
cells are cultured in 2D or 3D environment [Schmeichel and Bissell,
2003]. A549 cells cultured on 2D display some features of type II
epithelial cells and show cobblestone morphology with cell
surface expression of E-cadherin. Primary SAECs, which have
not been adapted to monolayer culture, showed abundant levels of
E-cadherin but it was mainly localized intracellularly. Furthermore,
primary cells rapidly lose the alveolar type II cell phenotype in 2D
monolayer cultures. We found that under 3D culture conditions,
SAEC cells displayed abundant cell surface E-cadherin, produced
surfactant proteins characteristic to type II epithelial cells and
were sensitive to asbestos-induced dowregulation of E-cadherin. In
conclusion, our results suggest that asbestos can induce epithelial
plasticity in both primary cells and A549 cell line displaying type II
cell features.
A549 cells provide a tool for the characterization of molecular
mechanisms contributing to asbestos pathogenicity in epithelial
cells. In the current report, we illustrate a clear asbestos-induced
downregulation of epithelial proteins E-cadherin and ZO-1, which is
associated with a decrease in cell–cell contacts and a morphological
change towards more elongated phenotype characterized by actin
reorganization. Asbestos was able to efﬁciently induce E-cadherin
downregulation both in two- and three-dimensional cell culture
models. Interestingly, downregulation of E-cadherin protein level
was not associated with downregulation of E-cadherin transcription.
In agreement with this, only a small and late induction of
transcription factors Snail and Slug was detected in asbestos
exposed cells. The delayed time and modest nature of Snail and Slug
induction by asbestos could be one reason why it was not associated
with transcriptional repression of E-cadherin at 6 days. Asbestos-
induced late induction of Snail and Slug may, however, become
signiﬁcant during later times and lead to transcriptional repression
of E-cadherin. Time points beyond 6 days were, however, not
investigated in this study. Transcriptional downregulation of
E-cadherin has been suggested to be a late event in EMT [Janda
et al., 2002]. However, TGF-b stimulation did result in down-
regulation of E-cadherin mRNA levels pointing to different
mechanisms of action. Possible mechanisms for asbestos-induced
downregulation of E-cadherin are post-translational regulation or
proteolytic processing and degradation.
Asbestos containing iron can induce ROS generation, which in
turn has been suggested to activate latent forms of TGF-b [Pociask
et al., 2004]. Sullivan et al. [2008] propose a model where asbestos
elicits TNF-a expression, which leads to increased TGF-b expression
by activating MAPK/Erk pathway and that these increased amounts
of latent TGF-b are activated by asbestos-induced ROS. We have
also previously found that high concentrations of asbestos can
induce TGF-b signaling activity in primary human bronchial
epithelial cells [Mylla¨rniemi et al., 2008]. Therefore, it was
unexpected to ﬁnd that in A549 cells asbestos did not induce
TGF-b signaling activity nor was the downregulation of E-cadherin
fully reversed by blocking TGF-b receptor-mediated signaling.
Relatively small and late induction of Snail and Slug transcription
factors and the proﬁle of mesenchymal gene induction reinforced
the notion that asbestos and TGF-b are not likely to share a common
mechanism of action at least in A549 lung carcinoma cells.
However, it is likely that there exists co-operation between asbestos-
induced pathways and TGF-b in in vivo lung.
Analyses of differences in signaling pathway activities between
A549 cells and primary SAECs in monolayer cultures highlighted
MAPK/JNK, MAPK/Erk, and NF-kB pathway activities. All these
pathways have been linked to various EMT-processes, mostly
induced by TGF-b [Min et al., 2008; Kalluri and Weinberg, 2009].
Inhibition of MAPK/Erk [Li and Mattingly, 2008] or NF-kB [Huber
et al., 2004] prevents EMT in Ras-transformed mammary epithelial
cells. A549 cells have homozygous G12S K-Ras, but these cells likely
do not depend on Ras for survival [Singh et al., 2009]. As reported
earlier [Jiang et al., 2001] blocking NF-kB activity severely impaired
the proliferation/survival of A549 cells, but did not appear to
interfere with asbestos mediated downregulation of E-cadherin or
induction of a-SMA expression. Asbestos can induce NF-kB activity
[Nymark et al., 2007], which is likely to play a role in cell survival
[Sartore-Bianchi et al., 2007]. However, NF-kB activity did not
contribute to asbestos induced EMT-like transition in cell systems
used here.
Asbestos is known to induce EGFR activation by direct interaction
leading to activation of the MAPK/Erk pathway [Zanella et al.,
1996]. In agreement with previous studies, we observed asbestos-
mediated induction or Erk1/2 phosphorylation in A549 cells.
Inhibition of MAPK/Erk activity clearly prevented asbestos-
mediated downregulation of E-cadherin protein levels and restored
cell–cell contacts. These results suggest that MAPK/Erk activation
plays an important role in asbestos-induced loss of the epithelial
phenotype and is in agreement with a previous study showing that
MAPK inhibitors were effective in restoring E-cadherin localization
to cell–cell junctions in breast epithelial cells with moderate Ras
activity without signiﬁcant effect on E-cadherin expression levels
[Li and Mattingly, 2008]. Furthermore, in normal mammary
epithelial cells MAPK/Erk activation by ionizing radiation co-
operates with TGF-b1 to induce EMT [Andarawewa et al., 2007].
However, a recent article by Ramos et al. [2010] reports reversal of
TGF-b1 induced E-cadherin downregulation by co-expression of
FGF-1. Particularly, MAPK/Erk activity was shown to contribute
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to this FGF-1-mediated inhibitory activity suggesting context-
dependent regulation of E-cadherin.
Induction of a-SMA expression by asbestos was not blocked
by the inhibition of MAPK/Erk activity. In kidney tubular cells
disruption of cell contacts or forced actin polymerization can
activate the a-SMA promoter [Fan et al., 2007]. However, in A549
cells restoration of cell–cell contacts by inhibition of MAPK/Erk
activity was not able to block a-SMA expression suggesting other
mechanism for asbestos-mediated a-SMA expression. We have
recently identiﬁed GATA-6 transcription factor as an important
mediator of TGF-b induced a-SMA expression [Leppa¨ranta et al.,
2010]. Although asbestos was not able to induce TGF-b signaling
activity in A549 cells, activation of GATA-6 by asbestos through
other mechanisms is an interesting possibility.
Induction of EMT is a shared pathogenic mechanism in ﬁbrotic
and malignant lung diseases. Here, we reveal the role of asbestos
ﬁbers in the initiation of EMT and the importance of the MAPK/Erk
pathway in reduced E-cadherin levels and altered cell morphology
leading to reduced cell–cell contacts characteristic to a motile
phenotype. However, in A549 cells asbestos induced the expression
of certain proﬁbrotic genes, but not ﬁbronectin or N-cadherin and
induced only slightly the expression of the transcription factors
Snail and Slug associated with the transcriptional shift during the
progression of EMT. Thus, it is possible that asbestos induces a
transitional EMT and/or likely co-operates with other factors
activated in diseased lung, such as inﬂammatory cytokines and
growth factors. Our results support the concept of blocking MAPK/
Erk signaling as one strategy to develop anti-ﬁbrotic and anti-
cancer therapies [Leivonen et al., 2005; Roberts and Der, 2007].
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SUPPLEMENTARY DATA   
 
 
Figure 1. Asbestos fails to induce Snail or Slug expression during early exposure times. Total 
cellular RNA was isolated at the indicated time points after asbestos (5 μg/cm²) or TGF-β1 (2 
ng/ml) exposure followed by quantitative RT-PCR analyses using specific primers for Snail and 
Slug. The mRNA expression levels were normalized to the expression levels of TBP and are 
expressed relative to control.  
 
 
 
 
 
Figure 2. Asbestos fails to induce gremlin expression. Total cellular RNA was isolated at the 
indicated time points after asbestos (5 μg/cm²) or TGF-β1 (2 ng/ml) exposure followed by 
quantitative RT-PCR analyses using specific primer for gremlin 1. The mRNA expression levels 
were normalized to the expression levels of TBP and are expressed relative to control (n=2).  
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Gremlin-1 associates with ﬁbrillin microﬁbrils in vivo and
regulates mesothelioma cell survival through transcription
factor slug
JA Tamminen1,2, V Parviainen2, M Ro¨nty3,4, AP Wohl5, L Murray1,2, S Joenva¨a¨ra¨2, M Varjosalo6, O Leppa¨ranta7, O Ritvos3,8, G Sengle5,
R Renkonen2,3, M Mylla¨rniemi7 and K Koli1,2
Malignant mesothelioma is a form of cancer that is highly resistant to conventional cancer therapy for which no major therapeutic
advances have been introduced. Here, we identify gremlin-1, a known bone morphogenetic protein inhibitor crucial for embryonic
development, as a potential therapeutic target for mesothelioma. We found high expression levels of gremlin-1 in the
mesothelioma tumor tissue, as well as in primary mesothelioma cells cultured from pleural effusion samples. Downregulation of
gremlin-1 expression by siRNA-mediated silencing in a mesothelioma cell line inhibited cell proliferation. This was associated with
downregulation of the transcription factor slug as well as mesenchymal proteins linked to cancer epithelial-to-mesenchymal
transition. Further, resistance to paclitaxel-induced cell death was associated with high gremlin-1 and slug expression. Treatment of
gremlin-1-silenced mesothelioma cells with paclitaxel or pemetrexed resulted in efﬁcient loss of cell survival. Finally, our data
suggest that concomitant upregulation of ﬁbrillin-2 in mesothelioma provides a mechanism for extracellular localization of gremlin-
1 to the tumor microenvironment. This was supported by the demonstration of interactions between gremlin-1, and ﬁbrillin-1 and
-2 peptides as well as by colocalization of gremlin-1 to ﬁbrillin microﬁbrils in cells and tumor tissue samples. Our data suggest that
gremlin-1 is also a potential target for overcoming drug resistance in mesothelioma.
Oncogenesis (2013) 2, e66; doi:10.1038/oncsis.2013.29; published online 26 August 2013
Subject Categories: Molecular oncology
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INTRODUCTION
Malignant mesothelioma is an aggressive tumor, which originates
from the mesothelial surface cells lining the serous body cavities
such as the pleura, peritoneum or pericardium.1 Mesothelioma is
strongly linked to asbestos exposure, and it may take several
decades to develop after initial exposure.2 Because of the long
latency, the incidence of mesothelioma will increase in the near
future worldwide.3,4 Mesothelioma is resistant to chemo- and
radiotherapy, leading to poor prognosis for patients suffering from
this malignancy.4 New markers for screening and monitoring the
disease and in particular new drug targets are needed.
Cancer progression is associated with a re-expression of
developmental programs, which contribute to the proliferative
and invasive properties of tumor cells.5,6 Gremlin-1 is a cysteine
knot protein, which belongs to the DAN family of bone
morphogenetic protein (BMP) antagonists. Gremlin-1 can bind to
and inhibit the functions of BMP-2, -4 and -7.7,8 These three BMP
isoforms are targeted to ﬁbrillin microﬁbrils, suggesting
extracellular regulation of bioavailability.9 Gremlin-1-mediated
BMP antagonism is crucial for mouse lung and kidney
development.10 In adult mouse and human tissues gremlin-1
expression is low. Originally, gremlin-1 was identiﬁed as a gene
downregulated in v-mos-transformed ﬁbroblasts and therefore
called Drm.11 However, recent studies suggest the overexpression
of gremlin-1 in epithelial cancers including lung carcinomas.12,13
The role of gremlin-1 in cancer has remained largely unclear. As
our preliminary results suggested an upregulation of gremlin in
mesothelioma tissue, we set out to ﬁnd molecular interactions of
gremlin and study the biological function of gremlin in
mesothelioma.
RESULTS
Gremlin-1 interacts with ﬁbrillin-1 and -2
A search for new gremlin interacting proteins was carried out
using systematic afﬁnity puriﬁcation coupled with mass spectro-
metry identiﬁcation (AP-MS). We used the well-characterized Flip-
In-HEK293 cell system to produce C-terminally tagged gremlin-1
and a standardized workﬂow for the puriﬁcation of protein
complexes from cell lysates14 (Figure 1a). A low tetracycline
concentration (25 ng/ml) was selected for gremlin-1 induction
(Figure 1b). Immunoblotting analyses after different afﬁnity
puriﬁcation steps suggested that gremlin was well recovered
(Figure 1c).
In order to characterize the interactome of gremlin-1, immuno-
puriﬁed proteins were identiﬁed using mass spectrometry. Proteins
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were ﬁrst digested using trypsin and then fractionated
with reverse-phase chromatography online using a mass spectro-
meter. The resulting peptide spectra were identiﬁed with
two different search engines. A total of 12 proteins were identiﬁed
to interact with gremlin-1 in three replicate experiments and
with both search engines. The interaction data were ﬁltered using
a protein list (data not shown) of 377 unspeciﬁc binding proteins
acquired using Flip-In-HEK293 cell line transfected with the afﬁnity
tag containing plasmid. The ﬁnal ﬁltered list contained
four proteins: cytokeratin-9 (Swiss-Prot: P35527), ﬁbrillin-2 (Swiss-
Prot: P35556), cytokeratin-2a (Swiss-Prot: P35908) and APOBEC1-
binding protein 2 (Swiss-Prot: Q9UBS4). Fibrillin-2 was identiﬁed in
all three replicate experiments and with both search engines,
which improves the conﬁdence of the identiﬁcation. In addition,
ﬁbrillin-2 was identiﬁed with up to three distinct and good scoring
peptides in two of the replicates further validating the interaction
of ﬁbrillin-2 and gremlin-1. Fibrillins are constituents of extracellular
microﬁbrils and have a role in elastin assembly.15 They also
sequester and regulate the bioavailability of growth factors such as
BMP isoforms.9
In order to conﬁrm our ﬁndings, we tested direct interactions
between puriﬁed gremlin-1 and recombinant N-terminal peptides
of ﬁbrillin-1 and -2 in protein–protein interaction assays using
surface plasmon resonance technology. When puriﬁed gremlin-1
(Figure 1d) was used as a ligand immobilized on the sensor chip
surface and N-terminal ﬁbrillin were ﬂown over as analytes direct
interactions with molecular afﬁnities in the low nanomolar range
(Table 1) could be measured (Figure 1e). This suggests a high
Figure 1. Gremlin-1 interacts with ﬁbrillin-1 and -2. (a) Gremlin-1 protein interaction screen outline. (b) Flip-In HEK293/gremlin-1 cells were
treated with increasing concentrations of tetracycline for 24 h followed by immunoblotting analyses using anti-HA antibodies. Ponceau
staining of proteins indicates equal loading. (c) Immunoblotting analyses of gremlin-1, using anti-HA antibodies, after Strep-tactin and anti-HA
afﬁnity puriﬁcation steps. (d) Puriﬁcation of gremlin-1 from conditioned media of stably transfected HEK293 cells. After elution from a CoCl2-
loaded HiTrap column using a C-terminally placed His6-afﬁnity-tag protein, bands corresponding to monomeric, dimeric and multimeric
gremlin-1 were detected via SDS–PAGE followed by Coomassie staining. A subsequent second puriﬁcation step via a HiTrap heparin column
yielded mostly dimeric gremlin-1, which shifted to the position of monomeric gremlin under reducing conditions (þ SH). (e) Interaction
studies between gremlin-1 and N-terminal peptides of ﬁbrillin-1 and -2 using a surface plasmon resonance technology. Gremlin-1 was
immobilized on a sensor chip and ﬁbrillin-1 and -2 peptides in a concentration range from 80 to 0 nM were ﬂown over as analytes. Afﬁnity
constants (Kd) for both interactions were about 10 nM (Table 1), indicating a high afﬁnity interaction between gremlin-1 and the main building
blocks of ﬁbrillin microﬁbrils.
Table 1. Surface plasmon resonance afﬁnity data for tested
interactions between gremlin-1 and ﬁbrillin-1 and -2 N-terminal
peptides
Interaction (ligand/analyte) kon (1/M*s)/koff (1/s) Kd (nM)
gremlin-1 dimer/ ﬁbrillin-2
(rF86)
2.41 105/
2.18 10 3
9.05
gremlin-1 dimer/ ﬁbrillin-1
(rF11)
1.92 105/
1.45 10 3
7.55
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molecular interaction between gremlin-1 and the two main
building blocks of ﬁbrillin microﬁbrils.
Gremlin-1 and ﬁbrillin-2 are overexpressed in the mesothelioma
tumor tissue and colocalize in vivo
To analyze whether gremlin-1 and ﬁbrillins are coexpressed
in vivo, tissue biopsies from mesothelioma patients included in
this study were stained with speciﬁc antibodies. We had
previously shown low levels of gremlin expression in the normal
lung.16 Here, we detected low expression of gremlin in normal
mesothelial cells (Figure 2a). Gremlin-1 staining was, however,
detected in non-malignant, reactive mesothelial cells in control
samples (pneumothorax). Intense gremlin-1 immunoreactivity was
observed in all mesothelioma samples (n¼ 6). Fibrillin-2 immu-
noreactivity was shown in a strikingly similar staining pattern as
observed for gremlin-1 in these tumor samples, suggesting
concomitant upregulation of these developmental genes in
mesothelioma. Some ﬁbrillin-2 staining was detectable also in
non-malignant reactive mesothelium. Calretinin and WT1 (Wilm’s
tumor 1) are diagnostic markers for mesothelioma and were used
here to identify the tumor tissue. Analyses of serial tissue sections
suggested that gremlin-1 and ﬁbrillin-2 staining localizes to
calretinin-positive and -negative tumor areas (Figure 2b). Some
WT-1 positivity, however, was observed in calretinin-negative
areas, which represent sarcomatoid part of the tumor with more
diffuse growth properties. Fibrillin-1 staining was negative in 5/6
mesothelioma and in control pleura samples. Only one
mesothelioma sample showed ﬁbrillin-1 immunoreactivity, which
was speciﬁcally detected in stromal-like areas (not shown).
We analyzed colocalization of gremlin-1 with ﬁbrillin-2 in tumor
tissue using the proximity ligation assay. Intensive colocalization
signals were observed for gremlin-1 and ﬁbrillin-2 throughout the
tumor tissues, suggesting that they localize to similar structures
in vivo (Figure 3).
Primary human mesothelioma cells express high levels of gremlin-1
and ﬁbrillin-2
Primary cells were cultured from mesothelioma patients’ pleural
effusion samples (JP1-5). Cells were characterized by immuno-
ﬂuorescence staining using mesothelial markers calretinin and
cytokeratin (CK)-7 as well as vimentin, which is commonly
expressed by tumor cells. Majority of the cells were calretinin-
and/or CK-7 positive and stained also for vimentin (Figure 4a). This
suggests that the cells, which were able to proliferate, were mainly
primary tumor cells. Gremlin-1 mRNA expression levels were high
in these primary cells compared with Met5A cells, which are
immortalized but non-tumorigenic mesothelial cells (Figure 4b).
Further, the mRNA expression levels of ﬁbrillin-1 and -2 were high
in these cells (Figure 4b). The results show that primary
mesothelioma cells can be cultured from pleural effusion samples
and that the cells retain the phenotypic expression of these
developmental genes.
Gremlin-1 is known to inhibit the functions of BMP-2, -4 and to
some extent also BMP-7.7,8 Therefore, the expression levels of
these BMP isoforms were analyzed in primary mesothelioma cells.
Figure 2. Overexpression of gremlin-1 and ﬁbrillin-2 in mesothelioma. (a) Immunohistochemical staining of mesothelioma and control pleura
samples using calretinin, gremlin-1, ﬁbrillin-1 and ﬁbrillin-2 antibodies. Hematoxylin and eosin (HE) staining is shown on the left. Abundant
gremlin-1 and ﬁbrillin-2 immunoreactivity is observed in both calretinin-negative and -positive tumor areas. Normal mesothelium (pleura, left
panel) shows very low levels of staining, whereas reactive normal mesothelium (pleura, right panel) shows faint ﬁbrillin-2 and moderate
gremlin-1 staining. (b) Immunohistochemical staining of serial mesothelioma sections suggests similar staining patterns for gremlin-1 and
ﬁbrillin-2. Staining was observed also in calretinin-negative stromal-like areas, which contained isolated Wilms’ tumor protein (WT1)-positive
tumor cells (white arrows).
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Interestingly, abundant expression of BMP-2 was observed
(Figure 4b), whereas BMP-4 levels were comparable and BMP-7
levels only slightly higher compared with Met5A cells (not shown).
The expression patterns of gremlin-1, ﬁbrillins and BMP-2 were
also analyzed in four established mesothelioma cell lines (211H,
H28, H2452 and H2052). Only one of these cell lines, H2052,
resembled primary mesothelioma cells and expressed high levels
of gremlin-1, ﬁbrillin-2 and BMP-2 (Figure 4c). Therefore, this cell
line was chosen for further mechanistic studies.
Gremlin-1 associates with ﬁbrillin-1 in cultured mesothelioma cells
Mesothelioma cells were cultured for 1 week and then analyzed by
immunoﬂuorescence staining using antibodies speciﬁc for gremlin-1
or ﬁbrillins. Although expressed at the mRNA level, ﬁbrillin-2 protein
was not detected in any of the cultured mesothelioma cells analyzed
at this time point (not shown), which may reﬂect late extracellular
matrix (ECM) deposition in vitro. Primary mesothelioma cells and
H2052 cells in vitro also expressed ﬁbrillin-1 mRNA, and this was
reﬂected in the staining pattern showing ﬁbrillar staining for ﬁbrillin-
1 and gremlin-1 (Figure 5a). No staining was observed in H2452 cells.
Double immunoﬂuorescence labeling suggested colocalization and
targeting of gremlin-1 into ﬁbrillin-1 containing microﬁbrils in vitro.
H2052 cells transfected with ﬁbrillin-1-speciﬁc siRNA showed
reduced mRNA expression levels (Figure 5b) and signiﬁcantly
reduced ﬁbrillin-1 staining, indicating efﬁcient silencing of protein
expression (Figure 5c). This led to reduced deposition of gremlin into
ﬁbrillar structures suggesting that extracellular targeting of gremlin
is dependent on ﬁbrillins.
Gremlin-1 silencing severely impairs mesothelioma cell growth
and survival
To investigate the role of gremlin-1 in mesothelioma cell growth,
H2052 cells were transfected with gremlin-speciﬁc siRNAs.
Efﬁcient silencing of gremlin-1 expression was observed at mRNA
and protein levels (Figures 6a and b). Cell proliferation was
assayed by counting cells 1–5 days after transfection. Two
independent siRNAs targeted against gremlin-1 were observed
to signiﬁcantly decrease the number of cells at all time points
(Figure 6c). This suggests that H2052 cell proliferation is
dependent on gremlin expression.
To determine whether lack of gremlin induces apoptosis, H2052
cells were cultured on coverslips, transfected with siRNAs and
analyzed with TUNEL assay 3 days after transfection (Figure 6d).
Hardly any TUNEL-positive cells were detected in control or
gremlin siRNA-transfected cells. DAPI staining also showed intact
nuclei in both groups. These results suggest that although lack of
gremlin impaired cell proliferation, it did not induce apoptosis.
Cellular signaling pathway activities are altered in gremlin-1-
silenced cells
Changes in BMP signaling activity were analyzed. Gremlin-1
silencing increased BMP-dependent reporter activity in H2052
cells (Figure 7a) as well as the expression of a BMP target gene Id1
(inhibitor of differentiation/DNA binding 1, Figure 7b), suggesting
that endogenous gremlin-1 regulates BMP activity negatively.
Further, Id1 expression was found signiﬁcantly reduced in primary
mesothelioma cells compared with Met5A cells (Figure 7c).
To further investigate cellular signaling pathways regulated by
gremlin, we analyzed alteration in phospho-kinase levels using a
commercial array (see Materials and methods). H2052 cells were
found to have high basal level of phospho-Akt (S473), which was
not altered in gremlin-1-silenced cells (Figures 7d–f). However,
phosphorylation of the Akt substrate and regulator of mTOR
signaling, PRAS40 (T246), was increased. Erk1/2 phosphorylation
was also signiﬁcantly increased in gremlin-1-silenced cells (g).
Further, increased levels of p53 phosphorylation (S46 and S392)
Figure 3. Colocalization analyses of gremlin-1 with ﬁbrillin-2 in mesothelioma tumor tissue. Proximity ligation assay was used to detect
colocalization of gremlin-1 with ﬁbrillin-2 in mesothelioma tumor tissue. Positive colocalization signals (red dots) were abundant throughout
the tumor tissue. Negative control with gremlin antibody plus mouse isotype control is shown on the upper right panel.
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were reﬂected in increased mRNA expression levels of p21 (Cip1/
Waf1) in H2052 cells (Figure 7h). In agreement, overexpression of
gremlin-1 in H2052 and H28 cells decreased p21 expression levels
(Figure 7i).
Gremlin-1 expression is associated with EMT phenotype and
chemoresistance
Gremlin-1 expression has been linked to EMT processes. Therefore,
we determined whether mesothelioma cells with high gremlin
levels express transcription factors snail and slug, which are
transcriptional repressors of E-cadherin and induce EMT.17
Whereas the mRNA expression levels of snail were comparable
in mesothelioma cells and Met5A cells, slug expression levels were
high in primary mesothelioma cells (Figure 8a). Slug expression in
mesothelioma tumor samples was analyzed using immunohisto-
chemical staining (Figures 8b and c). All of the analyzed tumor
samples (n¼ 6) were positive for slug. Mesothelioma tumors
exhibited mostly diffuse and granular cytoplasmic staining, but
also nuclear staining was detected in certain tumor areas. Slug
staining localized to gremlin-positive areas and was detected also
in calretinin-negative areas.
Similar to primary mesothelioma cells H2052 cells, which
express high levels of gremlin-1, exhibited high slug expression
(Figure 8d). Conversely, Met5A and H2452 cells showed very low
levels of slug mRNA expression consistent with low gremlin-1
expression levels. Slug protein levels also showed a dramatic
difference between H2052 and H2452 cells (Figure 8d). Silencing
of gremlin-1 by siRNA transfection signiﬁcantly reduced slug
mRNA and protein expressions in H2052 cells (Figure 8e and i).
Similar results were also obtained with primary mesothelioma cells
(Figure 8f). Further, overexpression of gremlin-1 in H28 cells led to
increased slug mRNA expression (Figure 8g). The mRNA and
especially protein expression levels of mesenchymal proteins,
N-cadherin, vimentin and a-smooth muscle actin were signiﬁ-
cantly downregulated in gremlin-1-silenced H2052 cells (Figures
Figure 4. Primary mesothelioma cells express high levels of gremlin-1. Primary mesothelioma cells (JP cells) were isolated from pleural effusion
samples. (a) Immunoﬂuorescence staining suggests that the cells were positive for the mesothelial marker calretinin. Co-staining with
cytokeratine (CK)-7 and vimentin antibodies suggests that the tumor cells co-express these marker proteins. (b) Primary mesothelioma cells
were analyzed for gremlin-1, ﬁbrillin-1 and -2 and BMP-2 mRNA expression by quantitative RT–PCR. The levels were normalized to the
expression levels of TATA-binding protein and are expressed relative to the expression levels in Met5A cells (immortalized, non-tumorigenic
mesothelial cells), which were set to 1. (c) Established mesothelioma cell lines were analyzed for gremlin-1, ﬁbrillin-1 and -2 and BMP-2 mRNA
expression by quantitative RT–PCR. The error bars represent s.d. (n¼ 2).
Gremlin in mesothelioma cell survival
JA Tamminen et al
5
& 2013 Macmillan Publishers Limited Oncogenesis (2013), 1 – 13
8h and i). Fibrillin-1 and -2 mRNA expression levels were also
signiﬁcantly reduced (Figure 8h), suggesting that gremlin-1
maintains the expression of microﬁbrillar genes. Further, ﬁbro-
nectin expression was downregulated (Figure 8h), and the
epithelial marker E-cadherin was upregulated (Figure 8j). These
results suggest that EMT-related alterations are reversed in
gremlin-1-silenced cells.
Slug expression and EMT-phenotype are also associated with
tumor chemoresistance.18–21 The importance of high gremlin and
slug expression to sensitivity to paclitaxel-mediated mesothelioma
cell death was analyzed using the MTT proliferation/viability assay.
H2052 cells, which express high levels of gremlin-1 and slug, were
found more resistant to paclitaxel than H2452 cells (Figure 8k).
Next, control and gremlin-1 siRNA-transfected H2052 cells were
treated with paclitaxel or pemetrexed, and cell numbers were
quantiﬁed 3 days after transfection. Treatment with paclitaxel or
pemetrexed in combination with gremlin-1 siRNA led to efﬁcient
cell death (Figure 8l).
DISCUSSION
Gremlin-1-mediated inhibition of BMP-signaling is important for
normal development. Mice lacking gremlin-1 die before birth
because of severe defects in kidney and lung development.10 In
Figure 5. Gremlin-1 and ﬁbrillin-1 co-localize in mesothelioma cell ECM in vitro. (a) Mesothelioma cell lines (H2052 and H2452) and primary
mesothelioma cells (JP5) were co-stained for gremlin-1 and ﬁbrillin-1 and analyzed using immunoﬂuorescence microscopy. A ﬁbrillar staining
pattern was observed in H2052 and JP5 cells. (b) In control (ctrl) and ﬁbrillin-1 siRNA-transfected H2052 cells, the mRNA expression levels of
gremlin-1 and ﬁbrillin-1 were analyzed by quantitative RT-PCR. The levels were normalized to the expression levels of TATA-binding protein
and are expressed relative to each control, which was set to 1. The error bars represent s.d. (n¼ 2). (c) Double-immunoﬂuorescence staining of
siRNA-treated H2052 cells with gremlin-1 and ﬁbrillin-1 antibodies. Note the lack of ﬁbrillar gremlin-1 staining in ﬁbrillin-1-silenced cells.
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adult tissues including lung gremlin-1 expression is low. In
idiopathic pulmonary ﬁbrosis , gremlin-1 is highly upregulated in
the lung parenchyma, where it contributes to idiopathic
pulmonary ﬁbrosis pathogenesis by blocking BMP-mediated
signals.16 Gremlin-1 has been found to be upregulated also in
many carcinoma tissues as well as in mesothelioma.12,13,22 The
role of gremlin-1 in malignant tissue appears complex and is
likely mediated both by BMP-dependent and -independent
functions. There are reports suggesting tumor-speciﬁc gremlin-1
expression,12 while other reports suggest expression in cancer-
associated stromal cells.13 Here, we ﬁnd high gremlin
immunoreactivity in the mesothelioma tumor tissue. Analyses of
serial mesothelioma tissue sections suggested that gremlin-1 can
localize to calretinin-positive, epithelial-appearing tumor areas
and also to aberrant looking and stromal-like calretinin-negative
areas. These tissue areas contained some WT1-positive tumor cells.
Figure 6. Gremlin-1 silencing impairs H2052 mesothelioma cell proliferation. (a) The efﬁciency of gremlin-1 siRNA silencing was analyzed with
quantitative RT-PCR as in ﬁgure 5. The error bars represent s.d. (n¼ 4). (b) Double immunoﬂuorescence staining of siRNA-treated H2052 cells
with gremlin-1 and ﬁbrillin-1 antibodies. Note the lack of ﬁbrillar gremlin-1 staining, which is suggestive of efﬁcient silencing using gremlin
siRNA3. (c) H2052 cell proliferation was analyzed by counting cells 1–5 days after siRNA transfection. Both gremlin siRNAs reduced
dramatically the number of cells 3–5 days after transfection (left panel, a representative experiment is shown). Same effect was seen also at
earlier time points (right panel). The error bars represent s.d. (n¼ 3, *P¼ 0.05). (d) Silencing gremlin-1 by siRNA3 did not induce apoptosis as
measured using TUNEL staining. DNase I-treated cells (control) show positive staining. Nuclei are stained with DAPI.
Gremlin in mesothelioma cell survival
JA Tamminen et al
7
& 2013 Macmillan Publishers Limited Oncogenesis (2013), 1 – 13
Our results suggest that gremlin-1 localizes mainly in and around
mesothelioma tumor cells.
Using a sophisticated large-scale protein interaction screen, we
were able to identify ﬁbrillin-2 as a novel gremlin-1 interacting
protein. The interaction was also veriﬁed using a cell surface
plasmon resonance technology. Fibrillin-2 is a developmental
gene, which is found in adult vasculature and is upregulated in
idiopathic pulmonary ﬁbrosis, scleroderma and during skin
wound healing.23,24 Idiopathic pulmonary ﬁbrosis and cancer
pathogenesis have common features including aberrant activation
of mediators of tissue repair processes.25 Our discovery that high
ﬁbrillin-2 immunoreactivity is associated with mesothelioma
tumor tissue is a novel ﬁnding and supports this idea. Fibrillins
(ﬁbrillin-1 and -2) are large extracellular glycoproteins, which form
heteromeric ﬁbrillar structures, the so called ﬁbrillin microﬁbrils,
which are essential for elastin assembly.26 Fibrillins also regulate
growth factor signaling by sequestering TGF-b complexes as well
as BMP-isoforms into extracellular matrix structures.27 Gremlin-1
can bind to and inhibit the functions of BMP-2, -4 and -7, all of
which have been shown to associate with ﬁbrillins.9 Here, we ﬁnd
that gremlin-1 can bind to ﬁbrillin-1 and -2 in vitro and colocalizes
with ﬁbrillin-2 in mesothelioma tumor tissue in vivo. Conceptually
this is a new ﬁnding, spatially localizing a BMP inhibitor molecule
with its target proteins through ﬁbrillin microﬁbrils. High levels of
ﬁbrillin-2 are likely to contribute to tumor cell behavior through
aberrant extracellular matrix structure and regulation of gremlin-1
function.
Primary mesothelioma cells were cultured from patients’ pleural
effusion samples and analyzed after few passages of culture.
Immunoﬂuorescence microscopy analyses indicated that the cells,
which were able to grow, represented mostly tumor cells. Gremlin-
1 was expressed at mRNA and protein levels and ﬁbrillin-2 at
mRNA level by these primary cells, suggesting that they retain the
pathological expression pattern of these genes. Interestingly,
ﬁbrillin-1 but not ﬁbrillin-2 protein was detected in the matrix
structures after 1 week culture of the primary cells. This likely
reﬂects the temporal production of ECM proteins and remodeling
of matrix structures during in vitro cell cultures.28,29 Fibrillin-2 is
likely assembled late during this process. In agreement with the
protein interaction studies, gremlin-1 localized to ﬁbrillin-1-
Figure 7. Cellular signaling in gremlin-1-silenced cells. (a) BMP-dependent reporter activity was analyzed in control and gremlin-1 siRNA-
treated H2052 cells. The levels are expressed relative to control, which was set to 1. The error bars represent s.d. (n¼ 4, *Po0.01). (b) Id1 mRNA
expression levels were analyzed by quantitative RT–PCR. The levels are expressed relative to control. n¼ 3, *Po0.05. (c) Id1 mRNA expression
levels in primary mesothelioma cells. The levels are expressed relative to the expression levels in Met5A cells. (d) Cell lysates from control and
gremlin-1 siRNA-treated H2052 cells were analyzed using a commercial phospho-protein array. (e) Quantiﬁcation of alterations in the amounts
of phospho-proteins (n¼ 2). Changes were also veriﬁed by immunoblotting analyses of Akt (f ) and ERK (g) pathway proteins. Molecular
weight markers are indicated on the left. Expression levels of p21 (Cip1/Waf1), a p53 target gene, were analyzed in gremlin-1 siRNA-treated (h)
and gremlin-1-transfected cells (i) by quantitative RT-PCR. The levels are expressed relative to control, which was set to 1. n¼ 3, *Po0.05. I,
inset. Gremlin-1 overexpression in H2052 and H28 cells was veriﬁed by immunoblotting using an antibody against the V5 tag.
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Figure 8. Gremlin-1 regulates slug expression and EMT phenotype. (a) Primary human mesothelioma cells (JP) were analyzed for snail and slug
mRNA expression by quantitative RT-PCR. The levels were normalized to the expression levels of TATA-binding protein and are expressed
relative to the expression levels in Met5A cells, which were set to 1. (b, c) Immunohistochemical staining of a mesothelioma section using slug
antibodies shows mostly diffuse and granular cytoplasmic staining in the tumor tissue. Nuclear staining was also observed in certain tumor
areas (b, right panel). (c) Analyses of serial mesothelioma tissue sections suggested that slug and gremlin staining colocalized in the same
tumor areas. (d) Slug mRNA expression levels in H2052 and H2452 cells were analyzed by quantitative RT–PCR. The levels are expressed
relative to H2452 expression levels, which were set to 1. The error bars represent s.d. (n¼ 5). INSET: immunoblotting analyses of slug. Tubulin is
used as a loading control. Molecular weight markers are indicated on the left. (e–g) Slug mRNA expression levels were analyzed in control and
gremlin-1 siRNA-treated H2052 and JP5 cells or H28 cells transfected with gremlin-1 (grem1) or control vector (mock). The levels are expressed
relative to control, which was set to 1. The error bars represent s.d. (JP5, n¼ 3, *Po0.05; H2052, n¼ 4, *Po0.01; H28, n¼ 3, *P¼o0.05).
(h) N-cadherin, vimentin, a-SMA, ﬁbronectin and ﬁbrillin mRNA expression levels were analyzed in control and gremlin siRNA-treated H2052
cells by quantitative RT-PCR. The error bars represent s.d. (nX3, *Po0.05). (i) Immunoblotting analyses of slug, N-cadherin, vimentin and
a-SMA in control and gremlin-1 siRNA-treated H2052 cells. Tubulin is used as a loading control. (j) E-cadherin mRNA expression levels were
analyzed in control and gremlin siRNA-treated H2052 cells by quantitative RT–PCR. Error bars represent s.d. (n¼ 3, *Po0.05). (k) H2052 and
H2452 cells were treated with the indicated concentrations of paclitaxel after which cell proliferation/viability was analyzed with MTT assay
(n¼ 4, *Po0.05). (l) Quantiﬁcation of cell numbers after combined treatment with control or gremlin-1 siRNA and paclitaxel (0.1 nM, 24 h) or
pemetrexed (1 mM, 48 h). Cell numbers were counted 3 days after transfection (nX4, *P¼ 0.002).
Gremlin in mesothelioma cell survival
JA Tamminen et al
9
& 2013 Macmillan Publishers Limited Oncogenesis (2013), 1 – 13
containing structures in mesothelioma cell ECM. Gene expression
analyses suggested that compared with immortalized but non-
tumorigenic mesothelial cells (Met5A), primary mesothelioma cells
also expressed signiﬁcantly higher levels of BMP-2. This is an
interesting ﬁnding as BMP-2 has been linked to tumor invasion
and metastasis.30–32 Future studies will reveal whether BMP-2 is
functional in the presence of high levels of its inhibitor protein.
We used the knowledge of gene expression patterns of primary
mesothelioma cells to ﬁnd a representative established mesothe-
lioma cell line for mechanistic studies. H2052 cells expressed high
levels of gremlin-1, ﬁbrillin-2 and BMP-2 similar to all of the
primary cells. Gremlin-1 silencing in these cells reduced cell
proliferation dramatically. This is in agreement with previous
studies suggesting that gremlin-1 can induce proliferation
of cancer cells.33–35 Interestingly, we observed gremlin-1
immunoreactivity also in reactive mesothelium, which associates
gremlin-1 expression to a proliferative phenotype even in non-
malignant mesothelial cells. Gremlin-1 expression has been linked
to mesenchymal cells surrounding stem cell niches, which support
proliferation of epithelial cells through blocking BMP activities.13,36
Mesenchymal stem cells also express high levels of gremlin-1
(GeneSapiens database37). Our data suggest a model in which
cancer cells can acquire the ability to produce high levels of
gremlin-1, which is targeted to the tumor microenvironment
through ﬁbrillin binding (see Figure 9).
Signaling pathways linked to the regulation of cell survival,
apoptosis and autophagy were altered in gremlin-1-silenced H2052
cells. Similar to our ﬁndings, negative regulation of Erk1/2
phosphorylation by gremlin-1 has been previously found in
osteosarcoma cells;38 however, gremlin overexpression in Saos-2
cell was found to reduce proliferation. We observed increased p53
phosphorylation and expression of its target gene, p21, in gremlin-1-
silenced cells, suggesting a link to reduced cell survival. Further, the
phosphorylation of the Akt substrate PRAS40 was signiﬁcantly
increased. Although PRAS40 has been linked to diabetes and cancer,
its pathological functions are not well understood.39 Interestingly,
gremlin-1 has been shown to bind directly to a 14-3-3 protein,12
which in turn binds and regulates the PRAS40 and other Akt/mTOR
pathway proteins. Future studies will reveal the mechanistic details
how cellular and secreted gremlin-1 regulates these pathways.
We and others have previously linked gremlin-1 expression to
EMT processes.16,40,41 In cancer cells, markers of EMT often
suggest more advanced disease, invasive capacity and
chemoresistance.21,42 We found that the transcription factor
slug, a master regulator of EMT, was upregulated in
mesothelioma cells concurrently with gremlin-1. Silencing of
gremlin-1 expression led to reduced slug mRNA and protein
levels. Further, mesenchymal markers of EMT, vimentin, a-smooth
muscle actin, ﬁbronectin and N-cadherin were downregulated in
gremlin-1-silenced cells, whereas epithelial marker E-cadherin
was upregulated. These results are in agreement with previous
studies linking the expression of EMT-related transcription factors
to mesothelioma43,44 and provide evidence that gremlin
functions as a regulator of these transitional processes. EMT
and slug expression have also been suggested to be involved in
regulating cancer stemness as well as chemoresistance.18,20,42
In agreement, we observed that high gremlin-1 and slug
expressions in mesothelioma cells were associated with
reduced sensitivity to paclitaxel-mediated cell death. Combined
treatment with paclitaxel and gremlin-1 siRNA led to efﬁcient cell
death in vitro. Similar results were obtained with pemetrexed,
which is a relatively new cancer drug used in the treatment of
mesothelioma in combination with platinum compounds.45 This
indicates that blocking gremlin-1 function may be beneﬁcial in
mesothelioma especially when combined with chemotherapy.
Mesothelioma is an aggressive tumor with limited treatment
options. Further, an increase is expected in the incidence of
mesothelioma,3,4 which sets an urgent need for new drug target
molecules. Although the number of patient tissues analyzed in our
study was relatively small (n¼ 6), the pathological expression of
gremlin-1 was a clear concept. It is also reinforced by other studies
suggesting a role for gremlin-1 in cancer cell proliferation.12,13,33,34
Gremlin-1 has also BMP-independent angiogenic functions,46
which may well contribute to tumor progression. Blocking
gremlin-1 function in mesothelioma might offer means to ﬁght
the chemoresistance of this tumor.
Figure 9. A model for the functions of gremlin-1 and ﬁbrillin-2 in mesothelioma. Gremlin-1 induces proliferation and epithelial-to-
mesenchymal transition (EMT) in mesothelioma cells. EMT is mediated by induction of the transcription factor slug and leads to
chemoresistance and acquisition of invasive properties. Gremlin-1 is targeted to the tumor microenvironment through binding to ﬁbrillin-2
microﬁbrils.
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MATERIALS AND METHODS
Antibodies
Antibodies used in the study are summarized in Table 2.
Patients and tissues specimen
A statement for the use of human tissue and pleural effusion materials was
received from the Ethics Committee of the Helsinki University Hospital,
Helsinki, Finland (number 308/13/0301/2010). All patients gave informed
consent to participate in the study. Tissue biopsies and pleural effusion
samples were obtained from patients undergoing diagnostic procedures
and had a clinical and/or radiological suspicion of malignant mesothe-
lioma. All patients included in the study (n¼ 7) were later diagnosed to
have mesothelioma (Table 3). Control pleural samples were obtained from
two male smokers who were operated for pneumothorax.
Cell culture and transient transfection
Immortalized normal mesothelial cells (Met5A),47 and mesothelioma
cell lines (211H, H28, H2452 and H2052) were from ATCC. Primary
mesothelioma cells (named JP cells) were acquired from pleural effusion
samples from patients suffering from malignant mesothelioma. Cells were
centrifuged, washed and seeded on plastic culture dishes in RPMI-1640
medium (Sigma, St Louis, MO, USA) supplemented with 10% fetal bovine
serum (Sigma) and antibiotics. The medium was changed every 3–4 days.
Cells were passaged 2–3 times before immunoﬂuorescence analysis of
mesothelioma marker proteins was performed. Cells were also cultured for
6–7 days for RNA isolation and gene expression analyses. For further
experiments JP5 cells were cultured and used between passages 3–7.
Transfection of cells was carried out using siRNAs for gremlin, ﬁbrillin-1 or a
negative control (Life Technologies, Paisley, UK) as described.48 The BMP
reporter construct (Bre2-luc, kindly provided by Dr Peter ten Dijke, Leiden
University Medical Center, the Netherlands) was transfected into H2052
cells to assess BMP-dependent signaling activity as described.49
Expression constructs and stable transfection
C-terminal gremlin-1 construct was generated by Gateway-cloning, the
gremlin-1 construct from the Human Orfeome Collection (Thermo
Scientiﬁc, FL, USA) to a pTO-SHc-GW-FRT plasmid with c-terminal Strep-
tag III and human inﬂuenza hemagglutinin (HA)-tag.14 Flip-In human
embryonic kidney (HEK) 293 cells (Life Technologies) were grown as
recommended. Stable transfection of cells was carried out as described.50
After 2 weeks of culture, hygromycin B-resistant clones were tested for
tetracycline (Sigma)-inducible gremlin-1 expression (see Figure 1b).
Afﬁnity puriﬁcation
Transfected Flip-In HEK293 cells were stimulated with tetracycline (25 ng/
ml) to induce gremlin-1 expression. After a 24-h stimulation, cells were
lysed in HNN-lysis buffer (50mM HEPES pH 8, 150mM NaCl, 50mM NaF,
1mM PMSF, 1.5mM Na-vanadate, 0.5% NP-40 and protease inhibitors
(Sigma)) followed by double afﬁnity puriﬁcation as described.50 Brieﬂy, cell
lysates were passed through Strep-Tactin columns (IBA GmbH) followed by
elution of bound proteins with 2.5mM biotin. Next, the eluate was
immunoprecipitated using anti-HA agarose (Sigma). Proteins were ﬁnally
eluted using 0.2 M glycine and neutralized.
Protein digestion
The total protein amount from the elution fractions was precipitated using
trichloroacetic acid (TCA). First, TCA was added to the elution fractions to
ﬁnal concentration of 25% followed by incubation for 30min on ice. The
precipitates were centrifuged, washed once with ice cold 0.1 M HCl in
acetone and once with acetone. The pellets were then allowed to dry. For
trypsin digestion the precipitated proteins were dissolved in 50mM
ammonium bicarbonate, pH 8.9, containing 0.1% Rapigest detergent
(Waters, Milford, MA, USA). Proteins were reduced using DTT for 30min at
60 1C followed by alkylation using iodoacetamide for 30min at room
temperature in dark. Proteins were digested with trypsin (Promega,
Madison, WI, USA) for 18 h at 37 1C, and then the Rapigest detergent was
hydrolyzed with HCl for 45min at 37 1C. Peptides were puriﬁed with
PepClean C18 Spin Columns (Thermo Fisher, Rockford, IL, USA) according
to the manufacturer’s protocol. Finally, the puriﬁed peptides were
dissolved in 0.1% formic acid for MS analysis.
Table 2. List of antibodies used in the study
Name Source Application Supplier
calretinin mouse/DAK-Calret1 IF, IHC DAKO, Glostrup, Denmark, Germany
cytokeratin-7 rabbit /EP16204 IF Novus Biologicals, Littleton, CO, USA
vimentin mouse/V9 IF, IB Santa Cruz, Santa Cruz, CA, USA
N-cadherin mouse/32 IB BD Biosciences, Franklin Lakes, NJ, USA
a-SMA mouse/1A4 IB Sigma, St Louis, MO, USA
HA mouse/16B12 IB Covance, Princeton, NJ, USA
ﬁbrillin-1 mouse/2499 IF Millipore, Billerica, MA, USA
ﬁbrillin-1 rabbit/ pAb9543 IHC, IF Professor Lynn Sakai
ﬁbrillin-2 mouse/48 IHC, PLA Millipore
gremlin-1 rabbit pAb IHC Abcam, Cambridge, UK
gremlin-1 goat pAb IHC, PLA Santa Cruz
gremlin-1 rabbit pAb IF Santa Cruz
Slug rabbit pAb IB, IHC Sigma
WT1 mouse/WT49 IHC Novocastra, Newcastle, UK
p-Akt (S473) rabbit pAb IB Cell Signaling, Danvers, MA, USA
p-Akt (T308) rabbit pAb IB Cell Signaling
Akt rabbit pAb IB Cell Signaling
p-Erk1/2 rabbit mAb/D13.14.4E IB Cell Signaling
Erk1 mouse/3A7 IB Cell Signaling
V5 Mouse mAb IB Invitrogen
Abbreviations: IB, immunoblotting; IF, immunoﬂuorescence; IHC, immunohistochemistry; PLA, proximity ligation assay.
Table 3. Mesothelioma patient characteristics
Patient Type Location Age Gender IHC Cells
JP1 Epithelial Pleura 53 Male þ þ
JP2 Biphasic Pleura 71 Male þ 
JP3 Epithelial Pleura 63 Male þ þ
JP4 Biphasic Peritoneum 72 Female  þ
JP5 Epithelial Pleura 69 Female þ þ
JP6 Biphasic Pleura 71 Female þ 
JP7 Epithelial Pleura 61 Male þ 
Tissues analyzed by immunohistochemistry (IHC) and pleural effusion
samples obtained for cell culture (cells) are indicated.
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LC-MS/MS analysis
Mass spectrometric analysis was performed using nanoAcquity UPLC –
liquid chromatography system on-line with a Waters Synapt G2 mass
spectrometer (Waters S.A.S., Saint-Quentin, France). Waters nanoAcquity
UPLC Trap Column (Symmetry C18, 180mm 20mm, 5 mm) was used as
trapping and Waters nanoAcquity UPLC Column (BEH130 C18, 75mm 150
mm, 1.7mm) as analytical column. Four microliters of sample was injected
and run using 90min gradient from 3 to 40% mobile phase B (0.1% formic
acid in acetonitrile). 0.1% formic acid in water was used as mobile phase A.
Data were collected with data dependent acquisition manner collecting
eight fragmentation spectra simultaneously. Switch limit from MS to MS/
MS was set to peak intensity of 200. Fragmentation data for detected
peaks were collected for 5 s and then excluded from fragmentation for
120 s. Scan time for both MS and MS/MS was one second. No lockmass
correction was used.
The raw data were processed with Mascot Distiller software (version
2.3.1.0, Matrix Science, London, UK), and database search was performed
using Mascot search engine (version 2.2.04) against Swiss-Prot human
database (dated 16.6.2010). MudPIT scoring and Ion score cutoff limit of 20
were used to identify peptides. Require bold red- speciﬁcation was used to
limit the results to those proteins that have at least one unique peptide.
Carbamidomethylated cysteine was set as ﬁxed modiﬁcation and oxidation
of methionine as variable modiﬁcation. Peptide mass tolerance for search
was 0.2Da and 0.1Da for fragment ion search. A maximum of two missed
trypsin cleavages was allowed. The Mascot Distiller processed data were also
searched using GPM X!Tandem search engine51 using same parameters.
Expression and puriﬁcation of recombinant gremlin-1
The expression construct pGremlin-1_V5/HIS in pEF-IRES-P contains cDNA
encoding human gremlin-1 with C-terminal tags (V5 and 6HIS). H2052 and
H28 cells were transiently transfected with this construct or the expression
vector using Fugene HD transfection reagent (Promega). CHO cells were
stably transfected, and gremlin-containing cell culture supernatants were
produced as described.52 The media was then dialyzed against 50mM
sodium phosphate buffer, pH 7.2 and 1 M NaCl (buffer A) and loaded on a
1-ml HiTrap column (GE Health Care, Waukesha, WI, USA) previously
charged with CoCl2 and equilibrated with buffer A. The loaded column was
washed with 40 column volumes of buffer A and subjected to a fast
protein liquid chromatography (GEHC) gradient run starting with buffer A
containing 0–100% buffer B (buffer A with 250mM imidazole). Fractions
were analyzed using SDS–PAGE for their purity and molecular mass, and
imidazole in these fractions was removed by dialysis against buffer A. For
further concentration and puriﬁcation, gremlin-1-containing fractions were
dialyzed against TBS and subjected to afﬁnity chromatography using a
1-ml HiTrap heparin column (GEHC). Bound gremlin-1 was eluted in a 0–1M
NaCl gradient.
Surface plasmon resonance
Binding analyses were performed using a BIAcore2000 (GEHC). 2000 Rus of
gremlin-1 were covalently coupled to carboxymethyldextran hydrogel
500 M sensor chips (XanTec, Du¨sseldorf, Germany) using the amine
coupling kit following the manufacturer’s instructions (GEHC). Binding
assays with N-terminal ﬁbrillin-1 (rF11) and -2 peptides (rF86) as analytes
were performed as previously described.9 Kinetic constants were
calculated by nonlinear ﬁtting of association and dissociation curves
(BIAevaluation 4.1 software).
Immunohistochemical staining and proximity ligation assay
Immunohistochemical staining of tumor tissues and proximity ligation
assay were performed as described.24 Images were captured with Nikon
DS-Fi1 or with Axio Imager with ApoTome (Zeiss, Go¨ttingen, Germany) or
with using Axio Vison 4.8 software (Zeiss).
SDS–PAGE and immunoblotting
Cells were lysed in RIPA lysis buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl,
1mM EDTA, 1% NP-40, 0.2% sodium deoxycholate) containing protease
inhibitors (Roche, Mannheim, Germany) for 15min on ice. Protein
concentrations were measured using a BCA protein assay Kit (Pierce,
Rockfors, IL, USA). SDS–PAGE and immunoblotting were performed as
described.53
RNA isolation and gene expression analyses
Isolation of total cellular RNA, reverse transcription and quantitative real-
time PCR were carried out as described.53 The relative gene expression
differences were calculated with the comparative delta delta cycle
threshold (DDCT) method, and the results have been expressed as
mRNA expression levels normalized to the levels of a gene with a constant
expression (TATA-binding protein).
Immunoﬂuorescence analyses and microscopy
Cells were grown on glass coverslips for the indicated times and ﬁxed with
4% paraformaldehyde in PBS at room temperature for 10min or with ice
cold methanol at  20 1C for 20min. Immunoﬂuorescence staining was
carried out as described.53 Images were captured with a Axioplan 2
epiﬂuorescence microscope (Zeiss) and AxioCam HRm 14-bit grayscale
CCD camera Axiovision 4.6 software (Zeiss).
Human phospho-kinase array
Control and gremlin-1 siRNA-treated cells were lysed, and alterations in
phospho-kinase levels were analyzed using a Proteome proﬁler array
(ARY003b, R&D Systems, Gaitherburg, MD, USA) according to the
manufacturer’s instructions. Quantity One version 4.6 (BioRad, Hercules,
CA, USA) was used for quantiﬁcation. The kinase array was performed
twice, and the results are expressed as average of the two experiments.
Measurements of cell viability and apoptosis
Cell proliferation/viability was assessed using MTT assay (R&D Systems).
Brieﬂy, cells were seeded on 96-well plates (10 000/well) and were treated
the next day with different concentrations of paclitaxel (Hospira, Lake
Forest, IL, USA). The metabolic activity of cells was measured after 48 h
according to the manufacturer’s instructions. Apoptosis was assayed using
a TUNEL technology using In Situ cell death detection kit (Roche). Cells
were seeded on glass coverslips, cultured overnight and transfected with
siRNAs. Cells were then ﬁxed and stained, according to the manufacturer’s
instructions, 3 days after transfection.
Statistical analyses
Data were analyzed using PASW Statistics 18 program for Windows (SPSS,
Chicago, IL, USA). Statistical difference between two independent groups
was evaluated using nonparametric Mann–Whitney U-test. Statistical
difference between more than two independent groups was evaluated
using nonparametric Kruskal–Wallis test. A P-value of o0.05 was
considered statistically signiﬁcant.
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ABSTRACT 
Activin-A and activin-B, members of the TGF-β superfamily, are regulators of reproductive 
functions, inflammation and wound healing. These dimeric molecules regulate various cellular 
activities such as proliferation, migration and suvival. Malignant mesothelioma is an asbestos 
exposure related tumor affecting mainly pleura and it usually has a dismal prognosis. Here, we 
demonstrate that both activin-A and -B are abundantly expressed in mesothelioma tumor tissue as 
well as in cultured primary and established mesothelioma cells. Migratory and invasive 
mesothelioma cells were also found to have attenuated activation of the Smad2/3 pathway in 
response to activins. Migration and invasive growth of the cells in three-dimentional matrix was 
prevented by inhibition of activin activity using a soluble activin receptor 2B (sActR2B-Fc). This 
was associated with decreased ERK activity. Furthermore, migration and invasive growth was 
significantly inhibited by blocking ERK phosphorylation. Mesothelioma tumors are locally invasive 
and our results clearly suggest that acivins have a tumor-promoting function in mesothelioma 
through increasing expression and switching from canonical Smad3 pathway to non-canonical ERK 
pathway signaling. Blocking activin activity offers a new therapeutic approach for inhibition of 
mesothelioma invasive growth.  
 
Key words: mesothelioma, activin, invasive growth 
 
Abbreviations: ACVR2, type 2 activin receptor; ALK, activin receptor-like kinase; ERK, 
extracellular signal-regulated kinase; FST, follistatin; FSTL3, follistatin like 3; JNK, c-Jun N-
terminal kinase; TGF-β, transforming growth factor- β  
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INTRODUCTION 
Malignant mesothelioma is a rare but very aggressive tumor originating from mesothelial cells 
lining body cavities. Most commonly mesothelioma affects pleura, sometimes peritoneum and very 
rarely pericardium. Mesothelioma is usually related to previous asbestos exposure and develops 
during a latency of 20-40 years [1]. The incidence of mesothelioma is expected to increase 
worldwide in the near future [2,3]. Late stage of the disease at the time of diagnosis as well as only 
moderate effectiveness of current therapies lead to negligible survival time of the patients after 
diagnosis. Novel potential diagnostic markers for early detection and drug targets are needed for 
mesothelioma.  
 
Activins, members of the TGF-β superfamily of growth factors, are known regulators of 
development and reproductive functions [4]. Currently, activins, especially activin-A, are also 
recognised as important regulators of immune responses, wound healing and cancer [5]. Activins 
enhance cell proliferation and migration as well as scar formation during wound healing [5]. 
Increased cell proliferation and migration are also characteristics of cancer cells. In addition, 
activins may also promote tumor progression indirectly by altering the tumor microenvironment 
through regulation of immune functions and angiogenesis. Whether activins promote or inhibit 
carcinogenesis depends on the cell, tissue and cancer type [5-7]. A recent study reports that activin-
A promotes mesothelioma cell growth and migration through regulation of cyclin D [8].  
 
The genes INHBA and INHBB code for the activin β-subunits, which form disulfide-linked 
functional dimers. Homodimerization of the βA-subunits generates activin-A and βB-subunits form 
activin-B [9]. The β-subunits can also heterodimerizise and form activin-AB. The β-subunits 
heterodimerisize also with α- subunits and form inhibins, which inhibit activin action by competing 
for activin receptors. Activin signaling is also regulated by soluble inhibitors follistatin (FST) and 
follistatin like-3 (FSTL3) [10], which inhibit activin action by binding to activins and blocking 
association with cell surface receptors [11]. 
 
Activins signal through activin type 1 and type 2 transmembrane serine/threonine kinase receptors. 
Activin action is initiated when activin binds to a type 2 activin receptor (ACVR2A or ACVR2B). 
This binding leads to recruitment, phosphorylation and activation of type 1 activin receptor 
followed by phosphorylation and activation of Smad proteins. Both activins-A and -B can activate 
the Smad2/3 pathway through type 2 receptors and common type 1 receptor ActR1B (activin like 
kinase-4, ALK-4) [12]. Activin-B can also activate Smad2/3 via ActR1C (ALK7) [13,14]. 
Furthermore, activin-B has been reported to activate Smad1/5/8 through BMPR1A (ALK3)[15]. 
The receptors that bind TGF-β-family members can also activate non-Smad proteins [16]. Activin-
A can induce ERK and p38 MAP kinase phosphorylation [17], and activin-B has been reported to 
be able to phosphorylate SAPK/JNK and to induce keratinocyte migration [18] and wound healing 
[19]. Furthermore, activation of both JNK and ERK is required for activin-B induced migration in 
bone marrow-derived mesenchymal stem cells [20]. Activin-A and activin-B have partially 
overlapping expression patterns but are functionally distinct [21]. 
 
In this study, we characterized activin-A and -B expression and their receptors in mesothelioma 
tissue and in cultured primary and established mesothelioma cells. We aimed to clarify the role of 
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Smad mediated and non-canonical activin signaling in mesothelioma cell migration and invasion. 
We report here that activins are abundantly expressed in mesothelioma cells and that by blocking 
activin activity the migration and invasive growth of mesothelioma cells can be significantly 
reduced. Furthermore, our results suggest a new mechanism through which mesothelioma cells 
promote migration and invasive growth: switching activin signaling from canonical Smad3 pathway 
to non-canonical ERK pathway signaling. 
 
 
 
MATERIALS AND METHODS 
 
Antibodies and growth factors 
Mouse monoclonal antibodies against human activin-A (mAb 18/26A) and activin-B (mAb 12/9A 
for IHC, 46A/F for Western blotting) subunits and follistatin (mAb 4/73C for IHC, 4/208 for 
Western blotting) were generated by AnshLabs LLC (Webster, TX). Rabbit monoclonal p-ERK1/2 
and mouse monoclonal ERK1 were from Cell Signaling (Danvers, MA). Human recombinant 
activins were from R&D Systems (Gaithersburg, MD) and used at 25 ng/ml. The recombinant 
fusion protein contaning the ectodomain of human ActR2B (sActR2B-Fc) or anti-Müllerian 
hormone receptor (sAMHR2-Fc) fused to the Fc domain of human IgG1 was produced as described 
previously [22] and used at 650 ng/ml (2D) or 10 μg/ml (3D). Soluble receptors sequester ligands 
and inhibit their binding to cell surface receptors. MAP kinase kinase (MEK) inhibitor PD98059 
was from Calbiochem (Merck, Darmstadt, Germany) and used at 30 μM. 
 
Patients and tissues specimen  
A statement for the use of human tissue and pleural effusion materials was approved by the Ethics 
Committee of the Helsinki University Hospital, Helsinki, Finland (permit number 
308/13/0301/2010). All patients gave written informed consent to participate in the study. Tissue 
biopsies and pleural effusion samples were obtained from patients who were undergoing diagnostic 
procedures and who had a clinical and/or radiological suspicion of malignant mesothelioma. All 
patients included in the study (n=12) were later diagnosed to have mesothelioma confirmed by a 
biopsy from the tumor tissue (Table 1). 
 
Immunohistochemical staining  
Paraffin-embedded tissue from mesothelioma tumor samples were processed and stained using the 
Novolink Polymer Detection System (Novocastra, Leica Biosystems, Newcastle upon Tyne, UK) 
and visualized by diaminobenzidine (DAB, Vector Laboratories) has been reported previously [23]. 
For follistatin staining, the formalin-fixed paraffin embedded specimens were stained on Leica 
BOND-MAX fully automated staining system as defined in the manufacturer’s staining protocol 
[with the Leica Bond Polymer Refine Detection-kit, Bond Epitope Retrievel Solution 2, 20 mins, 
R.T.U. Normal Horse serum 2,5% (Vector Laboratories, Burlingame, CA) blocking]. Images of 
IHC sections were captured with Nikon DS-Fi1 (Nikon, Amsterdam, Netherlands).  
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Cell culture  
Immortalized normal mesothelial cells (Met5A) [24] and mesothelioma cell lines (211H, H28, 
H2452, H2052) were from ATCC. Primary mesothelioma cells (JP cells) were obtained from 
pleural effusion samples from malignant mesothelioma patients as described in Tamminen et al. 
2013[25]. Cells were cultured in RPMI-1640 media (Sigma, St Luis, MO) supplemented with 10% 
fetal bovine serum (Gibco, Paisley, UK) and antibiotics (Gibco, Grand Island NY). Cells were 
stimulated with activin-A (25 ng/ml), activin-B (25 ng/ml) or sActR2B-Fc (650 ng/ml) for 90 
minutes under serum-free conditions.  
 
Transient transfection and luciferase assay 
Cells to be transfected were seeded in 96-well plates. The cells were co-transfected with promoter 
constructs (CAGA)12-luc (Smad3 responsive), ARE-luc/Fast-1 (Smad2 responsive) or (Bre)2-luc 
(Smad 1/5 responsive), kindly provided by Dr. Peter ten Dijke (Leiden University Medical Center, 
the Netherlands), together with pRL-TK (Renilla Luciferase control, Promega, Madison, WI) 
plasmid using Fugene HD transfection reagent (Roche, Basel, Switzerland). The transfection, cell 
lysis and the measurement of the luciferase activity were performed as described in Tamminen et al. 
2012 [26]. The cells were stimulated for 24 hours under serum-free conditions where indicated.  
 
RNA isolation and quantitative RT-PCR 
Total cellular RNA was isolated using RNeasy Mini kit (Qiagen, Hilden, Germany) and reverse 
transcribed to cDNA using iScript cDNA synthesis Kit (Bio-Rad, Hercules, CA) according to the 
manufacturer's instructions. The quantitative RT-PCR was performed as previously described 
[26].  
 
SDS-PAGE and Western blotting 
Cells were lysed and protein concentrations were measured as described earlier [26].  Equal 
amounts of protein were separated by SDS-PAGE using 4-20% gradient Tris-glycine gels (Bio-
Rad). Conditioned media from mesothelioma cell cultures were collected during 2 days, 
concentrated using Amicon Ultra 10K centrifugal filters (Millipore, Merck, Darmstadt, Germany) 
and separated by SDS-PAGE. The transfer of the proteins to Protran nitrocellulose membranes 
(Whatman, Springfield Mill, UK),  Western blotting and final detection of the proteins were 
performed as described previously [26]. Relative band densities were quantified using ImageJ 
software (National Institutes of Health, Bethesda, MA, USA).  
 
Cell migration assays 
The migratory capacity of the cell lines was analyzed using Incucyte ZOOM 2013A kinetic live cell 
imaging system (Essen Bioscience, Hertfordshire, UK) according to the manufacturer’s 
instructions. Briefly, the cells were plated on 96-well plates and the next day a wound was applied 
using a woundmaker (Essen Bioscience). The media was replaced with serum-free media 
supplemented with sActR2B-Fc where indicated. Two distinct pictures were taken of each well 
every 2 hours for 48 hours. Data were analyzed with Incucyte ZOOM 2013A software and the 
relative wound density was used as a measure of the wound closure. Alternatively, cells were 
seeded on 12-well plates and wounds were made in confluent monolayers using a P200 pipette tip. 
The media was replaced with serum-free media supplemented with DMSO, PD98059 or sActR2B-
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Fc where indicated. Two pictures per well were taken after 0, 6, 24 and 48 hours using Nikon 
Eclipse TS 100 and Digital Sight DS-L2 (Nikon). The wound density was quantified using Image 
ProPlus 7.0 software (Media Cybernetics, Inc., Rockville, MD) and is shown as % area occupied by 
cells relative to % wound area and has been normalized to wound density data at the 0 hour time 
point. The control treated wound density has been set to one. 
 
3D invasive growth assay  
The lower Matrigel gel (BD Biosciences, San Jose, CA) was laid on the bottom of the well on a 96-
well plate and allowed to solidify at 37˚C for 45 minutes. Next, 3000-4000 cells per well were 
seeded and allowed to attach for 1 hour after which the media was carefully removed and replaced 
with the top gel. Before seeding, the cells were pre-treated with sActR2B-Fc, sAMHR2-Fc, DMSO 
or PD98059 for 15 minutes where indicated. The top gel was allowed to solidify for 30 minutes 
after which media was added. Inhibitors were also added to Matrigel and cell culture media on top 
of the gel.  
 
Statistical analyses 
Data were analyzed using PASW Statistics 21 program for Windows (SPSS, Chicago, IL). 
Statistical difference between two independent groups was evaluated using nonparametric Mann-
Whitney U-test. Statistical difference between more than two independent groups was evaluated 
using nonparametric Kruskal-Wallis test. A p-value of less than 0.05 was considered statistically 
significant. 
 
 
RESULTS 
 
Activin-A and -B are highly expressed in malignant mesothelioma 
Activins are known regulators of inflammation and tissue repair processes [5,27]. Activin 
expression has also been linked to malignant and fibrotic conditions [7]. To analyze the expression 
of activin-A and -B in mesothelioma, tissue biopsies from patients were stained with specific 
antibodies against inhibin βA and βB subunits. Immunoreactivity for both activins was abundantly 
detected in mesothelioma tumors (Fig. 1A). All tumor samples (n=10) were positive for both 
activins. In 8 out of 10 samples the immunoreactivity of activin-A was stronger compared to the 
immunoreactivity of activin-B (Table 2). The immunoreactivity localized into the mesothelioma 
tumor cells, while the stroma was mainly negative. Capillary endothelium in the stroma was found 
positive. In addition, normal and reactive pleura showed immunoreactivity for both activins (not 
shown). Tumor cells were also positive for follistatin immunoreactivity, which was observed in a 
more heterogeneous pattern (Table 2). In addition to tumor cells, follistatin was detected in the 
stroma, endothelium and strongly in normal and reactive pleura (not shown).  
 
We have previously described isolation and culture of primary mesothelioma cells from patients’ 
pleural effusion samples [25]. The cells retain gene expression characteristics of the tumor at early 
passage cultures. The mRNA expression levels of activin-A (INHBA) and -B (INHBB) in primary 
cells were analyzed using quantitative RT-PCR. Met5A cells, immortalized but non-tumorigenic 
mesothelial cells that were used as controls, expressed both activin-A and -B. The levels of activin-
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A were about 10-fold higher than activin-B levels (Fig. 1B). All primary mesothelioma cells 
expressed considerably higher levels of activins when compared to Met5A cells (Fig. 1B). Primary 
cells that overexpressed mainly activin-A were isolated from a patient with biphasic mesothelioma 
(JP4), while the other primary cells were from patients with epithelioid type mesothelioma. We also 
analyzed activin expression levels in established mesothelioma cell lines (211H, H2052, H28, 
H2452) and found that there was more heterogeneity in the expression levels of activin subunits 
compared to primary cells (Fig. 1C). In general, activin mRNA expression levels were significantly 
higher, especially in 211H and H2052 cell lines, than in Met5A cells. Interestingly, similar to what 
was found in JP4 primary cells we observed specific upregulation of the activin-A subunit in the 
211H cell line, which is also isolated from a patient with biphasic mesothelioma. Secretion of 
activin subunits into the culture media was analyzed by Western blot analysis and found to correlate 
with the mRNA expression data (Fig. 1D).  
 
Follistatin and follistatin like-3 (FSTL-3) are extracellular inhibitors of TGF-β family growth 
factors. They can bind to all activins and inhibit their biological functions [10]. The mRNA 
expression levels of FST and FSTL3 in mesothelioma cells were analyzed next. In primary 
mesothelioma cells FST expression levels were downregulated, in some cells (JP1 and JP4) more 
clearly than in others. FSTL3 mRNA expression levels were elevated in 3 out of 4 primary 
mesothelioma cells (Fig. 1E). In the established mesothelioma cell lines FST and FSTL3 expression 
levels showed more variability. FST levels were downregulated in H28 and H2452 cell lines, while 
upregulated in 211H and H2052 cell lines (Fig. 1F). FSTL3 mRNA expression levels tended to 
decrease, which is in contrast to what was observed in the primary cells. Secretion of FST into the 
culture media was analyzed by Western blot analysis and found to correlate with the mRNA 
expression data (Fig. 1D).  
 
ALK7 and ACVR2A are overexpressed in mesothelioma cells  
The cells’ sensitivity to activins and other TGF-β superfamily growth factors is defined by cell 
surface receptor expression and the specificity of the signal is defined by the type 1 receptor [12]. 
Both activin-A and -B activate Smad2/3 pathway through ALK4 [12]. In addition, activin-B can 
activate Smad2/3 pathway through ALK7 [13,14] and Smad1/5/8 pathway through ALK3 [15]. The 
activin receptor mRNA expression levels were analyzed using quantitative RT-PCR. Met5A cells 
expressed activin type 1 receptors ALK3 and ALK4 and very low levels of ALK7 (Fig. 2A). 
Overall, ALK3 and ALK4 mRNA expression levels were not consistently altered in primary 
mesothelioma cells or in established mesothelioma cell lines (Fig. 2A and C). However, ALK7 
receptor expression was highly increased in primary mesothelioma cells (Fig. 2B). In addition, all 
the established mesothelioma cell lines showed higher levels of ALK7 when compared to Met5A 
cells (Fig. 2D).  
 
Met5A cells expressed both activin type 2 receptors ACVR2A and ACVR2B. The levels of receptor 
2B were about 3-fold higher than receptor 2A expression levels (Fig. 2E and F). This is in contrast 
to what was observed in all primary mesothelioma cells. The 2A receptor expression levels 
increased significantly, while receptor 2B levels decreased (~13-fold higher level of receptor 2A 
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compared to receptor 2B on average) (Fig. 2E), suggesting that there is a switch in the predominant 
type 2 receptor in mesothelioma cells. This was also noted in 3 out of 4 established mesothelioma 
cell lines (Fig. 2F). The H28 cell line was the only one showing elevated levels of both type 2 
receptors. 
 
 
Mesothelioma cells have altered Smad activation in response to activins  
Activin-A and -B induced Smad responses were studied in mesothelioma cells using transient 
transfection of Smad3 responsive [(CAGA)12-luc], Smad2 responsive [ARE-luc] or Smad1/5 
responsive [(Bre)2-luc] promoter-luciferase constructs followed by overnight stimulation by activin-
A or -B (see Methods). Basal Smad3 activity was somewhat higher in primary cells (JP5) compared 
to established mesothelioma cell lines or Met5A cells (Fig. 3A). Smad3 activity increased ~80-fold 
in activin-A and ~60-fold in activin-B treated Met5A cells (Fig. 3B). The H28 mesothelioma cell 
line showed similar responses. In contrast, H2052 and 211H cell lines as well as JP5 primary cells 
had strongly attenuated activin induced Smad3 activation.  
 
Basal Smad2 activity differed between the cells. Significantly lower basal Smad2 activity was 
observed in 211H and H2052 cells (Fig. 3C). Both activins induced Smad2 activity in Met5A cells. 
Induction of activity was also observed in 211H cells, whereas H2052 and H28 cells showed only a 
moderate 2-fold increase in Smad2 activity in response to activin-A and -B (Figure 3D). In JP5 
primary cells activins failed to induce Smad2 activity.  
 
A tendency towards higher basal Smad1/5 activity levels were noted in JP5 primary cells as well as 
in 211H and H2052 cells compared to Met5A cells (Fig. 3E). H28 cell line showed significantly 
increased basal level Smad1/5 activity. Interestingly, activin-B increased Smad1/5 activity in this 
particular cell line, but not in any other cells tested (Fig. 3F). 
 
 
Mesothelioma cells differ in migratory capacity  
To analyze the migratory capacity of established mesothelioma cell lines, a scratch-wound assay 
was performed. Cell migration was monitored using a live-cell imaging system (see Methods). 
Clear differences in mesothelioma cell migration were observed (Fig. 4A). H2052 and 211H cells 
migrated efficiently to close the wound. These two cell lines exhibited increased mRNA and protein 
expression of activin-A as well as altered Smad3 signaling responses. H2452 cells were less 
migratory and H28 cells were able to close the wound only after extended periods of time (Fig. 4A). 
Migration of 211H cells reduced with addition of a soluble activin inhibitor (sActR2B-Fc), 
suggesting that endogenous activins contribute to 211H mesothelioma cell migration (Fig. 4B and 
C). The migratory capacity of JP5 primary cells was measured using a scratch-wound assay and 
imaging at 0, 6, 24 and 48 hour time points. JP5 cells were also found to migrate rapidly. Treatment 
with the activin inhibitor sActR2B-Fc clearly delayed wound closure (Fig. 4 D and E). Similar to 
what was observed in 211H cells the inhibition was clearly detectable at 24 hours (Fig. 4D) and was 
sustained at 48 hours, when sActR2B-Fc treated wounds were approximately half as dense as the 
untreated control wounds (Fig. 4E).  
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Migratory mesothelioma cells also show invasive growth in 3D 
To analyze the invasive growth of mesothelioma cell lines, they were seeded into 3D matrices and 
monitored for 36 hours (see Methods). The highly migratory cell lines 211H and H2052 were able 
to form irregular shaped spheroids and invade through the Matrigel forming a network of sprouts 
(Fig. 5A), whereas H28 and H2452 cells were unable to do this. Next we analyzed whether activin 
signals contribute to invasive growth. The cells were pretreated with sActR2B-Fc, which binds and 
inhibits the action of both activin-A and -B, before they were seeded into Matrigel. Interestingly, 
addition of sActR2B-Fc was able to inhibit the invasive growth of 211H and H2052 mesothelioma 
cell lines (Fig. 5B, C) as well as JP5 primary cells (Fig. 5D). Addition of a soluble anti-Müllerian 
hormone receptor (sAMHR2-Fc), which was used as a control treatment, had no impact on invasive 
growth (Fig. 5B). These results suggest that activins contribute to the invasive growth properties of 
mesothelioma cells.  
 
 
ERK activity contributes to mesothelioma cell migration and invasive growth  
Activins can also induce non-canonical signaling pathways. These include the ERK and JNK MAP 
kinase pathways, which have been shown to contribute to cell migration [17,20]. ERK 
phosphorylation, i.e., activation was analyzed by Western blotting after treatment of cells with 
activin-A or -B for 90 minutes. In Met5A control cells activins did not induce ERK 
phosphorylation, instead, pERK levels seemed to decrease. In contrast, in H2052 and JP5 primary 
cells activins induced robust ERK phosphorylation (Fig. 6A). Activin-A seemed to induce a 
stronger response than activin-B. To determine whether endogenous activins support ERK 
activation, mesothelioma cells were treated with the soluble activin inhibitor sActR2B-Fc. In all 
migratory and invasive mesothelioma cells (211H, H2052 and JP5) sActR2B-Fc treatment reduced 
ERK phosphorylation levels significantly (Fig. 6B and C). Due to a limited possibility to do 
experiments with early passage primary cells (n=2), the decrease in JP5 cells did not, however, 
reach statistical significance. In the other cell lines (Met5A, H28 or H2452) treatment with 
sActR2B-Fc did not lead to similar reduction in ERK phosphorylation (not shown). No significant 
changes in JNK1/2 phosphorylation in response to activin stimulation were detected (not shown).  
 
To analyze the involvement of ERK activity in mesothelioma cell migration a scratch-wound assay 
was performed in the presence or absence of an inhibitor of the upstream kinase MEK (PD98059). 
In JP5 primary cells as well as in 211H and H2052 cells wound closure was considerably delayed 
by the MEK inhibitor (Fig. 6D and E). Compared to DMSO treated control cells, in MEK inhibitor 
treated 211H and JP5 primary cells a significantly delayed wound closure was observed at 48 hours. 
In H2052 cells the delay in wound closure was significant already at 6 hours when the wounds were 
approximately half as dense as the control wounds (Fig. 6E). Unlike in the DMSO treated control, 
H2052 wounds remained open in the presence of the MEK inhibitor at 24 hours (Fig. 6D). Activin-
A increased H2052 cell migration. After six hours, the wounds were approximately twice as dense 
as the control wounds (Fig. 6F and G). Treatment with the MEK inhibitor significantly delayed the 
wound closure also in activin-A stimulated cells (Fig. 6F and G).    
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The contribution of ERK pathway activity to the invasive growth of mesothelioma cells was 
analyzed next. Cells were pretreated with the MEK inhibitor or DMSO, after which the cells were 
seeded into 3D matrices. Inhibition of ERK pathway activity significantly inhibited invasive growth 
of 211H and JP5 primary cells (Fig. 6 H). This was similar to what was observed with sActR2B-Fc. 
In addition, H2052 cells showed a similar trend of decreased ability for invasive growth (not 
shown). However, this observation was not so clear due to the sensitivity of H2052 cells to DMSO 
control treatment in a three-dimensional setting. Taken together, our data suggest that inhibition of 
ERK activity efficiently prevents mesothelioma cell invasive growth. 
 
 
 
DISCUSSION  
TGF-β family growth factors have an important role during development and adult tissue 
homeostasis. There is also ample evidence linking aberrant growth factor activity to cancer 
progression [28]. TGF-β activity has been linked to mesothelioma, but the role of activins is less 
well understood. There is one study showing overexpression of activin-A in mesothelioma and 
suggesting a function in the regulation of mesothelioma cell proliferation [8]. Here, we provide 
evidence that activin-A and activin-B are important regulators of mesothelioma cell migration and 
invasive growth properties. By blocking activin activity using a soluble inhibitor, we can efficiently 
inhibit invasive growth in a three-dimensional culture system. Mesothelioma cells showed a clear 
difference in signaling responses to activins, which may be a key mechanism for the invasive 
growth inducing activity. Similar to what has been described for TGF-β [29,30], we speculate that 
increased activin production and altered signaling responses in malignant cells mediate a switch in 
their function from a tumor suppressor to a tumor promoter. Interestingly, suppression of Smad 
activity and concomitant increase in ERK activation has been suggested to mediate the switch in 
TGF-β function during tumor progression [31].     
 
All mesothelioma tumors showed consistently high immunoreactivity for activin-A, which is in 
agreement with a previous report [8]. In addition, activin-B immunoreactivity was observed in all 
tumors. Immunoreactivity for the activin inhibitor follistatin, on the other hand, was more variable 
and not consistently altered in tumors. We have analyzed primary mesothelioma tumor cells 
isolated from pleural effusion samples [25] and found very consistent changes in the activin 
signaling pathway. Established mesothelioma cell lines showed clearly more heterogeneity, which 
suggests that it is important to use cell lines with similar characteristics as the primary tumors in 
mechanistic studies. Primary mesothelioma cells and migratory and invasive mesothelioma cell 
lines showed increased expression of activin-A, activin-B, ALK7 and ACVR2A, as well as ERK 
activation and attenuated Smad2/3 signaling responses. These alterations were clearly associated 
with a migratory and invasive growth phenotype, which could be blocked using a soluble activin 
inhibitor (sActR2B-Fc) or MEK inhibitor.  
 
Activins can use different receptor heterodimers to mediate signaling. We found a significant 
upregulation of ALK7 receptor in mesothelioma. As ALK7 is an activin-B preferring receptor 
coexpression of ACVR2 and ALK7 should provide sensitivity to activin-B. In addition to activin-B 
also Nodal is a ligand for ALK7 [32]. Nodal is a developmental morphogen, which has been linked 
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to cancer stem cell phenotype, epithelial-to-mesenchymal transition and invasion in other 
malignancies [33]. The possible role of Nodal in mesothelioma remains to be elucidated. Another 
interesting finding was a switch from a predominant expression of type 2 receptor ACVR2B to 
ACVR2A. This may lead to changes in activin mediated intracellular signaling and function as an 
adaptation mechanism required for cells to escape growth/invasion limiting actions of activins. 
Since activin type 2 receptors are involved in a variety of receptor signaling complexes, the switch 
of the predominantly expressed receptor may also alter responses to other TGF-β family ligands. 
We observed a clear association of type 2 receptor expression profile with loss of Smad3 
responsiveness and migratory and invasive phenotype. H28 mesothelioma cells did not show this 
receptor swich, were sensitive to Smad3 activation and did not show high migratory or invasive 
growth phenotype. H28 cells have been shown to lack β-catenin [34], which is not a typical feature 
of mesothelioma [35]. This suggests that H28 is a unique mesothelioma cell line.  
 
Activins can induce inhibition of proliferation and apoptosis [5]. Cancer cells can avoid these 
suppressive functions through various mechanisms. Loss of the CDKN2A/ARF locus is the most 
common genetic alteration in mesothelioma and leads to inactivation of the p16INK4a tumor 
suppressor gene [36]. This may also reduce activin induced apoptotic responses [37]. Smad-
mediated signaling is also crucial for activin induced growth arrest [38]. We have shown here a 
clear transformation in activin induced intracellular signaling cascades in mesothelioma cells. 
Smad3 activation, measured using a promoter assay, was almost lost in migratory and invasive 
mesothelioma cells, while Smad2 activation was partially retained in some cell lines. In addition, 
TGF-β was still able to induce Smad3 activation (our unpublished data), suggesting an activin 
specific loss of responsiveness. Higher follistatin expression levels in established mesothelioma cell 
lines could not explain the loss of responsiveness, since activins induced a robust ERK activation in 
H2052 cells. Furthermore, JP5 primary cells had low levels of follistatin expression but attenuated 
Smad3 activation. We have previously shown high P-Smad2 immunoreactivity in mesothelioma 
tumor samples [39], but P-Smad3 levels in vivo have not been specifically analyzed and remain to 
be determined.  
 
Previously it has been observed that activin-B induces skin wound re-epithelialization through 
Smad3-independent mechanisms [40]. This is also demonstrated by accelerated wound healing in 
Smad3 knockout mice [41]. The ERK pathway has been found important for activin induced 
epithelial wound healing [40]. The migratory and invasive growth phenotype in mesothelioma cells 
was also clearly associated with activin induced ERK activity, since inhibition of both activin-A 
and -B by using a soluble type 2 receptor reduced levels of ERK phosphorylation and migration and 
invasive growth in 3D matrix. Similar effects were observed when ERK phosphorylation was 
blocked with an inhibitor of the upstream kinase MEK. ERK is one of the well-known activators of 
cyclin D [42]. Our results are in agreement with a report by Hoda et al. (2012) [8] suggesting that 
activin-A can also function through cyclin D in mesothelioma. The ERK pathway is involved in the 
regulation of cell cycle progression, apoptosis and differentiation. It is also commonly activated in 
tumors [43]. ERK is known to be highly activated in mesothelioma [44] and central to 
mesothelioma cell migration, proliferation as well as tumor development and chemoresistance [45]. 
In addition to TGF-β family ligands, receptor tyrosine kinases can contribute to ERK pathway 
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activity in mesothelioma cells. Fibroblast growth factor receptor (FGFR)1 was recently found 
upregulated in mesothelioma cells and in patient samples [46]. Inhibition of growth caused by 
FGFR inhibition was associated with downregulation of basal ERK activity [46].  
 
The exact molecular mechanism of the swich from Smad3 signaling to ERK pathway signaling in 
activin responsive mesothelioma cells remains to be elucidated. Changes in activin type 2 receptor 
expression profile may contribute to this switch. Downregulation of TGF-β type 2 receptor has been 
implicated in the loss of responsiveness to the anti-proliferative effects of TGF-β in lung cancer 
cells [47]. In addition to changes in receptor expression, it has been suggested that a specific 
isoform of PP2A is differentially recruited to TGF-β type 1 receptor in normal and malignant cells 
leading to differential activation of ERK [31]. Similar mechanisms may play a role in the observed 
activin pathway alterations.  
 
Mesotheliomas are characterized with aggressive and locally invasive phenotypes. Understanding 
of the mechanisms that the tumor invasion is vital for the development of treatment strategies. 
Cancer cells and the tumor microenvironment both contribute to the invasive phenotype of the 
tumors. We have shown here that mesothelioma cells produce activin-A and -B, which both 
contribute to the invasive and migratory phenotype of the cancer cells. High expression levels of 
activins are associated with attenuation of the canonical Smad3 signaling and increase in non-
canonical ERK signaling responses. Similar changes in the signaling pathways have been associated 
with the function of TGF-β as a tumor promoter in cancer cells [31]. In conclusion, inhibition of 
activin or ERK activity, or both, represents a therapeutic approach for inhibition of invasive 
mesothelioma tumors. Novel inhibitors of activin signaling are under development for clinical use, 
which makes activins a plausible target for adjunctive therapy in mesothelioma. 
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FIGURE LEGENDS 
 
Fig. 1 
Activins are abundantly expressed in mesothelioma tumor tissue as well as in cultured 
mesothelioma cells. (A) Immunohistochemical staining of mesothelioma tumor samples using 
activin-A, activin-B or follistatin antibodies. See Table 2 for scoring of the staining intensity in 
tumors. The mRNA expression levels of activin-A (INHBA) and activin-B (INHBB) were analyzed 
in primary mesothelioma cells (B) and mesothelioma cell lines (C) using quantitative RT-PCR. The 
expression levels were normalized to the expression levels of TATA-binding protein and are shown 
relative to the expression levels of activin-A in Met5A cells. (D) Mesothelioma cell conditioned 
media were analyzed using Western blotting. The ~15 kDa activin-A monomer as well as ~55 kDa 
prodomain and ~30 kDa dimer of activin-B and follistatin (FST) are shown. Recombinant proteins 
used as positive controls (pos. ctrl) and molecular weight markers are shown on the right. The 
mRNA levels of follistatin (FST) and follistatin-like 3 (FSTL3) were analyzed in primary 
mesothelioma cells (E) and mesothelioma cell lines (F). The expression levels were normalized to 
the expression levels of TATA-binding protein and are shown relative to the expression levels of 
FST in Met5A cells. Error bars represent standard deviation (n=3). 
 
Fig. 2 
The expression of ACVR2A and ALK7 is increased in mesothelioma cells. The mRNA expression 
levels of activin type 1 (ALK3, ALK4 and ALK7) and type 2 (ACVR2A and ACVR2B) receptors were 
analyzed in primary mesothelioma cells (A, B, E) and in mesothelioma cell lines (C, D, F). The 
expression levels were normalized to the expression levels of TATA-binding protein and are shown 
relative to the expression levels of ALK4 (A, C), ALK7 (B, D) or ACVR2A (E, F) in Met5A cells. 
Error bars represent standard deviation (n=2). * p≤ 0.025 Kruskal-Wallis Test. 
 
Fig. 3 
Activin induced Smad3 activation is attenuated in mesothelioma cells. Met5A and mesothelioma 
cells were transfected with Smad3 (A, B), Smad2 (C, D) or Smad1/5 (E, F) responsive promoters 
and stimulated overnight with activin-A or -B. Promoter activity is shown relative to the level in 
Met5A cells. (A) Basal Smad3 activity was somewhat elevated in primary mesothelioma cells (JP5, 
n=2). (B) Activin induced Smad3 activation was dramatically decreased in primary mesothelioma 
cells and in 211H and H2052 cell lines (n=2). (C) Basal Smad2 activity was downregulated 
significantly in 211H and H2052 mesothelioma cells [**p=0.007 Kruskal-Wallis Test comparing all 
samples; *p=0.008 Mann-Whitney Test comparing two groups (Met5A vs. 211H and Met5A vs. 
H2052) (n≥3)]. (D) Activin-A and -B induced robust Smad2 activation in Met5A and 211H cells 
whereas other cells showed attenuated Smad2 response (n≥2). (E) Basal Smad1/5 activity was 
significantly increased in H28 cells and slightly increased in other mesothelioma cells [**p=0.006 
Kruskal-Wallis Test (n≥2); *p=0.007 Mann-Whitney Test comparing two groups (Met5A vs. H28) 
(n≥3)]. (F) Activin-B induced Smad1/5 activation only in H28 cell line (n≥3). Error bars represent 
standard deviation.  
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Fig. 4 
Inhibition of activin activity reduces mesothelioma cell migration. Cell migration was analyzed 
using a scratch-wound assay and monitored by 48-hour live cell imaging (A-C) or imaging at 0, 6, 
24 and 48 hour time points (D, E). The results are presented as relative wound density. H2052 and 
211H mesothelioma cells were found to rapidly close the wound. Inhibition of activin signaling 
using a soluble type 2 receptor (sActR2B-Fc) delayed wound closure in 211H cells. Error bars 
represent standard deviation (n=2). (C) Representative pictures of 211H cells at the 24 hour time 
point are shown. (D, E) Representative pictures of JP5 primary mesothelioma cell scratch-wound 
assay. Inhibition of activin signaling (by sActR2B-Fc) delayed wound closure in primary cells 
[p=0.1 Mann-Whitney Test, (n=3)]. Error bars represent standard deviation. 
 
Fig. 5 
Invasive growth of mesothelioma cells was analyzed in three-dimensional matrix. (A) 211H and 
H2052 cells, but not H28 and H2452 cells, embedded in Matrigel were able to form irregular 
shaped spheroids as well as invade and sprout through the surrounding matrix. (B-D) Inhibition of 
activin signaling (by sActR2B-Fc) prevented invasive growth of 211H, H2052 and JP5 primary 
cells. Soluble anti-Müllerian hormone receptor (sAMHR2-Fc) was used as a negative control and 
had no effect on invasive growth. Representative pictures are shown. Original magnification 100x. 
Inset: high magnification picture.  
  
Fig. 6 
ERK activity is essential for activin induced mesothelioma cell migration and invasive growth. (A) 
Cells were stimulated with activin-A or -B for 90 minutes and analyzed for ERK phosphorylation 
using Western blotting. (B, C) When mesothelioma cells were treated with sActR2B-Fc (90 
minutes) to inhibit activin signaling, ERK phosphorylation levels decreased significantly [*p=0.029 
Mann-Whitney Test (n=4); JP5 primary cells (n=2)]. (D) Representative pictures of 211H (48h), 
H2052 (24h) and JP5 (48h) scratch-wound assay are shown. (E) Compared to DMSO treated 
control cells MEK-inhibitor (PD98059) significantly delayed wound closure. H2052 cell wound 
density was analyzed at the 6 hour time point. JP5 primary and 211H cell wound density was 
analyzed at the 48 hour time point [*p=0.029 Mann-Whitney Test (n=4); JP5 primary cells, (n=3)]. 
Error bars represent standard deviation. (F) Representative pictures of H2052 scratch wound assay 
are shown. (G) H2052 cell wound density was analyzed at the 6 hour time point. The wound density 
in activin-A stimulated cells was twice as high compared to the DMSO treated control cells. The 
MEK-inhibitor (PD98059) significantly delayed wound closure in activin-A stimulation cells 
[*p=0.029 Mann-Whitney Test (n=4)]. (H) The effect of inhibition of ERK activity to 
mesothelioma cell invasive growth in three-dimensional matrix was analyzed using the MEK-
inhibitor (PD98059). PD98059 prevented invasive growth of 211H and JP5 primary cells. 
Representative pictures are shown.   
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TABLES 
 
Table 1. Mesothelioma patient characteristics. 
Patient Type Location Age Gender 
JP1 epithelial pleura 53 male 
JP2 biphasic pleura 71 male 
JP3 epithelial pleura 63 male 
JP4 biphasic peritoneum 72 female 
JP5 epithelial pleura 69 female 
JP6 biphasic pleura 71 female 
JP7 epithelial pleura 62 male 
JP8 epithelial pleura 63 male 
JP9 epithelial pleura 54 male 
JP10 epithelial pleura 75 male 
JP11 epithelial pleura 65 male 
JP12 epithelial pleura 60 male 
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Table 2. Scoring of activin-A, activin-B and follistatin immunoreactivity in mesothelioma patient 
samples. 
 
Patient activin-A activin-B follistatin 
JP2 +++ +++ ++ 
JP3 + + ++ 
JP5 +++ ++ + 
JP6 +++ + ++ 
JP7 +++ ++ ++ 
JP8 +++ + ++ 
JP9 ++++ +++ +++ 
JP10 ++ + ++ 
JP11 ++++ ++ + 
JP12 ++++ ++ ++ 
 
Extent of staining (score): no staining (0), weak staining (+), moderate staining (++), strong staining 
(+++) and very strong staining (++++).   
 
 
???
??
??
??
???
?????
???
???
??? ??? ???
???
???
???
???
???
?
?
?
?
?
??
???
?????
?
??
??
??
?? ?????????
?????????
???
????
???
????
???
???
????
??? ??? ???
?
??
??
??
??
?? ?????????
?????????
?????
????????????????????? ???
?
??
??
??
???
?
?
??
?
??
??
??
??
?
?
?
??
??
??
??
??
??
???????????????????????? ??????????????????
??
????????????????? ???????????????? ????????????????????
?
??
??
??
??
?
??
??
?
??
??
??
???
??
???
???
???
???
???
?????????
?????????
?
??
?????
??
??
??
???
???
???
???
??
??
???????????????????????? ???????????????????????????
????????????????? ???????????????? ???????????
????????
???
???
???
???
???
??? ???
???
???
???
?????
??? ??? ??? ???
?
?
?
?
?
? ????
????
????
?
??
???
???
??? ????
?
???
???
???
???
?
???
???
???
???
????
?
?
?
?
?
??
??
?? ??????
??????
???
????
????
???? ????
??? ??? ??? ??? ???
?
?
??
??
??
??
??????
??????
?
?
?
?
?
?
????
????
?
??
??
??
??
?
?
?
??
??
??
??
??
??
????
?
??
??
??
??
?
?
?
??
??
??
??
??
??
????
?
??
??
??
??
?
?
?
??
??
??
??
??
??
?? ??
?
?
???????????????????????? ??????????????????
???????? ?????????? ???????????????????? ????????????
??? ?????????
???????????????????????? ???????????????????????
???????????????????????? ??????????????? ????????
????????? ?????? ?????????????? ? ? ? ????????
????????????????? ???????????????? ????????????
????????
??
?
?
?
?
?
?
??
??
??
??
?
?
?
?
? ?????
????
?????
???
???
?
?
?
?
?
??
??
??
?????
????
?????
???
???
?
??
??
??
??
???
??? ?????
????
?????
???
???
?
?
?
?
?
??
??
??
?
??
??
??
??
??
??
??
??
??
??
??
??
???
????
??
??????????????????????
??????????????????????????????????
????????????????????????
?
??
??
??
??
??
??
??
??
??
??
??
??
??? ?
?????????????????????????????????
?????????????????
??????????????
??????????????????????????????????????????
?????????????????????????????????????????????
??
??????????????
?????????????????????????????????????????????
??
??
??????????????????????
?
??
??
??
??
??
??
??
??
??
??
??
??
???
?????????????????????????????????????
? ?
? ?
? ?
????????
????
?
?
??
??
??
??
???
? ?? ?? ?? ?? ?? ??
?????????
???????????????
?
??
??
??
??
???
? ?? ?? ?? ?? ?? ??
?????
???
????
?????
??
?
??
??
??
??
?
??
??
??
??
??
??
?????
??
????
????
??
?????
??????????
??????????????
???
?
??
??
??
??
?
??
??
??
??
??
??
????????????????????
????
????????
??
???? ???????????
?????
?????????????????
????
?????????
?????
???? ???????????
???? ??????????
???
??
??
??
????????
????
?
?
???
? ????
???
?
?
?
?
?
????
???????
?
???
? ????
?????
???
?? ?? ???? ???????
?????
??
????
??????
???
???
???
??
??
??
??
?
??
??
??
??
??
??
??
???? ???
???? ???????????
???
???
??
??
??
??
??
??
???
??
??
???
????????????????
??
????????
??
?
?
??????????? ???? ???????
? ?
???????
?????
?????
????????????????????????????????????????????????????????
?????????????????????????????? ? ?? ????????????????????
?????
??
??
??
??????
?????
????
???
???
????????????????????
?????
??
?
????
?????
??
?
????
???????? ??????
? ????
??
?
????
?????
??
?
???? ???
???
???
???
??????
? ??
????????????????
???
??
??
??
??
?
??
??
??
??
??
??
?
? ?
??
??????
??
????????????????????? ??????????????
????????
